% $ biblatex auxiliary file $
% $ biblatex bbl format version 3.2 $
% Do not modify the above lines!
%
% This is an auxiliary file used by the 'biblatex' package.
% This file may safely be deleted. It will be recreated as
% required.
%
\begingroup
\makeatletter
\@ifundefined{ver@biblatex.sty}
  {\@latex@error
     {Missing 'biblatex' package}
     {The bibliography requires the 'biblatex' package.}
      \aftergroup\endinput}
  {}
\endgroup

\datalist[entry]{none/global//global/global}
  \entry{centersfordiseasecontrolandpreventionHeartDiseaseFacts2022}{online}{}
    \name{author}{1}{}{%
      {{hash=fDCaPC}{%
         prefix={for},
         prefixi={f\bibinitperiod},
         family={Disease Control {and}\bibnamedelima Prevention},
         familyi={D\bibinitperiod\bibinitdelim C\bibinitperiod\bibinitdelim
  a\bibinitperiod\bibinitdelim P\bibinitperiod},
         given={Centers},
         giveni={C\bibinitperiod},
      }}%
    }
    \list{organization}{1}{%
      {{Centers for Disease Control and Prevention}}%
    }
    \strng{namehash}{DCaPCf1}
    \strng{fullhash}{DCaPCf1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{labeldatesource}{}
    \field{abstract}{%
    Learn facts about how race, ethnicity, age, and other risk factors can
  contribute to heart disease risk.%
    }
    \field{title}{Heart {{Disease Facts}} | Cdc.Gov}
    \verb{url}
    \verb https://www.cdc.gov/heartdisease/facts.htm
    \endverb
    \field{langid}{american}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\7AW6JIBV\\facts.html
    \endverb
    \field{day}{07}
    \field{month}{02}
    \field{year}{2022}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{fryarPrevalenceUncontrolledRisk2012}{article}{}
    \name{author}{1}{}{%
      {{hash=FCD}{%
         family={Fryar},
         familyi={F\bibinitperiod},
         given={Cheryl\bibnamedelima D},
         giveni={C\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
    }
    \strng{namehash}{FCD1}
    \strng{fullhash}{FCD1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2012}
    \field{labeldatesource}{}
    \field{abstract}{%
    In 2009–2010, approximately 46.5\% of U.S. adults aged 20 and over had at
  least one of three risk factors for CVD and stroke. More than one-quarter
  were current smokers, more than 23\% had uncontrolled high levels of LDL-C,
  and almost 12\% had uncontrolled high blood pressure. Adults who were male,
  or female aged 60 and over, or non-Hispanic black, or of lower income were
  more likely to have one of the risk factors for CVD compared with their
  counterparts.%
    }
    \field{number}{103}
    \field{pages}{8}
    \field{title}{Prevalence of {{Uncontrolled Risk Factors}} for
  {{Cardiovascular Disease}}: {{United States}}, 1999–2010}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\AL7889VJ\\Fryar - 2012 - Prevalen
    \verb ce of Uncontrolled Risk Factors for Cardio.pdf
    \endverb
    \field{year}{2012}
  \endentry

  \entry{nationalhealthserviceHeartAttack2017}{online}{}
    \name{author}{1}{}{%
      {{hash=N}{%
         family={{National Health Service}},
         familyi={N\bibinitperiod},
      }}%
    }
    \strng{namehash}{N1}
    \strng{fullhash}{N1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2017}
    \field{labeldatesource}{}
    \field{abstract}{%
    Find out about heart attacks, a serious medical emergency in which the
  supply of blood to the heart is suddenly blocked, usually by a blood clot%
    }
    \field{title}{Heart Attack}
    \verb{url}
    \verb https://www.nhs.uk/conditions/heart-attack/
    \endverb
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\S72D8L36\\heart-attack.html
    \endverb
    \field{day}{24}
    \field{month}{10}
    \field{year}{2017}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{montalescot2013ESCGuidelines2013}{article}{useprefix}
    \name{author}{83}{}{%
      {{hash=MG}{%
         family={Montalescot},
         familyi={M\bibinitperiod},
         given={Gilles},
         giveni={G\bibinitperiod},
      }}%
      {{hash=SU}{%
         family={Sechtem},
         familyi={S\bibinitperiod},
         given={Udo},
         giveni={U\bibinitperiod},
      }}%
      {{hash=AS}{%
         family={Achenbach},
         familyi={A\bibinitperiod},
         given={Stephan},
         giveni={S\bibinitperiod},
      }}%
      {{hash=AF}{%
         family={Andreotti},
         familyi={A\bibinitperiod},
         given={Felicita},
         giveni={F\bibinitperiod},
      }}%
      {{hash=AC}{%
         family={Arden},
         familyi={A\bibinitperiod},
         given={Chris},
         giveni={C\bibinitperiod},
      }}%
      {{hash=BA}{%
         family={Budaj},
         familyi={B\bibinitperiod},
         given={Andrzej},
         giveni={A\bibinitperiod},
      }}%
      {{hash=BR}{%
         family={Bugiardini},
         familyi={B\bibinitperiod},
         given={Raffaele},
         giveni={R\bibinitperiod},
      }}%
      {{hash=CF}{%
         family={Crea},
         familyi={C\bibinitperiod},
         given={Filippo},
         giveni={F\bibinitperiod},
      }}%
      {{hash=CT}{%
         family={Cuisset},
         familyi={C\bibinitperiod},
         given={Thomas},
         giveni={T\bibinitperiod},
      }}%
      {{hash=DMC}{%
         family={Di\bibnamedelima Mario},
         familyi={D\bibinitperiod\bibinitdelim M\bibinitperiod},
         given={Carlo},
         giveni={C\bibinitperiod},
      }}%
      {{hash=FJR}{%
         family={Ferreira},
         familyi={F\bibinitperiod},
         given={J.\bibnamedelima Rafael},
         giveni={J\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=GBJ}{%
         family={Gersh},
         familyi={G\bibinitperiod},
         given={Bernard\bibnamedelima J.},
         giveni={B\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=GAK}{%
         family={Gitt},
         familyi={G\bibinitperiod},
         given={Anselm\bibnamedelima K.},
         giveni={A\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=HJS}{%
         family={Hulot},
         familyi={H\bibinitperiod},
         given={Jean-Sebastien},
         giveni={J\bibinithyphendelim S\bibinitperiod},
      }}%
      {{hash=MN}{%
         family={Marx},
         familyi={M\bibinitperiod},
         given={Nikolaus},
         giveni={N\bibinitperiod},
      }}%
      {{hash=OLH}{%
         family={Opie},
         familyi={O\bibinitperiod},
         given={Lionel\bibnamedelima H.},
         giveni={L\bibinitperiod\bibinitdelim H\bibinitperiod},
      }}%
      {{hash=PM}{%
         family={Pfisterer},
         familyi={P\bibinitperiod},
         given={Matthias},
         giveni={M\bibinitperiod},
      }}%
      {{hash=PE}{%
         family={Prescott},
         familyi={P\bibinitperiod},
         given={Eva},
         giveni={E\bibinitperiod},
      }}%
      {{hash=RF}{%
         family={Ruschitzka},
         familyi={R\bibinitperiod},
         given={Frank},
         giveni={F\bibinitperiod},
      }}%
      {{hash=SM}{%
         family={Sabaté},
         familyi={S\bibinitperiod},
         given={Manel},
         giveni={M\bibinitperiod},
      }}%
      {{hash=SR}{%
         family={Senior},
         familyi={S\bibinitperiod},
         given={Roxy},
         giveni={R\bibinitperiod},
      }}%
      {{hash=TDP}{%
         family={Taggart},
         familyi={T\bibinitperiod},
         given={David\bibnamedelima Paul},
         giveni={D\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=vdWEE}{%
         prefix={van\bibnamedelima der},
         prefixi={v\bibinitperiod\bibinitdelim d\bibinitperiod},
         family={Wall},
         familyi={W\bibinitperiod},
         given={Ernst\bibnamedelima E.},
         giveni={E\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=VCJ}{%
         family={Vrints},
         familyi={V\bibinitperiod},
         given={Christiaan\bibnamedelima J.M.},
         giveni={C\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=E}{%
         family={{ESC Committee for Practice Guidelines (CPG)}},
         familyi={E\bibinitperiod},
      }}%
      {{hash=ZJL}{%
         family={Zamorano},
         familyi={Z\bibinitperiod},
         given={Jose\bibnamedelima Luis},
         giveni={J\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=AS}{%
         family={Achenbach},
         familyi={A\bibinitperiod},
         given={Stephan},
         giveni={S\bibinitperiod},
      }}%
      {{hash=BH}{%
         family={Baumgartner},
         familyi={B\bibinitperiod},
         given={Helmut},
         giveni={H\bibinitperiod},
      }}%
      {{hash=BJJ}{%
         family={Bax},
         familyi={B\bibinitperiod},
         given={Jeroen\bibnamedelima J.},
         giveni={J\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=BH}{%
         family={Bueno},
         familyi={B\bibinitperiod},
         given={Héctor},
         giveni={H\bibinitperiod},
      }}%
      {{hash=DV}{%
         family={Dean},
         familyi={D\bibinitperiod},
         given={Veronica},
         giveni={V\bibinitperiod},
      }}%
      {{hash=DC}{%
         family={Deaton},
         familyi={D\bibinitperiod},
         given={Christi},
         giveni={C\bibinitperiod},
      }}%
      {{hash=EC}{%
         family={Erol},
         familyi={E\bibinitperiod},
         given={Cetin},
         giveni={C\bibinitperiod},
      }}%
      {{hash=FR}{%
         family={Fagard},
         familyi={F\bibinitperiod},
         given={Robert},
         giveni={R\bibinitperiod},
      }}%
      {{hash=FR}{%
         family={Ferrari},
         familyi={F\bibinitperiod},
         given={Roberto},
         giveni={R\bibinitperiod},
      }}%
      {{hash=HD}{%
         family={Hasdai},
         familyi={H\bibinitperiod},
         given={David},
         giveni={D\bibinitperiod},
      }}%
      {{hash=HAW}{%
         family={Hoes},
         familyi={H\bibinitperiod},
         given={Arno\bibnamedelima W.},
         giveni={A\bibinitperiod\bibinitdelim W\bibinitperiod},
      }}%
      {{hash=KP}{%
         family={Kirchhof},
         familyi={K\bibinitperiod},
         given={Paulus},
         giveni={P\bibinitperiod},
      }}%
      {{hash=KJ}{%
         family={Knuuti},
         familyi={K\bibinitperiod},
         given={Juhani},
         giveni={J\bibinitperiod},
      }}%
      {{hash=KP}{%
         family={Kolh},
         familyi={K\bibinitperiod},
         given={Philippe},
         giveni={P\bibinitperiod},
      }}%
      {{hash=LP}{%
         family={Lancellotti},
         familyi={L\bibinitperiod},
         given={Patrizio},
         giveni={P\bibinitperiod},
      }}%
      {{hash=LA}{%
         family={Linhart},
         familyi={L\bibinitperiod},
         given={Ales},
         giveni={A\bibinitperiod},
      }}%
      {{hash=NP}{%
         family={Nihoyannopoulos},
         familyi={N\bibinitperiod},
         given={Petros},
         giveni={P\bibinitperiod},
      }}%
      {{hash=PMF}{%
         family={Piepoli},
         familyi={P\bibinitperiod},
         given={Massimo\bibnamedelima F.},
         giveni={M\bibinitperiod\bibinitdelim F\bibinitperiod},
      }}%
      {{hash=PP}{%
         family={Ponikowski},
         familyi={P\bibinitperiod},
         given={Piotr},
         giveni={P\bibinitperiod},
      }}%
      {{hash=SPA}{%
         family={Sirnes},
         familyi={S\bibinitperiod},
         given={Per\bibnamedelima Anton},
         giveni={P\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=TJL}{%
         family={Tamargo},
         familyi={T\bibinitperiod},
         given={Juan\bibnamedelima Luis},
         giveni={J\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=TM}{%
         family={Tendera},
         familyi={T\bibinitperiod},
         given={Michal},
         giveni={M\bibinitperiod},
      }}%
      {{hash=TA}{%
         family={Torbicki},
         familyi={T\bibinitperiod},
         given={Adam},
         giveni={A\bibinitperiod},
      }}%
      {{hash=WW}{%
         family={Wijns},
         familyi={W\bibinitperiod},
         given={William},
         giveni={W\bibinitperiod},
      }}%
      {{hash=WS}{%
         family={Windecker},
         familyi={W\bibinitperiod},
         given={Stephan},
         giveni={S\bibinitperiod},
      }}%
      {{hash=D}{%
         family={{Document Reviewers}},
         familyi={D\bibinitperiod},
      }}%
      {{hash=KJ}{%
         family={Knuuti},
         familyi={K\bibinitperiod},
         given={Juhani},
         giveni={J\bibinitperiod},
      }}%
      {{hash=VM}{%
         family={Valgimigli},
         familyi={V\bibinitperiod},
         given={Marco},
         giveni={M\bibinitperiod},
      }}%
      {{hash=BH}{%
         family={Bueno},
         familyi={B\bibinitperiod},
         given={Héctor},
         giveni={H\bibinitperiod},
      }}%
      {{hash=CMJ}{%
         family={Claeys},
         familyi={C\bibinitperiod},
         given={Marc\bibnamedelima J.},
         giveni={M\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=DBN}{%
         family={Donner-Banzhoff},
         familyi={D\bibinithyphendelim B\bibinitperiod},
         given={Norbert},
         giveni={N\bibinitperiod},
      }}%
      {{hash=EC}{%
         family={Erol},
         familyi={E\bibinitperiod},
         given={Cetin},
         giveni={C\bibinitperiod},
      }}%
      {{hash=FH}{%
         family={Frank},
         familyi={F\bibinitperiod},
         given={Herbert},
         giveni={H\bibinitperiod},
      }}%
      {{hash=FBC}{%
         family={Funck-Brentano},
         familyi={F\bibinithyphendelim B\bibinitperiod},
         given={Christian},
         giveni={C\bibinitperiod},
      }}%
      {{hash=GO}{%
         family={Gaemperli},
         familyi={G\bibinitperiod},
         given={Oliver},
         giveni={O\bibinitperiod},
      }}%
      {{hash=GJJR}{%
         family={Gonzalez-Juanatey},
         familyi={G\bibinithyphendelim J\bibinitperiod},
         given={José\bibnamedelima R.},
         giveni={J\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=HM}{%
         family={Hamilos},
         familyi={H\bibinitperiod},
         given={Michalis},
         giveni={M\bibinitperiod},
      }}%
      {{hash=HD}{%
         family={Hasdai},
         familyi={H\bibinitperiod},
         given={David},
         giveni={D\bibinitperiod},
      }}%
      {{hash=HS}{%
         family={Husted},
         familyi={H\bibinitperiod},
         given={Steen},
         giveni={S\bibinitperiod},
      }}%
      {{hash=JSK}{%
         family={James},
         familyi={J\bibinitperiod},
         given={Stefan\bibnamedelima K.},
         giveni={S\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=KK}{%
         family={Kervinen},
         familyi={K\bibinitperiod},
         given={Kari},
         giveni={K\bibinitperiod},
      }}%
      {{hash=KP}{%
         family={Kolh},
         familyi={K\bibinitperiod},
         given={Philippe},
         giveni={P\bibinitperiod},
      }}%
      {{hash=KSD}{%
         family={Kristensen},
         familyi={K\bibinitperiod},
         given={Steen\bibnamedelima Dalby},
         giveni={S\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=LP}{%
         family={Lancellotti},
         familyi={L\bibinitperiod},
         given={Patrizio},
         giveni={P\bibinitperiod},
      }}%
      {{hash=MAP}{%
         family={Maggioni},
         familyi={M\bibinitperiod},
         given={Aldo\bibnamedelima Pietro},
         giveni={A\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=PMF}{%
         family={Piepoli},
         familyi={P\bibinitperiod},
         given={Massimo\bibnamedelima F.},
         giveni={M\bibinitperiod\bibinitdelim F\bibinitperiod},
      }}%
      {{hash=PAR}{%
         family={Pries},
         familyi={P\bibinitperiod},
         given={Axel\bibnamedelima R.},
         giveni={A\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=RF}{%
         family={Romeo},
         familyi={R\bibinitperiod},
         given={Francesco},
         giveni={F\bibinitperiod},
      }}%
      {{hash=RL}{%
         family={Rydén},
         familyi={R\bibinitperiod},
         given={Lars},
         giveni={L\bibinitperiod},
      }}%
      {{hash=SML}{%
         family={Simoons},
         familyi={S\bibinitperiod},
         given={Maarten\bibnamedelima L.},
         giveni={M\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=SPA}{%
         family={Sirnes},
         familyi={S\bibinitperiod},
         given={Per\bibnamedelima Anton},
         giveni={P\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=SPG}{%
         family={Steg},
         familyi={S\bibinitperiod},
         given={Ph.\bibnamedelima Gabriel},
         giveni={P\bibinitperiod\bibinitdelim G\bibinitperiod},
      }}%
      {{hash=TA}{%
         family={Timmis},
         familyi={T\bibinitperiod},
         given={Adam},
         giveni={A\bibinitperiod},
      }}%
      {{hash=WW}{%
         family={Wijns},
         familyi={W\bibinitperiod},
         given={William},
         giveni={W\bibinitperiod},
      }}%
      {{hash=WS}{%
         family={Windecker},
         familyi={W\bibinitperiod},
         given={Stephan},
         giveni={S\bibinitperiod},
      }}%
      {{hash=YA}{%
         family={Yildirir},
         familyi={Y\bibinitperiod},
         given={Aylin},
         giveni={A\bibinitperiod},
      }}%
      {{hash=ZJL}{%
         family={Zamorano},
         familyi={Z\bibinitperiod},
         given={Jose\bibnamedelima Luis},
         giveni={J\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
    }
    \strng{namehash}{MG+1}
  \strng{fullhash}{MGSUASAFACBABRCFCTDMCFJRGBJGAKHJSMNOLHPMPERFSMSRTDPvdWEEVCJEZJLASBHBJJBHDVDCECFRFRHDHAWKPKJKPLPLANPPMFPPSPATJLTMTAWWWSDKJVMBHCMJDBNECFHFBCGOGJJRHMHDHSJSKKKKPKSDLPMAPPMFPARRFRLSMLSPASPGTAWWWSYAZJL1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{shorttitle}
    \field{labelyear}{2013}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.1093/eurheartj/eht296
    \endverb
    \field{issn}{0195-668X}
    \field{number}{38}
    \field{pages}{2949\bibrangedash 3003}
    \field{shortjournal}{European Heart Journal}
    \field{shorttitle}{2013 {{ESC}} Guidelines on the Management of Stable
  Coronary Artery Disease}
    \field{title}{2013 {{ESC}} Guidelines on the Management of Stable Coronary
  Artery Disease: {{The Task Force}} on the Management of Stable Coronary
  Artery Disease of the {{European Society}} of {{Cardiology}}}
    \verb{url}
    \verb https://doi.org/10.1093/eurheartj/eht296
    \endverb
    \field{volume}{34}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\YTTELT65\\Task Force Members et a
    \verb l. - 2013 - 2013 ESC guidelines on the management of stable co.pdf;C\
    \verb :\\Users\\torbe\\Zotero\\storage\\QW48C67R\\442952.html
    \endverb
    \field{journaltitle}{European Heart Journal}
    \field{day}{07}
    \field{month}{10}
    \field{year}{2013}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{tuckerAnatomyBloodVessels2022a}{incollection}{}
    \name{author}{3}{}{%
      {{hash=TWD}{%
         family={Tucker},
         familyi={T\bibinitperiod},
         given={William\bibnamedelima D.},
         giveni={W\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=AY}{%
         family={Arora},
         familyi={A\bibinitperiod},
         given={Yingyot},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=MK}{%
         family={Mahajan},
         familyi={M\bibinitperiod},
         given={Kunal},
         giveni={K\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{StatPearls Publishing}}%
    }
    \strng{namehash}{TWD+1}
    \strng{fullhash}{TWDAYMK1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{labeldatesource}{}
    \field{abstract}{%
    The peripheral vascular system (PVS) includes all the blood vessels that
  exist outside the heart.~The peripheral vascular system is classified~as
  follows: The aorta and its branches: The arterioles. The capillaries. The
  venules and veins returning blood to the heart. The function and structure of
  each segment of the peripheral vascular system vary depending on the organ it
  supplies. Aside from capillaries, blood vessels are all made of three
  layers:~ The adventitia or outer layer which provides structural support and
  shape to the vessel. The tunica media or a middle layer composed of elastic
  and muscular tissue which regulates the internal diameter of the vessel. The
  tunic intima or an inner layer consisting of an endothelial lining which
  provides a frictionless pathway for the movement of blood. Within each layer,
  the amount of muscle and collagen fibrils varies,~depending on the size and
  location of the vessel.~ Arteries~ Arteries play a major role in nourishing
  organs with blood and nutrients. Arteries are always under high pressure. To
  accommodate this stress, they have an abundance of elastic tissue and less
  smooth muscle. The presence of elastin in the large blood vessels enables
  these vessels to increase in size and alter their diameter. When an artery
  reaches a particular organ, it undergoes a further division into smaller
  vessels that have more smooth muscle and less elastic tissue. As the diameter
  of the blood vessels decreases, the velocity of blood flow also diminishes.
  Estimates are that about 10\% to 15\% of the total blood volume is contained
  in the arterial system. This feature of high systemic pressure and low volume
  is typical of the arterial system.~~ ~There are two main types of arteries
  found in the body: (1) the elastic~arteries, and (2) the muscular arteries.
  Muscular arteries include the anatomically named arteries like the brachial
  artery, the radial artery, and the femoral artery, for example. Muscular
  arteries contain more smooth muscle cells in the tunica media layer than the
  elastic arteries.~Elastic arteries are those nearest the heart (aorta
  and~pulmonary arteries) that contain much more elastic tissue in the tunica
  media than muscular arteries. This feature of the elastic arteries allows
  them to maintain a relatively constant pressure gradient despite the constant
  pumping action of the heart.~~ Arterioles~ Arterioles provide blood to the
  organs and are chiefly composed of smooth muscle. The autonomic nervous
  system influences the diameter and shape of arterioles. They respond to the
  tissue's need for more nutrients/oxygen. Arterioles play a significant role
  in the systemic vascular resistance because of the lack of significant
  elastic tissue in the walls.~ The arterioles vary from~8~to 60 micrometers.
  The arterioles further subdivide into meta-arterioles.~ Capillaries~
  Capillaries are thin-walled vessels composed of a single endothelial layer.
  Because of the thin walls of the capillary, the exchange of nutrients and
  metabolites occurs primarily via diffusion. The arteriolar lumen regulates
  the flow of blood through the capillaries.~ Venules~ Venules are the smallest
  veins and receive blood from capillaries. They also play a role in the
  exchange of oxygen and nutrients for water products. There are post-capillary
  sphincters located~between the capillaries and venules. The venule is very
  thin-walled and easily prone to rupture with excessive volume.~ Veins~ Blood
  flows from venules into larger veins. Just like the arterial system, three
  layers make up the vein walls. But unlike the arteries, the venous pressure
  is low. Veins are thin-walled and are less elastic.~This feature permits the
  veins to~hold a very~high percentage of the blood in circulation.~The venous
  system can accommodate a large volume of blood at relatively low pressures, a
  feature termed~high capacitance. At any point in time, nearly three-fourths
  of the circulating blood volume is contained in the venous system. One can
  also find one-way valves inside veins that allow for blood flow, toward the
  heart,~in a forward direction.~Muscle contractions aid the blood flow in the
  leg veins. The forward blood flow from the lower extremities to the heart is
  also influenced by respiratory changes that affect pressure gradients in the
  abdomen and chest cavity. This pressure differential is highest during deep
  inspiration, but a small pressure differential is observable during the
  entire respiratory cycle.%
    }
    \field{booktitle}{{{StatPearls}}}
    \verb{eprint}
    \verb 29262226
    \endverb
    \field{title}{Anatomy, {{Blood Vessels}}}
    \verb{url}
    \verb http://www.ncbi.nlm.nih.gov/books/NBK470401/
    \endverb
    \field{langid}{english}
    \list{location}{1}{%
      {{Treasure Island (FL)}}%
    }
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\8UEUXC9F\\NBK470401.html
    \endverb
    \field{eprinttype}{pmid}
    \field{year}{2022}
    \field{urlday}{03}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{yapSixShadesVascular2021}{article}{useprefix}
    \name{author}{5}{}{%
      {{hash=YC}{%
         family={Yap},
         familyi={Y\bibinitperiod},
         given={Carmen},
         giveni={C\bibinitperiod},
      }}%
      {{hash=MA}{%
         family={Mieremet},
         familyi={M\bibinitperiod},
         given={Arnout},
         giveni={A\bibinitperiod},
      }}%
      {{hash=dVCJM}{%
         prefix={de},
         prefixi={d\bibinitperiod},
         family={Vries},
         familyi={V\bibinitperiod},
         given={Carlie J.\bibnamedelima M.},
         giveni={C\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim
  M\bibinitperiod},
      }}%
      {{hash=MD}{%
         family={Micha},
         familyi={M\bibinitperiod},
         given={Dimitra},
         giveni={D\bibinitperiod},
      }}%
      {{hash=dWV}{%
         prefix={de},
         prefixi={d\bibinitperiod},
         family={Waard},
         familyi={W\bibinitperiod},
         given={Vivian},
         giveni={V\bibinitperiod},
      }}%
    }
    \keyw{atherosclerosis,cardiovascular disease,myocytes,phenotype,smooth
  muscle}
    \strng{namehash}{YC+1}
    \strng{fullhash}{YCMAdVCJMMDdWV1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2021}
    \field{labeldatesource}{}
    \field{abstract}{%
    Multiple layers of vascular smooth muscle cells (vSMCs) are present in
  blood vessels forming the media of the vessel wall. vSMCs provide a vessel
  wall structure, enabling it to contract and relax, thus modulating blood
  flow. They also play a crucial role in the development of vascular diseases,
  such as atherosclerosis and aortic aneurysm formation. vSMCs display a
  remarkable high degree of plasticity. At present, the number of different
  vSMC phenotypes has only partially been characterized. By mapping vSMC
  phenotypes in detail and identifying triggers for phenotype switching, the
  relevance of the different phenotypes in vascular disease may be identified.
  Up until recently, vSMCs were classified as either contractile or
  dedifferentiated (ie, synthetic). However, single-cell RNA sequencing studies
  revealed such dedifferentiated arterial vSMCs to be highly diverse.
  Currently, no consensus exist about the number of vSMC phenotypes. Therefore,
  we reviewed the data from relevant single-cell RNA sequencing studies, and
  classified a total of 6 vSMC phenotypes. The central dedifferentiated vSMC
  type that we classified is the mesenchymal-like phenotype. Mesenchymal-like
  vSMCs subsequently seem to differentiate into fibroblast-like,
  macrophage-like, osteogenic-like, and adipocyte-like vSMCs, which contribute
  differentially to vascular disease. This phenotype switching between vSMCs
  requires the transcription factor KLF4 (Krüppel-like factor 4). Here, we
  performed an integrated analysis of the data about the recently identified
  vSMC phenotypes, their associated gene expression profiles, and previous vSMC
  knowledge to better understand the role of vSMC phenotype transitions in
  vascular pathology.%
    }
    \verb{doi}
    \verb 10.1161/ATVBAHA.121.316600
    \endverb
    \verb{eprint}
    \verb 34470477
    \endverb
    \field{issn}{1524-4636}
    \field{pages}{41:2693\bibrangedash 2707}
    \field{shortjournal}{Arterioscler Thromb Vasc Biol}
    \field{title}{Six {{Shades}} of {{Vascular Smooth Muscle Cells
  Illuminated}} by {{KLF4}} ({{Krüppel-Like Factor}} 4)}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\QQ6U5EQ8\\Yap et al. - 2021 - Six
    \verb  Shades of Vascular Smooth Muscle Cells Illumin.pdf
    \endverb
    \field{journaltitle}{Arteriosclerosis, Thrombosis, and Vascular Biology}
    \field{eprinttype}{pmid}
    \field{day}{02}
    \field{month}{09}
    \field{year}{2021}
  \endentry

  \entry{liuSmoothMuscleCell2019}{article}{}
    \name{author}{2}{}{%
      {{hash=LM}{%
         family={Liu},
         familyi={L\bibinitperiod},
         given={Mingjun},
         giveni={M\bibinitperiod},
      }}%
      {{hash=GD}{%
         family={Gomez},
         familyi={G\bibinitperiod},
         given={Delphine},
         giveni={D\bibinitperiod},
      }}%
    }
    \keyw{Animals,atherosclerosis,blood pressure,Cardiovascular Diseases,cell
  division,Cell Lineage,cell plasticity,Gene Expression
  Profiling,Humans,Muscle; Smooth; Vascular,Myocytes; Smooth
  Muscle,Phenotype,Sequence Analysis; RNA,Single-Cell Analysis,vascular
  remodeling,Vascular Remodeling}
    \strng{namehash}{LMGD1}
    \strng{fullhash}{LMGD1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2019}
    \field{labeldatesource}{}
    \field{abstract}{%
    Vascular smooth muscle cells (SMC) play a critical role in controlling
  blood pressure and blood distribution, as well as maintaining the structural
  integrity of the blood vessel. SMC also participate in physiological and
  pathological vascular remodeling due to their remarkable ability to
  dynamically modulate their phenotype. During the past decade, the development
  of in vivo fate mapping systems for unbiased identification and tracking of
  SMC and their progeny has led to major discoveries as well as the
  reevaluation of well-established concepts about the contribution of vascular
  SMC in major vascular diseases including atherosclerosis. Lineage tracing
  studies revealed that SMC undergoes multiple phenotypic transitions
  characterized by the expression of markers of alternative cell types (eg,
  macrophage-like and mesenchymal-stem cell-like) and populate injured or
  diseased vessels by oligoclonal expansion of a limited number of medial SMC.
  With the development of high-throughput transcriptomics and single-cell RNA
  sequencing (scRNAseq), the field is moving forward towards in-depth SMC
  phenotypic characterization. Herein, we review the major observations put
  forth by lineage and clonality tracing studies and the evidence in support
  for SMC phenotypic diversity in healthy and diseased vascular tissue. We will
  also discuss the opportunities and remaining challenges of combining lineage
  tracing and single-cell transcriptomics technologies, as well as studying the
  functional relevance of SMC phenotypic transitions and identifying the
  mechanisms controlling them.%
    }
    \verb{doi}
    \verb 10.1161/ATVBAHA.119.312131
    \endverb
    \verb{eprint}
    \verb 31340668
    \endverb
    \field{issn}{1524-4636}
    \field{number}{9}
    \field{pages}{1715\bibrangedash 1723}
    \field{shortjournal}{Arterioscler Thromb Vasc Biol}
    \field{title}{Smooth {{Muscle Cell Phenotypic Diversity}}}
    \field{volume}{39}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\UK9WTNVX\\Liu und Gomez - 2019 -
    \verb Smooth Muscle Cell Phenotypic Diversity.pdf
    \endverb
    \field{journaltitle}{Arteriosclerosis, Thrombosis, and Vascular Biology}
    \field{eprinttype}{pmid}
    \field{month}{09}
    \field{year}{2019}
  \endentry

  \entry{grootaertVascularSmoothMuscle2021}{article}{}
    \name{author}{2}{}{%
      {{hash=GMOJ}{%
         family={Grootaert},
         familyi={G\bibinitperiod},
         given={Mandy O\bibnamedelima J},
         giveni={M\bibinitperiod\bibinitdelim O\bibinitperiod\bibinitdelim
  J\bibinitperiod},
      }}%
      {{hash=BMR}{%
         family={Bennett},
         familyi={B\bibinitperiod},
         given={Martin\bibnamedelima R},
         giveni={M\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
    }
    \strng{namehash}{GMOJBMR1}
    \strng{fullhash}{GMOJBMR1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{shorttitle}
    \field{labelyear}{2021}
    \field{labeldatesource}{}
    \field{abstract}{%
    Vascular smooth muscle cells (VSMCs) are key participants in both early and
  late-stage atherosclerosis. VSMCs invade the early atherosclerotic lesion
  from the media, expanding lesions, but also forming a protective fibrous cap
  rich in extracellular matrix to cover the ‘necrotic’ core. Hence, VSMCs
  have been viewed as plaque-stabilizing, and decreased VSMC plaque
  content—often measured by expression of contractile markers—associated
  with increased plaque vulnerability. However, the emergence of
  lineage-tracing and transcriptomic studies has demonstrated that VSMCs
  comprise a much larger proportion of atherosclerotic plaques than originally
  thought, demonstrate multiple different phenotypes in vivo, and have roles
  that might be detrimental. VSMCs down-regulate contractile markers during
  atherosclerosis whilst adopting alternative phenotypes, including
  macrophage-like, foam cell-like, osteochondrogenic-like, myofibroblast-like,
  and mesenchymal stem cell-like. VSMC phenotypic switching can be studied in
  tissue culture, but also now in the media, fibrous cap and deep-core region,
  and markedly affects plaque formation and markers of stability. In this
  review, we describe the different VSMC plaque phenotypes and their presumed
  cellular and paracrine functions, the regulatory mechanisms that control VSMC
  plasticity, and their impact on atherogenesis and plaque stability.%
    }
    \verb{doi}
    \verb 10.1093/cvr/cvab046
    \endverb
    \field{issn}{0008-6363}
    \field{number}{11}
    \field{pages}{2326\bibrangedash 2339}
    \field{shortjournal}{Cardiovascular Research}
    \field{shorttitle}{Vascular Smooth Muscle Cells in Atherosclerosis}
    \field{title}{Vascular Smooth Muscle Cells in Atherosclerosis: Time for a
  Re-Assessment}
    \verb{url}
    \verb https://doi.org/10.1093/cvr/cvab046
    \endverb
    \field{volume}{117}
    \verb{file}
    \verb C\:\\Users\\torbe\\OneDrive\\Dokumente\\Uni\\Masterarbeit\\Paper\\oup
    \verb -accepted-manuscript-2021.pdf;C\:\\Users\\torbe\\Zotero\\storage\\MQ5
    \verb CDNR6\\6130794.html
    \endverb
    \field{journaltitle}{Cardiovascular Research}
    \field{day}{01}
    \field{month}{10}
    \field{year}{2021}
    \field{urlday}{13}
    \field{urlmonth}{10}
    \field{urlyear}{2021}
  \endentry

  \entry{goumansTGFvSignalingControl2018}{article}{}
    \name{author}{2}{}{%
      {{hash=GMJ}{%
         family={Goumans},
         familyi={G\bibinitperiod},
         given={Marie-José},
         giveni={M\bibinithyphendelim J\bibinitperiod},
      }}%
      {{hash=tDP}{%
         prefix={ten},
         prefixi={t\bibinitperiod},
         family={Dijke},
         familyi={D\bibinitperiod},
         given={Peter},
         giveni={P\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Cold Spring Harbor Lab}}%
    }
    \strng{namehash}{GMJDPt1}
    \strng{fullhash}{GMJDPt1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2018}
    \field{labeldatesource}{}
    \field{abstract}{%
    Genetic studies in animals and humans indicate that gene mutations that
  functionally perturb transforming growth factor β (TGF-β) signaling are
  linked to specific hereditary vascular syndromes, including
  Osler–Rendu–Weber disease or hereditary hemorrhagic telangiectasia and
  Marfan syndrome. Disturbed TGF-β signaling can also cause nonhereditary
  disorders like atherosclerosis and cardiac fibrosis. Accordingly, cell
  culture studies using endothelial cells or smooth muscle cells (SMCs),
  cultured alone or together in two- or three-dimensional cell culture assays,
  on plastic or embedded in matrix, have shown that TGF-β has a pivotal effect
  on endothelial and SMC proliferation, differentiation, migration, tube
  formation, and sprouting. Moreover, TGF-β can stimulate
  endothelial-to-mesenchymal transition, a process shown to be of key
  importance in heart valve cushion formation and in various pathological
  vascular processes. Here, we discuss the roles of TGF-β in vasculogenesis,
  angiogenesis, and lymphangiogenesis and the deregulation of TGF-β signaling
  in cardiovascular diseases.%
    }
    \verb{doi}
    \verb 10.1101/cshperspect.a022210
    \endverb
    \verb{eprint}
    \verb 28348036
    \endverb
    \field{issn}{, 1943-0264}
    \field{number}{2}
    \field{pages}{a022210}
    \field{shortjournal}{Cold Spring Harb Perspect Biol}
    \field{title}{{{TGF-β Signaling}} in {{Control}} of {{Cardiovascular
  Function}}}
    \verb{url}
    \verb http://cshperspectives.cshlp.org/content/10/2/a022210
    \endverb
    \field{volume}{10}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\HA5KI4YF\\Goumans und Dijke - 201
    \verb 8 - TGF-β Signaling in Control of Cardiovascular Funct.pdf;C\:\\User
    \verb s\\torbe\\Zotero\\storage\\5HICYZIN\\a022210.html
    \endverb
    \field{journaltitle}{Cold Spring Harbor Perspectives in Biology}
    \field{eprinttype}{pmid}
    \field{day}{02}
    \field{month}{01}
    \field{year}{2018}
    \field{urlday}{02}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{batlleTransformingGrowthFactorv2019}{article}{}
    \name{author}{2}{}{%
      {{hash=BE}{%
         family={Batlle},
         familyi={B\bibinitperiod},
         given={Eduard},
         giveni={E\bibinitperiod},
      }}%
      {{hash=MJ}{%
         family={Massagué},
         familyi={M\bibinitperiod},
         given={Joan},
         giveni={J\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Elsevier}}%
    }
    \strng{namehash}{BEMJ1}
    \strng{fullhash}{BEMJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2019}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.1016/j.immuni.2019.03.024
    \endverb
    \verb{eprint}
    \verb 30995507
    \endverb
    \field{issn}{1074-7613}
    \field{number}{4}
    \field{pages}{924\bibrangedash 940}
    \field{shortjournal}{Immunity}
    \field{title}{Transforming {{Growth Factor-β Signaling}} in {{Immunity}}
  and {{Cancer}}}
    \verb{url}
    \verb https://www.cell.com/immunity/abstract/S1074-7613(19)30141-4
    \endverb
    \field{volume}{50}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\XILQHY64\\Batlle und Massagué -
    \verb 2019 - Transforming Growth Factor-β Signaling in Immunity.pdf;C\:\\U
    \verb sers\\torbe\\Zotero\\storage\\IDVZDKYA\\S1074-7613(19)30141-4.html
    \endverb
    \field{journaltitle}{Immunity}
    \field{eprinttype}{pmid}
    \field{day}{16}
    \field{month}{04}
    \field{year}{2019}
    \field{urlday}{02}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{davis-dusenberyDownregulationKruppellikeFactor42011}{article}{}
    \name{author}{7}{}{%
      {{hash=DDBN}{%
         family={Davis-Dusenbery},
         familyi={D\bibinithyphendelim D\bibinitperiod},
         given={Brandi\bibnamedelima N.},
         giveni={B\bibinitperiod\bibinitdelim N\bibinitperiod},
      }}%
      {{hash=CMC}{%
         family={Chan},
         familyi={C\bibinitperiod},
         given={Mun\bibnamedelima Chun},
         giveni={M\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=RKE}{%
         family={Reno},
         familyi={R\bibinitperiod},
         given={Kelsey\bibnamedelima E.},
         giveni={K\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=WAS}{%
         family={Weisman},
         familyi={W\bibinitperiod},
         given={Alexandra\bibnamedelima S.},
         giveni={A\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=LMD}{%
         family={Layne},
         familyi={L\bibinitperiod},
         given={Matthew\bibnamedelima D.},
         giveni={M\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=LG}{%
         family={Lagna},
         familyi={L\bibinitperiod},
         given={Giorgio},
         giveni={G\bibinitperiod},
      }}%
      {{hash=HA}{%
         family={Hata},
         familyi={H\bibinitperiod},
         given={Akiko},
         giveni={A\bibinitperiod},
      }}%
    }
    \strng{namehash}{DDBN+1}
    \strng{fullhash}{DDBNCMCRKEWASLMDLGHA1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2011}
    \field{labeldatesource}{}
    \field{abstract}{%
    In the postnatal vasculature, fully differentiated and quiescent vascular
  smooth muscle cells (VSMCs) in a “contractile” phenotype are required for
  the normal regulation of vascular tone. The transforming growth factor-β
  (TGF-β) superfamily of growth factors (TGF-βs and bone morphogenetic
  proteins (BMPs)) are potent inducers of contractile phenotype and mediate (i)
  induction of contractile genes, and (ii) inhibition of VSMC growth and
  migration. Transcription of contractile genes is positively regulated by a
  regulatory DNA element called a CArG box. The CArG box is activated by the
  binding of serum response factor and its coactivators, myocardin (Myocd) or
  Myocd-related transcription factors (MRTFs). Krüppel-like factor-4 (KLF4) is
  known to inhibit activation of the CArG box. However, the potential role of
  KLF4 in the contractile activities of TGF-β or BMP has not been explored.
  Here, we demonstrate that TGF-β and BMP4 rapidly down-regulate KLF4 through
  induction of microRNA-143 (miR-143) and miR-145, which leads to a reduction
  of KLF4 transcripts and decreased KLF4 protein expression. Inhibition of
  miR-145 prevents down-regulation of KLF4 and activation of contractile genes
  by TGF-β or BMP4, suggesting that modulation of KLF4 is a prerequisite for
  induction of contractile genes by TGF-β and BMP4. Interestingly, both TGF-β
  and BMP4 activate transcription of the miR-143/145 gene cluster through the
  CArG box, however, TGF-β mediates this effect through induction of Myocd
  expression, whereas BMP4 utilizes nuclear translocation of MRTF-A. Thus, this
  study sheds light on both the similarities and the differences of TGF-β and
  BMP4 signaling in the regulation of KLF4 and contractile genes.%
    }
    \verb{doi}
    \verb 10.1074/jbc.M111.236950
    \endverb
    \verb{eprint}
    \verb 21673106
    \endverb
    \field{issn}{0021-9258}
    \field{number}{32}
    \field{pages}{28097\bibrangedash 28110}
    \field{shortjournal}{J Biol Chem}
    \field{title}{Down-Regulation of {{Krüppel-like Factor-4}} ({{KLF4}}) by
  {{MicroRNA-143}}/145 {{Is Critical}} for {{Modulation}} of {{Vascular Smooth
  Muscle Cell Phenotype}} by {{Transforming Growth Factor-β}} and {{Bone
  Morphogenetic Protein}} 4}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151055/
    \endverb
    \field{volume}{286}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\TUHVWKW5\\Davis-Dusenbery et al.
    \verb - 2011 - Down-regulation of Krüppel-like Factor-4 (KLF4) by.pdf
    \endverb
    \field{journaltitle}{The Journal of Biological Chemistry}
    \field{eprinttype}{pmid}
    \field{day}{12}
    \field{month}{08}
    \field{year}{2011}
    \field{urlday}{03}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{takahashiInductionPluripotentStem2007}{article}{}
    \name{author}{7}{}{%
      {{hash=TK}{%
         family={Takahashi},
         familyi={T\bibinitperiod},
         given={Kazutoshi},
         giveni={K\bibinitperiod},
      }}%
      {{hash=TK}{%
         family={Tanabe},
         familyi={T\bibinitperiod},
         given={Koji},
         giveni={K\bibinitperiod},
      }}%
      {{hash=OM}{%
         family={Ohnuki},
         familyi={O\bibinitperiod},
         given={Mari},
         giveni={M\bibinitperiod},
      }}%
      {{hash=NM}{%
         family={Narita},
         familyi={N\bibinitperiod},
         given={Megumi},
         giveni={M\bibinitperiod},
      }}%
      {{hash=IT}{%
         family={Ichisaka},
         familyi={I\bibinitperiod},
         given={Tomoko},
         giveni={T\bibinitperiod},
      }}%
      {{hash=TK}{%
         family={Tomoda},
         familyi={T\bibinitperiod},
         given={Kiichiro},
         giveni={K\bibinitperiod},
      }}%
      {{hash=YS}{%
         family={Yamanaka},
         familyi={Y\bibinitperiod},
         given={Shinya},
         giveni={S\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Elsevier}}%
    }
    \strng{namehash}{TK+1}
    \strng{fullhash}{TKTKOMNMITTKYS1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2007}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.1016/j.cell.2007.11.019
    \endverb
    \verb{eprint}
    \verb 18035408
    \endverb
    \field{issn}{0092-8674, 1097-4172}
    \field{number}{5}
    \field{pages}{861\bibrangedash 872}
    \field{shortjournal}{Cell}
    \field{title}{Induction of {{Pluripotent Stem Cells}} from {{Adult Human
  Fibroblasts}} by {{Defined Factors}}}
    \verb{url}
    \verb https://www.cell.com/cell/abstract/S0092-8674(07)01471-7
    \endverb
    \field{volume}{131}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\UE8NJ8Z8\\Takahashi et al. - 2007
    \verb  - Induction of Pluripotent Stem Cells from Adult Hum.pdf;C\:\\Users\
    \verb \torbe\\Zotero\\storage\\3GSM4URS\\S0092-8674(07)01471-7.html
    \endverb
    \field{journaltitle}{Cell}
    \field{eprinttype}{pmid}
    \field{day}{30}
    \field{month}{11}
    \field{year}{2007}
    \field{urlday}{03}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{panSingleCellGenomicsReveals2020}{article}{}
    \name{author}{22}{}{%
      {{hash=PH}{%
         family={Pan},
         familyi={P\bibinitperiod},
         given={Huize},
         giveni={H\bibinitperiod},
      }}%
      {{hash=XC}{%
         family={Xue},
         familyi={X\bibinitperiod},
         given={Chenyi},
         giveni={C\bibinitperiod},
      }}%
      {{hash=ABJ}{%
         family={Auerbach},
         familyi={A\bibinitperiod},
         given={Benjamin\bibnamedelima J.},
         giveni={B\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=FJ}{%
         family={Fan},
         familyi={F\bibinitperiod},
         given={Jiaxin},
         giveni={J\bibinitperiod},
      }}%
      {{hash=BAC}{%
         family={Bashore},
         familyi={B\bibinitperiod},
         given={Alexander\bibnamedelima C.},
         giveni={A\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=CJ}{%
         family={Cui},
         familyi={C\bibinitperiod},
         given={Jian},
         giveni={J\bibinitperiod},
      }}%
      {{hash=YDY}{%
         family={Yang},
         familyi={Y\bibinitperiod},
         given={Dina\bibnamedelima Y.},
         giveni={D\bibinitperiod\bibinitdelim Y\bibinitperiod},
      }}%
      {{hash=TSB}{%
         family={Trignano},
         familyi={T\bibinitperiod},
         given={Sarah\bibnamedelima B.},
         giveni={S\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=LW}{%
         family={Liu},
         familyi={L\bibinitperiod},
         given={Wen},
         giveni={W\bibinitperiod},
      }}%
      {{hash=SJ}{%
         family={Shi},
         familyi={S\bibinitperiod},
         given={Jianting},
         giveni={J\bibinitperiod},
      }}%
      {{hash=ICO}{%
         family={Ihuegbu},
         familyi={I\bibinitperiod},
         given={Chinyere\bibnamedelima O.},
         giveni={C\bibinitperiod\bibinitdelim O\bibinitperiod},
      }}%
      {{hash=BEC}{%
         family={Bush},
         familyi={B\bibinitperiod},
         given={Erin\bibnamedelima C.},
         giveni={E\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=WJ}{%
         family={Worley},
         familyi={W\bibinitperiod},
         given={Jeremy},
         giveni={J\bibinitperiod},
      }}%
      {{hash=VL}{%
         family={Vlahos},
         familyi={V\bibinitperiod},
         given={Lukas},
         giveni={L\bibinitperiod},
      }}%
      {{hash=LP}{%
         family={Laise},
         familyi={L\bibinitperiod},
         given={Pasquale},
         giveni={P\bibinitperiod},
      }}%
      {{hash=SRA}{%
         family={Solomon},
         familyi={S\bibinitperiod},
         given={Robert\bibnamedelima A.},
         giveni={R\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=CES}{%
         family={Connolly},
         familyi={C\bibinitperiod},
         given={Edward\bibnamedelima S.},
         giveni={E\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=CA}{%
         family={Califano},
         familyi={C\bibinitperiod},
         given={Andrea},
         giveni={A\bibinitperiod},
      }}%
      {{hash=SPA}{%
         family={Sims},
         familyi={S\bibinitperiod},
         given={Peter\bibnamedelima A.},
         giveni={P\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=ZH}{%
         family={Zhang},
         familyi={Z\bibinitperiod},
         given={Hanrui},
         giveni={H\bibinitperiod},
      }}%
      {{hash=LM}{%
         family={Li},
         familyi={L\bibinitperiod},
         given={Mingyao},
         giveni={M\bibinitperiod},
      }}%
      {{hash=RMP}{%
         family={Reilly},
         familyi={R\bibinitperiod},
         given={Muredach\bibnamedelima P.},
         giveni={M\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Heart Association}}%
    }
    \keyw{atherosclerosis,cardiovascular disease,retinoic acid
  signaling,single-cell RNA sequencing,smooth muscle cell}
    \strng{namehash}{PH+1}
    \strng{fullhash}{PHXCABJFJBACCJYDYTSBLWSJICOBECWJVLLPSRACESCASPAZHLMRMP1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2020}
    \field{labeldatesource}{}
    \field{abstract}{%
    Background: Smooth muscle cells (SMCs) play significant roles in
  atherosclerosis via phenotypic switching, a pathological process in which SMC
  dedifferentiation, migration, and transdifferentiation into other cell types.
  Yet how SMCs contribute to the pathophysiology of atherosclerosis remains
  elusive. Methods: To reveal the trajectories of SMC transdifferentiation
  during atherosclerosis and to identify molecular targets for disease therapy,
  we combined SMC fate mapping and single-cell RNA sequencing of both mouse and
  human atherosclerotic plaques. We also performed cell biology experiments on
  isolated SMC-derived cells, conducted integrative human genomics, and used
  pharmacological studies targeting SMC-derived cells both in vivo and in
  vitro. Results: We found that SMCs transitioned to an intermediate cell state
  during atherosclerosis, which was also found in human atherosclerotic plaques
  of carotid and coronary arteries. SMC-derived intermediate cells, termed
  “SEM” cells (stem cell, endothelial cell, monocyte), were multipotent and
  could differentiate into macrophage-like and fibrochondrocyte-like cells, as
  well as return toward the SMC phenotype. Retinoic acid (RA) signaling was
  identified as a regulator of SMC to SEM cell transition, and RA signaling was
  dysregulated in symptomatic human atherosclerosis. Human genomics revealed
  enrichment of genome-wide association study signals for coronary artery
  disease in RA signaling target gene loci and correlation between coronary
  artery disease risk alleles and repressed expression of these genes.
  Activation of RA signaling by all-trans RA, an anticancer drug for acute
  promyelocytic leukemia, blocked SMC transition to SEM cells, reduced
  atherosclerotic burden, and promoted fibrous cap stability. Conclusions:
  Integration of cell-specific fate mapping, single-cell genomics, and human
  genetics adds novel insights into the complexity of SMC biology and reveals
  regulatory pathways for therapeutic targeting of SMC transitions in
  atherosclerotic cardiovascular disease.%
    }
    \verb{doi}
    \verb 10.1161/CIRCULATIONAHA.120.048378
    \endverb
    \field{number}{21}
    \field{pages}{2060\bibrangedash 2075}
    \field{title}{Single-{{Cell Genomics Reveals}} a {{Novel Cell State During
  Smooth Muscle Cell Phenotypic Switching}} and {{Potential Therapeutic
  Targets}} for {{Atherosclerosis}} in {{Mouse}} and {{Human}}}
    \verb{url}
    \verb https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048378
    \endverb
    \field{volume}{142}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\TE6BRI76\\Pan et al. - 2020 - Sin
    \verb gle-Cell Genomics Reveals a Novel Cell State Du.pdf
    \endverb
    \field{journaltitle}{Circulation}
    \field{day}{24}
    \field{month}{11}
    \field{year}{2020}
    \field{urlday}{03}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{chenPlateletderivedGrowthFactors2013}{article}{}
    \name{author}{3}{}{%
      {{hash=CPH}{%
         family={Chen},
         familyi={C\bibinitperiod},
         given={Po-Han},
         giveni={P\bibinithyphendelim H\bibinitperiod},
      }}%
      {{hash=CX}{%
         family={Chen},
         familyi={C\bibinitperiod},
         given={Xiaoyan},
         giveni={X\bibinitperiod},
      }}%
      {{hash=HX}{%
         family={He},
         familyi={H\bibinitperiod},
         given={Xiaolin},
         giveni={X\bibinitperiod},
      }}%
    }
    \strng{namehash}{CPH+1}
    \strng{fullhash}{CPHCXHX1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{shorttitle}
    \field{labelyear}{2013}
    \field{labeldatesource}{}
    \field{abstract}{%
    The four types of platelet-derived growth factors (PDGFs) and the two types
  of PDGF receptors (PDGFRs, which belong to class III receptor tyrosine
  kinases) have important functions in the development of connective tissue
  cells. Recent structural studies have revealed novel mechanisms of PDGFs in
  propeptide loading and receptor recognition/activation. The detailed
  structural understanding of PDGF-PDGFR signaling has provided a template that
  can aid therapeutic intervention to counteract the aberrant signaling of this
  normally silent pathway, especially in proliferative diseases such as cancer.
  This review summarizes the advances in the PDGF system with a focus on
  relating the structural and functional understandings, and discusses the
  basic aspects of PDGFs and PDGFRs, the mechanisms of activation, and the
  insights into the therapeutic antagonism of PDGFRs.%
    }
    \verb{doi}
    \verb 10.1016/j.bbapap.2012.10.015
    \endverb
    \verb{eprint}
    \verb 23137658
    \endverb
    \field{issn}{0006-3002}
    \field{number}{10}
    \field{pages}{2176\bibrangedash 2186}
    \field{shortjournal}{Biochim Biophys Acta}
    \field{shorttitle}{Platelet-Derived Growth Factors and Their Receptors}
    \field{title}{Platelet-Derived Growth Factors and Their Receptors:
  Structural and Functional Perspectives}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612563/
    \endverb
    \field{volume}{1834}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\DCLKLNYI\\Chen et al. - 2013 - Pl
    \verb atelet-derived growth factors and their receptor.pdf
    \endverb
    \field{journaltitle}{Biochimica et biophysica acta}
    \field{eprinttype}{pmid}
    \field{month}{10}
    \field{year}{2013}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{heldinTargetingPDGFSignaling2013}{article}{}
    \name{author}{1}{}{%
      {{hash=HCH}{%
         family={Heldin},
         familyi={H\bibinitperiod},
         given={Carl-Henrik},
         giveni={C\bibinithyphendelim H\bibinitperiod},
      }}%
    }
    \keyw{Imatinib,Nilotinib,Pazopanib,Sorafenib,Sunitinib}
    \strng{namehash}{HCH1}
    \strng{fullhash}{HCH1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2013}
    \field{labeldatesource}{}
    \field{abstract}{%
    Platelet-derived growth factor (PDGF) isoforms and PDGF receptors have
  important functions in the regulation of growth and survival of certain cell
  types during embryonal development and e.g. tissue repair in the adult.
  Overactivity of PDGF receptor signaling, by overexpression or mutational
  events, may drive tumor cell growth. In addition, pericytes of the
  vasculature and fibroblasts and myofibroblasts of the stroma of solid tumors
  express PDGF receptors, and PDGF stimulation of such cells promotes
  tumorigenesis. Inhibition of PDGF receptor signaling has proven to useful for
  the treatment of patients with certain rare tumors. Whether treatment with
  PDGF/PDGF receptor antagonists will be beneficial for more common
  malignancies is the subject for ongoing studies.%
    }
    \verb{doi}
    \verb 10.1186/1478-811X-11-97
    \endverb
    \field{issn}{1478-811X}
    \field{number}{1}
    \field{pages}{97}
    \field{shortjournal}{Cell Communication and Signaling}
    \field{title}{Targeting the {{PDGF}} Signaling Pathway in Tumor Treatment}
    \verb{url}
    \verb https://doi.org/10.1186/1478-811X-11-97
    \endverb
    \field{volume}{11}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\TK6UBG4T\\Heldin - 2013 - Targeti
    \verb ng the PDGF signaling pathway in tumor trea.pdf;C\:\\Users\\torbe\\Zo
    \verb tero\\storage\\XCGS8C2U\\1478-811X-11-97.html
    \endverb
    \field{journaltitle}{Cell Communication and Signaling}
    \field{day}{20}
    \field{month}{12}
    \field{year}{2013}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{huTargetingPlateletderivedGrowth2015}{article}{}
    \name{author}{2}{}{%
      {{hash=HW}{%
         family={Hu},
         familyi={H\bibinitperiod},
         given={Weining},
         giveni={W\bibinitperiod},
      }}%
      {{hash=HY}{%
         family={Huang},
         familyi={H\bibinitperiod},
         given={Yu},
         giveni={Y\bibinitperiod},
      }}%
    }
    \keyw{cardiovascular disease,platelet-derived growth factor}
    \strng{namehash}{HWHY1}
    \strng{fullhash}{HWHY1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2015}
    \field{labeldatesource}{}
    \field{abstract}{%
    Over 40 years of studies on platelet-derived growth factors (PDGFs) and
  their receptors, the molecular mechanisms and functional roles of PDGFs in
  the development of embryos and human diseases, especially in cancer, are
  gradually being unravelled. PDGF-BB was approved by the United States Food
  and Drug Administration for promoting wound healing, while imatinib, which
  selectively inhibits tyrosine kinase activity of PDGF receptors (PDGFR), has
  been prescribed to treat patients with gastrointestinal stromal tumor and
  chronic eosinophilic leukaemia. However, much less often have these drugs
  been studied in relation to cardiovascular diseases. This brief review mainly
  describes the role of PDGF signalling in cardiovascular pathogenesis such as
  atherosclerosis, pulmonary arterial hypertension, diabetes, angiogenesis and
  inflammation with an emphasis on how PDGFs function in these situations and
  what components might serve as potential therapeutic targets against
  cardio-metabolic dysfunction.%
    }
    \verb{doi}
    \verb 10.1111/1440-1681.12478
    \endverb
    \field{issn}{1440-1681}
    \field{number}{12}
    \field{pages}{1221\bibrangedash 1224}
    \field{title}{Targeting the Platelet-Derived Growth Factor Signalling in
  Cardiovascular Disease}
    \verb{url}
    \verb https://onlinelibrary.wiley.com/doi/abs/10.1111/1440-1681.12478
    \endverb
    \field{volume}{42}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Downloads\\hu2015.pdf;C\:\\Users\\torbe\\Zotero\\s
    \verb torage\\J8JSZRLI\\1440-1681.html
    \endverb
    \field{journaltitle}{Clinical and Experimental Pharmacology and Physiology}
    \field{annotation}{%
    \_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.12478%
    }
    \field{year}{2015}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{andraeRolePlateletderivedGrowth2008}{article}{}
    \name{author}{3}{}{%
      {{hash=AJ}{%
         family={Andrae},
         familyi={A\bibinitperiod},
         given={Johanna},
         giveni={J\bibinitperiod},
      }}%
      {{hash=GR}{%
         family={Gallini},
         familyi={G\bibinitperiod},
         given={Radiosa},
         giveni={R\bibinitperiod},
      }}%
      {{hash=BC}{%
         family={Betsholtz},
         familyi={B\bibinitperiod},
         given={Christer},
         giveni={C\bibinitperiod},
      }}%
    }
    \strng{namehash}{AJ+1}
    \strng{fullhash}{AJGRBC1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2008}
    \field{labeldatesource}{}
    \field{abstract}{%
    Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have
  served as prototypes for growth factor and receptor tyrosine kinase function
  for more than 25 years. Studies of PDGFs and PDGFRs in animal development
  have revealed roles for PDGFR-α signaling in gastrulation and in the
  development of the cranial and cardiac neural crest, gonads, lung, intestine,
  skin, CNS, and skeleton. Similarly, roles for PDGFR-β signaling have been
  established in blood vessel formation and early hematopoiesis. PDGF signaling
  is implicated in a range of diseases. Autocrine activation of PDGF signaling
  pathways is involved in certain gliomas, sarcomas, and leukemias. Paracrine
  PDGF signaling is commonly observed in epithelial cancers, where it triggers
  stromal recruitment and may be involved in epithelial–mesenchymal
  transition, thereby affecting tumor growth, angiogenesis, invasion, and
  metastasis. PDGFs drive pathological mesenchymal responses in vascular
  disorders such as atherosclerosis, restenosis, pulmonary hypertension, and
  retinal diseases, as well as in fibrotic diseases, including pulmonary
  fibrosis, liver cirrhosis, scleroderma, glomerulosclerosis, and cardiac
  fibrosis. We review basic aspects of the PDGF ligands and receptors, their
  developmental and pathological functions, principles of their pharmacological
  inhibition, and results using PDGF pathway-inhibitory or stimulatory drugs in
  preclinical and clinical contexts.%
    }
    \verb{doi}
    \verb 10.1101/gad.1653708
    \endverb
    \verb{eprint}
    \verb 18483217
    \endverb
    \field{issn}{0890-9369}
    \field{number}{10}
    \field{pages}{1276\bibrangedash 1312}
    \field{shortjournal}{Genes Dev}
    \field{title}{Role of Platelet-Derived Growth Factors in Physiology and
  Medicine}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732412/
    \endverb
    \field{volume}{22}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\SZFER79B\\Andrae et al. - 2008 -
    \verb Role of platelet-derived growth factors in physiol.pdf
    \endverb
    \field{journaltitle}{Genes \& Development}
    \field{eprinttype}{pmid}
    \field{day}{15}
    \field{month}{05}
    \field{year}{2008}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{leveenMiceDeficientPDGF1994}{article}{}
    \name{author}{6}{}{%
      {{hash=LP}{%
         family={Levéen},
         familyi={L\bibinitperiod},
         given={P.},
         giveni={P\bibinitperiod},
      }}%
      {{hash=PM}{%
         family={Pekny},
         familyi={P\bibinitperiod},
         given={M.},
         giveni={M\bibinitperiod},
      }}%
      {{hash=GMS}{%
         family={Gebre-Medhin},
         familyi={G\bibinithyphendelim M\bibinitperiod},
         given={S.},
         giveni={S\bibinitperiod},
      }}%
      {{hash=SB}{%
         family={Swolin},
         familyi={S\bibinitperiod},
         given={B.},
         giveni={B\bibinitperiod},
      }}%
      {{hash=LE}{%
         family={Larsson},
         familyi={L\bibinitperiod},
         given={E.},
         giveni={E\bibinitperiod},
      }}%
      {{hash=BC}{%
         family={Betsholtz},
         familyi={B\bibinitperiod},
         given={C.},
         giveni={C\bibinitperiod},
      }}%
    }
    \keyw{Anemia,Animals,Arteries,Base Sequence,DNA Probes,Erythroblastosis;
  Fetal,Female,Fetal Death,Heart Defects; Congenital,Hematologic
  Diseases,Humans,Infant; Newborn,Kidney,Male,Mice,Mice; Inbred C57BL,Mice;
  Inbred CBA,Mice; Knockout,Molecular Sequence Data,Phenotype,Platelet-Derived
  Growth Factor,Pregnancy,Sequence Deletion,Thrombocytopenia}
    \strng{namehash}{LP+1}
    \strng{fullhash}{LPPMGMSSBLEBC1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{1994}
    \field{labeldatesource}{}
    \field{abstract}{%
    Platelet-derived growth factor (PDGF) affects the growth, migration, and
  function in vitro of mesenchymal cells, but little is known about its normal
  physiological functions in vivo. We show here that mice deficient for PDGF B
  die perinatally and display several anatomical and histological
  abnormalities. Kidney glomerular tufts do not form, apparently because of
  absence of mesangial cells. Instead, a single or a few distended capillary
  loops fill the glomerular space. The heart and some large arteries dilate in
  late-stage embryos. Most PDGF B mutant embryos develop fatal hemorrhages just
  prior to birth. Their hematological status includes erythroblastosis,
  macrocytic anemia, and thrombocytopenia. On the basis of these findings, we
  conclude that PDGF B has crucial roles in vivo in establishing certain renal
  and circulatory functions.%
    }
    \verb{doi}
    \verb 10.1101/gad.8.16.1875
    \endverb
    \verb{eprint}
    \verb 7958863
    \endverb
    \field{issn}{0890-9369}
    \field{number}{16}
    \field{pages}{1875\bibrangedash 1887}
    \field{shortjournal}{Genes Dev}
    \field{title}{Mice Deficient for {{PDGF B}} Show Renal, Cardiovascular, and
  Hematological Abnormalities}
    \field{volume}{8}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\X99Z8BZL\\Levéen et al. - 1994 -
    \verb  Mice deficient for PDGF B show renal, cardiovascul.pdf
    \endverb
    \field{journaltitle}{Genes \& Development}
    \field{eprinttype}{pmid}
    \field{day}{15}
    \field{month}{08}
    \field{year}{1994}
  \endentry

  \entry{robsonPlateletderivedGrowthFactor1992}{article}{}
    \name{author}{5}{}{%
      {{hash=RMC}{%
         family={Robson},
         familyi={R\bibinitperiod},
         given={M.\bibnamedelima C.},
         giveni={M\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=PLG}{%
         family={Phillips},
         familyi={P\bibinitperiod},
         given={L.\bibnamedelima G.},
         giveni={L\bibinitperiod\bibinitdelim G\bibinitperiod},
      }}%
      {{hash=TA}{%
         family={Thomason},
         familyi={T\bibinitperiod},
         given={A.},
         giveni={A\bibinitperiod},
      }}%
      {{hash=RLE}{%
         family={Robson},
         familyi={R\bibinitperiod},
         given={L.\bibnamedelima E.},
         giveni={L\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=PGF}{%
         family={Pierce},
         familyi={P\bibinitperiod},
         given={G.\bibnamedelima F.},
         giveni={G\bibinitperiod\bibinitdelim F\bibinitperiod},
      }}%
    }
    \keyw{Administration; Topical,Adult,Becaplermin,Combined Modality
  Therapy,Double-Blind Method,Drug Administration Schedule,Follow-Up
  Studies,Humans,Middle Aged,Platelet-Derived Growth Factor,Pressure
  Ulcer,Proto-Oncogene Proteins c-sis,Recombinant Proteins,Wound Healing}
    \strng{namehash}{RMC+1}
    \strng{fullhash}{RMCPLGTARLEPGF1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{1992}
    \field{labeldatesource}{}
    \field{abstract}{%
    A randomised, phase I/II, double-blind, placebo-controlled study was
  designed to assess the effect of topically applied recombinant human BB
  homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic
  pressure ulcers. Twenty patients were randomly allocated daily treatment for
  28 days with 1, 10, or 100 micrograms/ml rPDGF-BB (0.01, 0.1, or 1.0
  micrograms per cm2 ulcer area) or placebo. Patients treated with 100
  micrograms/ml rPDGF-BB showed a greater healing response than the placebo
  group, but the lower doses had little effect. After 28 days, ulcers treated
  with 100 micrograms/ml rPDGF-BB were smaller than those treated with placebo
  (mean [SE] volume 6.4 [4.0] vs 21.8 [5.6]\% of day 0 volume). There were no
  toxic effects. These preliminary findings suggest that rPDGF-BB is a potent
  wound-healing agent in soft tissue.%
    }
    \verb{doi}
    \verb 10.1016/0140-6736(92)90143-q
    \endverb
    \verb{eprint}
    \verb 1345953
    \endverb
    \field{issn}{0140-6736}
    \field{number}{8784}
    \field{pages}{23\bibrangedash 25}
    \field{shortjournal}{Lancet}
    \field{title}{Platelet-Derived Growth Factor {{BB}} for the Treatment of
  Chronic Pressure Ulcers}
    \field{volume}{339}
    \field{langid}{english}
    \field{journaltitle}{Lancet (London, England)}
    \field{eprinttype}{pmid}
    \field{day}{04}
    \field{month}{01}
    \field{year}{1992}
  \endentry

  \entry{rainesPDGFCardiovascularDisease2004}{article}{}
    \name{author}{1}{}{%
      {{hash=REW}{%
         family={Raines},
         familyi={R\bibinitperiod},
         given={Elaine\bibnamedelima W},
         giveni={E\bibinitperiod\bibinitdelim W\bibinitperiod},
      }}%
    }
    \strng{namehash}{REW1}
    \strng{fullhash}{REW1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2004}
    \field{labeldatesource}{}
    \field{abstract}{%
    Platelet-derived growth factor (PDGF) was identified in a search for serum
  factors that stimulate smooth muscle cell (SMC) proliferation. During the
  development of lesions of atherosclerosis that can ultimately lead to vessel
  occlusion, SMC are stimulated by inflammatory factors to migrate from their
  normal location in the media. They accumulate within the forming lesion where
  they contribute to lesion expansion by proliferation and deposition of
  extracellular matrix. Different genetic manipulations in vascular cells
  combined with various inhibitory strategies have provided strong evidence for
  PDGF playing a prominent role in the migration of SMC into the neointima
  following acute injury and in atherosclerosis. Other activities of PDGF
  identified in vivo suggest additional functions for PDGF in the pathogenesis
  of cardiovascular disease.%
    }
    \verb{doi}
    \verb 10.1016/j.cytogfr.2004.03.004
    \endverb
    \verb{eprint}
    \verb 15207815
    \endverb
    \field{issn}{1879-0305}
    \field{number}{4}
    \field{pages}{237\bibrangedash 254}
    \field{shortjournal}{Cytokine Growth Factor Rev}
    \field{title}{{{PDGF}} and Cardiovascular Disease}
    \verb{url}
    \verb https://doi.org/10.1016/j.cytogfr.2004.03.004
    \endverb
    \field{volume}{15}
    \field{langid}{english}
    \field{journaltitle}{Cytokine \& growth factor reviews}
    \field{eprinttype}{pmid}
    \field{day}{01}
    \field{month}{08}
    \field{year}{2004}
    \field{urlday}{02}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{hePDGFRvSignallingRegulates2015}{article}{}
    \name{author}{7}{}{%
      {{hash=HC}{%
         family={He},
         familyi={H\bibinitperiod},
         given={Chaoyong},
         giveni={C\bibinitperiod},
      }}%
      {{hash=MSC}{%
         family={Medley},
         familyi={M\bibinitperiod},
         given={Shayna\bibnamedelima C.},
         giveni={S\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=HT}{%
         family={Hu},
         familyi={H\bibinitperiod},
         given={Taishan},
         giveni={T\bibinitperiod},
      }}%
      {{hash=HME}{%
         family={Hinsdale},
         familyi={H\bibinitperiod},
         given={Myron\bibnamedelima E.},
         giveni={M\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=LF}{%
         family={Lupu},
         familyi={L\bibinitperiod},
         given={Florea},
         giveni={F\bibinitperiod},
      }}%
      {{hash=VR}{%
         family={Virmani},
         familyi={V\bibinitperiod},
         given={Renu},
         giveni={R\bibinitperiod},
      }}%
      {{hash=OLE}{%
         family={Olson},
         familyi={O\bibinitperiod},
         given={Lorin\bibnamedelima E.},
         giveni={L\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Atherosclerosis,Genetics research,Inflammation,Metabolic diseases}
    \strng{namehash}{HC+1}
    \strng{fullhash}{HCMSCHTHMELFVROLE1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2015}
    \field{labeldatesource}{}
    \field{abstract}{%
    Platelet-derived growth factor (PDGF) is a mitogen and chemoattractant for
  vascular smooth muscle cells (VSMCs). However, the direct effects of PDGF
  receptor β (PDGFRβ) activation on VSMCs have not been studied in the
  context of atherosclerosis. Here we present a new mouse model of
  atherosclerosis with an activating mutation in PDGFRβ. Increased PDGFRβ
  signalling induces chemokine secretion and leads to leukocyte accumulation in
  the adventitia and media of the aorta. Furthermore, PDGFRβD849V amplifies
  and accelerates atherosclerosis in hypercholesterolemic ApoE−/− or
  Ldlr−/− mice. Intriguingly, increased PDGFRβ signalling promotes
  advanced plaque formation at novel sites in the thoracic aorta and coronary
  arteries. However, deletion of the PDGFRβ-activated transcription factor
  STAT1 in VSMCs alleviates inflammation of the arterial wall and reduces
  plaque burden. These results demonstrate that PDGFRβ pathway activation has
  a profound effect on vascular disease and support the conclusion that
  inflammation in the outer arterial layers is a driving process for
  atherosclerosis.%
    }
    \verb{doi}
    \verb 10.1038/ncomms8770
    \endverb
    \field{issn}{2041-1723}
    \field{issue}{1}
    \field{number}{1}
    \field{pages}{7770}
    \field{shortjournal}{Nat Commun}
    \field{title}{{{PDGFRβ}} Signalling Regulates Local Inflammation and
  Synergizes with Hypercholesterolaemia to Promote Atherosclerosis}
    \verb{url}
    \verb https://www.nature.com/articles/ncomms8770
    \endverb
    \field{volume}{6}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\DMWA256L\\He et al. - 2015 - PDGF
    \verb Rβ signalling regulates local inflammation and.pdf;C\:\\Users\\torbe
    \verb \\Zotero\\storage\\E8TY9XIX\\ncomms8770.html
    \endverb
    \field{journaltitle}{Nature Communications}
    \field{day}{17}
    \field{month}{07}
    \field{year}{2015}
    \field{urlday}{06}
    \field{urlmonth}{05}
    \field{urlyear}{2022}
  \endentry

  \entry{newmanMultipleCellTypes2021}{article}{}
    \name{author}{17}{}{%
      {{hash=NAAC}{%
         family={Newman},
         familyi={N\bibinitperiod},
         given={Alexandra A.\bibnamedelima C.},
         giveni={A\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim
  C\bibinitperiod},
      }}%
      {{hash=SV}{%
         family={Serbulea},
         familyi={S\bibinitperiod},
         given={Vlad},
         giveni={V\bibinitperiod},
      }}%
      {{hash=BRA}{%
         family={Baylis},
         familyi={B\bibinitperiod},
         given={Richard\bibnamedelima A.},
         giveni={R\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=SLS}{%
         family={Shankman},
         familyi={S\bibinitperiod},
         given={Laura\bibnamedelima S.},
         giveni={L\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=BX}{%
         family={Bradley},
         familyi={B\bibinitperiod},
         given={Xenia},
         giveni={X\bibinitperiod},
      }}%
      {{hash=AGF}{%
         family={Alencar},
         familyi={A\bibinitperiod},
         given={Gabriel\bibnamedelima F.},
         giveni={G\bibinitperiod\bibinitdelim F\bibinitperiod},
      }}%
      {{hash=OK}{%
         family={Owsiany},
         familyi={O\bibinitperiod},
         given={Katherine},
         giveni={K\bibinitperiod},
      }}%
      {{hash=DRA}{%
         family={Deaton},
         familyi={D\bibinitperiod},
         given={Rebecca\bibnamedelima A.},
         giveni={R\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=KS}{%
         family={Karnewar},
         familyi={K\bibinitperiod},
         given={Santosh},
         giveni={S\bibinitperiod},
      }}%
      {{hash=SS}{%
         family={Shamsuzzaman},
         familyi={S\bibinitperiod},
         given={Sohel},
         giveni={S\bibinitperiod},
      }}%
      {{hash=SA}{%
         family={Salamon},
         familyi={S\bibinitperiod},
         given={Anita},
         giveni={A\bibinitperiod},
      }}%
      {{hash=RMS}{%
         family={Reddy},
         familyi={R\bibinitperiod},
         given={Mahima\bibnamedelima S.},
         giveni={M\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=GL}{%
         family={Guo},
         familyi={G\bibinitperiod},
         given={Liang},
         giveni={L\bibinitperiod},
      }}%
      {{hash=FA}{%
         family={Finn},
         familyi={F\bibinitperiod},
         given={Aloke},
         giveni={A\bibinitperiod},
      }}%
      {{hash=VR}{%
         family={Virmani},
         familyi={V\bibinitperiod},
         given={Renu},
         giveni={R\bibinitperiod},
      }}%
      {{hash=COA}{%
         family={Cherepanova},
         familyi={C\bibinitperiod},
         given={Olga\bibnamedelima A.},
         giveni={O\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=OGK}{%
         family={Owens},
         familyi={O\bibinitperiod},
         given={Gary\bibnamedelima K.},
         giveni={G\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \strng{namehash}{NAAC+1}
    \strng{fullhash}{NAACSVBRASLSBXAGFOKDRAKSSSSARMSGLFAVRCOAOGK1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2021}
    \field{extradate}{1}
    \field{labeldatesource}{}
    \field{abstract}{%
    Stable atherosclerotic plaques are characterized by a thick, extracellular
  matrix-rich fibrous cap populated by protective ACTA2+ myofibroblast
  (MF)-like cells, assumed to be almost exclusively derived from smooth muscle
  cells (SMCs). Herein, we show that in murine and human lesions, 20\% to 40\%
  of ACTA2+ fibrous cap cells, respectively, are derived from non-SMC sources,
  including endothelial cells (ECs) or macrophages that have undergone an
  endothelial-to-mesenchymal transition (EndoMT) or a macrophage-to-mesenchymal
  transition (MMT). In addition, we show that SMC-specific knockout of the
  Pdgfrb gene, which encodes platelet-derived growth factor receptor beta
  (PDGFRβ), in Apoe−/− mice fed a Western diet for 18 weeks resulted in
  brachiocephalic artery lesions nearly devoid of SMCs but with no changes in
  lesion size, remodelling or indices of stability, including the percentage of
  ACTA2+ fibrous cap cells. However, prolonged Western diet feeding of SMC
  Pdgfrb-knockout mice resulted in reduced indices of stability, indicating
  that EndoMT- and MMT-derived MFs cannot compensate indefinitely for loss of
  SMC-derived MFs. Using single-cell and bulk RNA-sequencing analyses of the
  brachiocephalic artery region and in vitro models, we provide evidence that
  SMC-to-MF transitions are induced by PDGF and transforming growth factor-β
  and dependent on aerobic glycolysis, while EndoMT is induced by
  interleukin-1β and transforming growth factor-β. Together, we provide
  evidence that the ACTA2+ fibrous cap originates from a tapestry of cell
  types, which transition to an MF-like state through distinct signalling
  pathways that are either dependent on or associated with extensive metabolic
  reprogramming.%
    }
    \verb{doi}
    \verb 10.1038/s42255-020-00338-8
    \endverb
    \field{issn}{2522-5812}
    \field{issue}{2}
    \field{number}{2}
    \field{pages}{166\bibrangedash 181}
    \field{shortjournal}{Nat Metab}
    \field{title}{Multiple Cell Types Contribute to the Atherosclerotic Lesion
  Fibrous Cap by {{PDGFRβ}} and Bioenergetic Mechanisms}
    \verb{url}
    \verb https://www.nature.com/articles/s42255-020-00338-8
    \endverb
    \field{volume}{3}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\4XDBHZ6T\\Newman et al. - 2021 -
    \verb Multiple cell types contribute to the atherosclero.pdf;C\:\\Users\\to
    \verb rbe\\Zotero\\storage\\QLSBUL79\\s42255-020-00338-8.pdf;C\:\\Users\\to
    \verb rbe\\Zotero\\storage\\DQ6454LC\\s42255-020-00338-8.html
    \endverb
    \field{journaltitle}{Nature Metabolism}
    \field{annotation}{%
    Bandiera\_abtest: a Cg\_type: Nature Research Journals Primary\_atype:
  Research Subject\_term: Atherosclerosis;Obesity Subject\_term\_id:
  atherosclerosis;obesity%
    }
    \field{month}{02}
    \field{year}{2021}
    \field{urlday}{07}
    \field{urlmonth}{10}
    \field{urlyear}{2021}
  \endentry

  \entry{siesReactiveOxygenSpecies2020}{article}{}
    \name{author}{2}{}{%
      {{hash=SH}{%
         family={Sies},
         familyi={S\bibinitperiod},
         given={Helmut},
         giveni={H\bibinitperiod},
      }}%
      {{hash=JDP}{%
         family={Jones},
         familyi={J\bibinitperiod},
         given={Dean\bibnamedelima P.},
         giveni={D\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Cell signalling,Mechanisms of disease}
    \strng{namehash}{SHJDP1}
    \strng{fullhash}{SHJDP1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2020}
    \field{labeldatesource}{}
    \field{abstract}{%
    ‘Reactive oxygen species’ (ROS) is an umbrella term for an array of
  derivatives of molecular oxygen that occur as a normal attribute of aerobic
  life. Elevated formation of the different ROS leads to molecular damage,
  denoted as ‘oxidative distress’. Here we focus on ROS at physiological
  levels and their central role in redox signalling via different
  post-translational modifications, denoted as ‘oxidative eustress’. Two
  species, hydrogen peroxide (H2O2) and the superoxide anion radical (O2·−),
  are key redox signalling agents generated under the control of growth factors
  and cytokines by more than 40 enzymes, prominently including NADPH oxidases
  and the mitochondrial electron transport chain. At the low physiological
  levels in the nanomolar range, H2O2 is the major agent signalling through
  specific protein targets, which engage in metabolic regulation and stress
  responses to support cellular adaptation to a changing environment and
  stress. In addition, several other reactive species are involved in redox
  signalling, for instance nitric oxide, hydrogen sulfide and oxidized lipids.
  Recent methodological advances permit the assessment of molecular
  interactions of specific ROS molecules with specific targets in redox
  signalling pathways. Accordingly, major advances have occurred in
  understanding the role of these oxidants in physiology and disease, including
  the nervous, cardiovascular and immune systems, skeletal muscle and metabolic
  regulation as well as ageing and cancer. In the past, unspecific elimination
  of ROS by use of low molecular mass antioxidant compounds was not successful
  in counteracting disease initiation and progression in clinical trials.
  However, controlling specific ROS-mediated signalling pathways by selective
  targeting offers a perspective for a future of more refined redox medicine.
  This includes enzymatic defence systems such as those controlled by the
  stress-response transcription factors NRF2 and nuclear factor-κB, the role
  of trace elements such as selenium, the use of redox drugs and the modulation
  of environmental factors collectively known as the exposome (for example,
  nutrition, lifestyle and irradiation).%
    }
    \verb{doi}
    \verb 10.1038/s41580-020-0230-3
    \endverb
    \field{issn}{1471-0080}
    \field{issue}{7}
    \field{number}{7}
    \field{pages}{363\bibrangedash 383}
    \field{shortjournal}{Nat Rev Mol Cell Biol}
    \field{title}{Reactive Oxygen Species ({{ROS}}) as Pleiotropic
  Physiological Signalling Agents}
    \verb{url}
    \verb https://www.nature.com/articles/s41580-020-0230-3
    \endverb
    \field{volume}{21}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\TVLW6MVW\\Sies und Jones - 2020 -
    \verb  Reactive oxygen species (ROS) as pleiotropic physi.pdf;C\:\\Users\\t
    \verb orbe\\Zotero\\storage\\EDLQJQDE\\s41580-020-0230-3.html
    \endverb
    \field{journaltitle}{Nature Reviews Molecular Cell Biology}
    \field{month}{07}
    \field{year}{2020}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{nayerniaNewInsightsNOX2014}{article}{}
    \name{author}{3}{}{%
      {{hash=NZ}{%
         family={Nayernia},
         familyi={N\bibinitperiod},
         given={Zeynab},
         giveni={Z\bibinitperiod},
      }}%
      {{hash=JV}{%
         family={Jaquet},
         familyi={J\bibinitperiod},
         given={Vincent},
         giveni={V\bibinitperiod},
      }}%
      {{hash=KKH}{%
         family={Krause},
         familyi={K\bibinitperiod},
         given={Karl-Heinz},
         giveni={K\bibinithyphendelim H\bibinitperiod},
      }}%
    }
    \keyw{Animals,Central Nervous System,Enzyme Inhibitors,Humans,Mice,NADPH
  Oxidases,Neurodegenerative Diseases,Oxidative Stress,Reactive Oxygen
  Species,Signal Transduction}
    \strng{namehash}{NZ+1}
    \strng{fullhash}{NZJVKKH1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2014}
    \field{labeldatesource}{}
    \field{abstract}{%
    SIGNIFICANCE: There is increasing evidence that the generation of reactive
  oxygen species (ROS) in the central nervous system (CNS) involves the NOX
  family of nicotinamide adenine dinucleotide phosphate oxidases. Controlled
  ROS generation appears necessary for optimal functioning of the CNS through
  fine-tuning of redox-sensitive signaling pathways, while overshooting ROS
  generation will lead to oxidative stress and CNS disease. RECENT ADVANCES:
  NOX enzymes are not only restricted to microglia (i.e. brain phagocytes) but
  also expressed in neurons, astrocytes, and the neurovascular system. NOX
  enzymes are involved in CNS development, neural stem cell biology, and the
  function of mature neurons. While NOX2 appears to be a major source of
  pathological oxidative stress in the CNS, other NOX isoforms might also be of
  importance, for example, NOX4 in stroke. Globally speaking, there is now
  convincing evidence for a role of NOX enzymes in various neurodegenerative
  diseases, cerebrovascular diseases, and psychosis-related disorders. CRITICAL
  ISSUES: The relative importance of specific ROS sources (e.g., NOX enzymes
  vs. mitochondria; NOX2 vs. NOX4) in different pathological processes needs
  further investigation. The absence of specific inhibitors limits the
  possibility to investigate specific therapeutic strategies. The uncritical
  use of non-specific inhibitors (e.g., apocynin, diphenylene iodonium) and
  poorly validated antibodies may lead to misleading conclusions. FUTURE
  DIRECTIONS: Physiological and pathophysiological studies with
  cell-type-specific knock-out mice will be necessary to delineate the precise
  functions of NOX enzymes and their implications in pathomechanisms. The
  development of CNS-permeant, specific NOX inhibitors will be necessary to
  advance toward therapeutic applications.%
    }
    \verb{doi}
    \verb 10.1089/ars.2013.5703
    \endverb
    \verb{eprint}
    \verb 24206089
    \endverb
    \field{issn}{1557-7716}
    \field{number}{17}
    \field{pages}{2815\bibrangedash 2837}
    \field{shortjournal}{Antioxid Redox Signal}
    \field{title}{New Insights on {{NOX}} Enzymes in the Central Nervous
  System}
    \field{volume}{20}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\3KHE72EK\\Nayernia et al. - 2014
    \verb - New insights on NOX enzymes in the central nervous.pdf
    \endverb
    \field{journaltitle}{Antioxidants \& Redox Signaling}
    \field{eprinttype}{pmid}
    \field{day}{10}
    \field{month}{06}
    \field{year}{2014}
  \endentry

  \entry{sundaresanRequirementGenerationH2O21995}{article}{}
    \name{author}{5}{}{%
      {{hash=SM}{%
         family={Sundaresan},
         familyi={S\bibinitperiod},
         given={M.},
         giveni={M\bibinitperiod},
      }}%
      {{hash=YZX}{%
         family={Yu},
         familyi={Y\bibinitperiod},
         given={Z.\bibnamedelima X.},
         giveni={Z\bibinitperiod\bibinitdelim X\bibinitperiod},
      }}%
      {{hash=FVJ}{%
         family={Ferrans},
         familyi={F\bibinitperiod},
         given={V.\bibnamedelima J.},
         giveni={V\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=IK}{%
         family={Irani},
         familyi={I\bibinitperiod},
         given={K.},
         giveni={K\bibinitperiod},
      }}%
      {{hash=FT}{%
         family={Finkel},
         familyi={F\bibinitperiod},
         given={T.},
         giveni={T\bibinitperiod},
      }}%
    }
    \keyw{Acetylcysteine,Adenoviridae,Animals,Calcium-Calmodulin-Dependent
  Protein Kinases,Catalase,Cell Line,Cells; Cultured,Chemotaxis,Endopeptidase
  K,Free Radical Scavengers,Humans,Hydrogen Peroxide,Mitogen-Activated Protein
  Kinase 1,Mitogen-Activated Protein Kinase 3,Mitogen-Activated Protein
  Kinases,Muscle; Smooth;
  Vascular,Phosphorylation,Phosphotyrosine,Platelet-Derived Growth
  Factor,Protein-Tyrosine Kinases,Rats,Serine Endopeptidases,Signal
  Transduction}
    \strng{namehash}{SM+1}
    \strng{fullhash}{SMYZXFVJIKFT1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{1995}
    \field{labeldatesource}{}
    \field{abstract}{%
    Stimulation of rat vascular smooth muscle cells (VSMCs) by platelet-derived
  growth factor (PDGF) transiently increased the intracellular concentration of
  hydrogen peroxide (H2O2). This increase could be blunted by increasing the
  intracellular concentration of the scavenging enzyme catalase or by the
  chemical antioxidant N-acetylcysteine. The response of VSMCs to PDGF, which
  includes tyrosine phosphorylation, mitogen-activated protein kinase
  stimulation, DNA synthesis, and chemotaxis, was inhibited when the growth
  factor-stimulated rise in H2O2 concentration was blocked. These results
  suggest that H2O2 may act as a signal-transducing molecule, and they suggest
  a potential mechanism for the cardioprotective effects of antioxidants.%
    }
    \verb{doi}
    \verb 10.1126/science.270.5234.296
    \endverb
    \verb{eprint}
    \verb 7569979
    \endverb
    \field{issn}{0036-8075}
    \field{number}{5234}
    \field{pages}{296\bibrangedash 299}
    \field{shortjournal}{Science}
    \field{title}{Requirement for Generation of {{H2O2}} for Platelet-Derived
  Growth Factor Signal Transduction}
    \field{volume}{270}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\GCTAC4LN\\Sundaresan et al. - 199
    \verb 5 - Requirement for generation of H2O2 for platelet-de.pdf
    \endverb
    \field{journaltitle}{Science (New York, N.Y.)}
    \field{eprinttype}{pmid}
    \field{day}{13}
    \field{month}{10}
    \field{year}{1995}
  \endentry

  \entry{bouziguesRegulationROSResponse2014a}{article}{}
    \name{author}{6}{}{%
      {{hash=BCI}{%
         family={Bouzigues},
         familyi={B\bibinitperiod},
         given={Cedric\bibnamedelima I.},
         giveni={C\bibinitperiod\bibinitdelim I\bibinitperiod},
      }}%
      {{hash=NTL}{%
         family={Nguyên},
         familyi={N\bibinitperiod},
         given={Thanh-Liêm},
         giveni={T\bibinithyphendelim L\bibinitperiod},
      }}%
      {{hash=RR}{%
         family={Ramodiharilafy},
         familyi={R\bibinitperiod},
         given={Rivo},
         giveni={R\bibinitperiod},
      }}%
      {{hash=CA}{%
         family={Claeson},
         familyi={C\bibinitperiod},
         given={Amy},
         giveni={A\bibinitperiod},
      }}%
      {{hash=TPL}{%
         family={Tharaux},
         familyi={T\bibinitperiod},
         given={Pierre-Louis},
         giveni={P\bibinithyphendelim L\bibinitperiod},
      }}%
      {{hash=AA}{%
         family={Alexandrou},
         familyi={A\bibinitperiod},
         given={Antigoni},
         giveni={A\bibinitperiod},
      }}%
    }
    \strng{namehash}{BCI+1}
    \strng{fullhash}{BCINTLRRCATPLAA1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2014}
    \field{labeldatesource}{}
    \field{abstract}{%
    Although reactive oxygen species (ROS) are better known for their harmful
  effects, more recently, H2O2, one of the ROS, was also found to act as a
  secondary messenger. However, details of spatiotemporal organization of
  specific signaling pathways that H2O2 is involved in are currently missing.
  Here, we use single nanoparticle imaging to measure the local H2O2
  concentration and reveal regulation of the ROS response dynamics and
  organization to platelet-derived growth factor (PDGF) signaling. We
  demonstrate that H2O2 production is controlled by PDGFR kinase activity and
  EGFR transactivation, requires a persistent stimulation, and is regulated by
  membrane receptor diffusion. This temporal filtering is impaired in cancer
  cells, which may determine their pathological migration. H2O2 subcellular
  mapping reveals that an external PDGF gradient induces an amplification-free
  asymmetric H2O2 concentration profile. These results support a general model
  for the control of signal transduction based only on membrane receptor
  diffusion and second messenger degradation.%
    }
    \verb{doi}
    \verb 10.1016/j.chembiol.2014.02.020
    \endverb
    \field{issn}{1074-5521}
    \field{number}{5}
    \field{pages}{647\bibrangedash 656}
    \field{shortjournal}{Chemistry \& Biology}
    \field{title}{Regulation of the {{ROS Response Dynamics}} and
  {{Organization}} to {{PDGF Motile Stimuli Revealed}} by {{Single Nanoparticle
  Imaging}}}
    \verb{url}
    \verb https://www.sciencedirect.com/science/article/pii/S1074552114001070
    \endverb
    \field{volume}{21}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\MTYUPBYX\\Bouzigues et al. - 2014
    \verb  - Regulation of the ROS Response Dynamics and Organi.pdf;C\:\\Users\
    \verb \torbe\\Zotero\\storage\\CEE2S5M3\\S1074552114001070.html
    \endverb
    \field{journaltitle}{Chemistry \& Biology}
    \field{day}{22}
    \field{month}{05}
    \field{year}{2014}
    \field{urlday}{07}
    \field{urlmonth}{05}
    \field{urlyear}{2022}
  \endentry

  \entry{uffelmannGenomewideAssociationStudies2021}{article}{useprefix}
    \name{author}{9}{}{%
      {{hash=UE}{%
         family={Uffelmann},
         familyi={U\bibinitperiod},
         given={Emil},
         giveni={E\bibinitperiod},
      }}%
      {{hash=HQQ}{%
         family={Huang},
         familyi={H\bibinitperiod},
         given={Qin\bibnamedelima Qin},
         giveni={Q\bibinitperiod\bibinitdelim Q\bibinitperiod},
      }}%
      {{hash=MNS}{%
         family={Munung},
         familyi={M\bibinitperiod},
         given={Nchangwi\bibnamedelima Syntia},
         giveni={N\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=dVJ}{%
         prefix={de},
         prefixi={d\bibinitperiod},
         family={Vries},
         familyi={V\bibinitperiod},
         given={Jantina},
         giveni={J\bibinitperiod},
      }}%
      {{hash=OY}{%
         family={Okada},
         familyi={O\bibinitperiod},
         given={Yukinori},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=MAR}{%
         family={Martin},
         familyi={M\bibinitperiod},
         given={Alicia\bibnamedelima R.},
         giveni={A\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=MHC}{%
         family={Martin},
         familyi={M\bibinitperiod},
         given={Hilary\bibnamedelima C.},
         giveni={H\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=LT}{%
         family={Lappalainen},
         familyi={L\bibinitperiod},
         given={Tuuli},
         giveni={T\bibinitperiod},
      }}%
      {{hash=PD}{%
         family={Posthuma},
         familyi={P\bibinitperiod},
         given={Danielle},
         giveni={D\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Genetic predisposition to disease,Genome-wide association studies}
    \strng{namehash}{UE+1}
    \strng{fullhash}{UEHQQMNSdVJOYMARMHCLTPD1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2021}
    \field{labeldatesource}{}
    \field{abstract}{%
    Genome-wide association studies (GWAS) test hundreds of thousands of
  genetic variants across many genomes to find those statistically associated
  with a specific trait or disease. This methodology has generated a myriad of
  robust associations for a range of traits and diseases, and the number of
  associated variants is expected to grow steadily as GWAS sample sizes
  increase. GWAS results have a range of applications, such as gaining insight
  into a phenotype’s underlying biology, estimating its heritability,
  calculating genetic correlations, making clinical risk predictions, informing
  drug development programmes and inferring potential causal relationships
  between risk factors and health outcomes. In this Primer, we provide the
  reader with an introduction to GWAS, explaining their statistical basis and
  how they are conducted, describe state-of-the art approaches and discuss
  limitations and challenges, concluding with an overview of the current and
  future applications for GWAS results.%
    }
    \verb{doi}
    \verb 10.1038/s43586-021-00056-9
    \endverb
    \field{issn}{2662-8449}
    \field{issue}{1}
    \field{number}{1}
    \field{pages}{1\bibrangedash 21}
    \field{shortjournal}{Nat Rev Methods Primers}
    \field{title}{Genome-Wide Association Studies}
    \verb{url}
    \verb https://www.nature.com/articles/s43586-021-00056-9
    \endverb
    \field{volume}{1}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\SUJBYYV5\\Uffelmann et al. - 2021
    \verb  - Genome-wide association studies.pdf;C\:\\Users\\torbe\\Zotero\\sto
    \verb rage\\7J5XNTA4\\s43586-021-00056-9.html
    \endverb
    \field{journaltitle}{Nature Reviews Methods Primers}
    \field{day}{26}
    \field{month}{08}
    \field{year}{2021}
    \field{urlday}{17}
    \field{urlmonth}{03}
    \field{urlyear}{2022}
  \endentry

  \entry{flintGWAS2013}{article}{}
    \name{author}{1}{}{%
      {{hash=FJ}{%
         family={Flint},
         familyi={F\bibinitperiod},
         given={Jonathan},
         giveni={J\bibinitperiod},
      }}%
    }
    \strng{namehash}{FJ1}
    \strng{fullhash}{FJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2013}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.1016/j.cub.2013.01.040
    \endverb
    \field{issn}{09609822}
    \field{number}{7}
    \field{pages}{R265\bibrangedash R266}
    \field{shortjournal}{Current Biology}
    \field{title}{{{GWAS}}}
    \verb{url}
    \verb https://linkinghub.elsevier.com/retrieve/pii/S0960982213000754
    \endverb
    \field{volume}{23}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\WPLMQ426\\Flint - 2013 - GWAS.pdf
    \endverb
    \field{journaltitle}{Current Biology}
    \field{month}{04}
    \field{year}{2013}
    \field{urlday}{17}
    \field{urlmonth}{03}
    \field{urlyear}{2022}
  \endentry

  \entry{schaidGenomewideAssociationsCandidate2018}{article}{}
    \name{author}{3}{}{%
      {{hash=SDJ}{%
         family={Schaid},
         familyi={S\bibinitperiod},
         given={Daniel\bibnamedelima J.},
         giveni={D\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=CW}{%
         family={Chen},
         familyi={C\bibinitperiod},
         given={Wenan},
         giveni={W\bibinitperiod},
      }}%
      {{hash=LNB}{%
         family={Larson},
         familyi={L\bibinitperiod},
         given={Nicholas\bibnamedelima B.},
         giveni={N\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
    }
    \strng{namehash}{SDJ+1}
    \strng{fullhash}{SDJCWLNB1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2018}
    \field{labeldatesource}{}
    \field{abstract}{%
    Advancing from statistical associations of complex traits with genetic
  markers to understanding the functional genetic variants that influence
  traits is often a complex process. Fine-mapping can select and prioritize
  genetic variants for further study, yet the multitude of analytical
  strategies and study designs makes it challenging to choose an optimal
  approach. We review the strengths and weakness of different fine-mapping
  approaches, emphasizing the main factors that affect performance. Topics
  include interpreting results from genome-wide association studies (GWAS), the
  role of linkage disequilibrium, statistical fine-mapping approaches,
  trans-ethnic studies, genomic annotation and data integration, and other
  analysis and design issues., Fine-mapping is the process by which a
  trait-associated region from a genome-wide association study (GWAS) is
  analysed to identify the particular genetic variants that are likely to
  causally influence the examined trait. This Review discusses the diverse
  statistical approaches to fine mapping, their foundations, strengths and
  limitations, including integration of trans-ethnic human population data and
  functional annotations.%
    }
    \verb{doi}
    \verb 10.1038/s41576-018-0016-z
    \endverb
    \verb{eprint}
    \verb 29844615
    \endverb
    \field{issn}{1471-0056}
    \field{number}{8}
    \field{pages}{491\bibrangedash 504}
    \field{shortjournal}{Nat Rev Genet}
    \field{title}{From Genome-Wide Associations to Candidate Causal Variants by
  Statistical Fine-Mapping}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050137/
    \endverb
    \field{volume}{19}
    \field{journaltitle}{Nature reviews. Genetics}
    \field{eprinttype}{pmid}
    \field{month}{08}
    \field{year}{2018}
    \field{urlday}{23}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{lichouFunctionalStudiesGWAS2020}{article}{}
    \name{author}{2}{}{%
      {{hash=LF}{%
         family={Lichou},
         familyi={L\bibinitperiod},
         given={Florence},
         giveni={F\bibinitperiod},
      }}%
      {{hash=TG}{%
         family={Trynka},
         familyi={T\bibinitperiod},
         given={Gosia},
         giveni={G\bibinitperiod},
      }}%
    }
    \strng{namehash}{LFTG1}
    \strng{fullhash}{LFTG1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2020}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.1038/s41467-020-20188-y
    \endverb
    \field{issn}{2041-1723}
    \field{number}{1}
    \field{pages}{6283}
    \field{shortjournal}{Nat Commun}
    \field{title}{Functional Studies of {{GWAS}} Variants Are Gaining Momentum}
    \verb{url}
    \verb http://www.nature.com/articles/s41467-020-20188-y
    \endverb
    \field{volume}{11}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\TA9WSFJS\\Lichou und Trynka - 202
    \verb 0 - Functional studies of GWAS variants are gaining mo.pdf
    \endverb
    \field{journaltitle}{Nature Communications}
    \field{month}{12}
    \field{year}{2020}
    \field{urlday}{08}
    \field{urlmonth}{05}
    \field{urlyear}{2022}
  \endentry

  \entry{slatkinLinkageDisequilibriumUnderstanding2008}{article}{}
    \name{author}{1}{}{%
      {{hash=SM}{%
         family={Slatkin},
         familyi={S\bibinitperiod},
         given={Montgomery},
         giveni={M\bibinitperiod},
      }}%
    }
    \strng{namehash}{SM1}
    \strng{fullhash}{SM1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2008}
    \field{labeldatesource}{}
    \field{abstract}{%
    Linkage disequilibrium — the nonrandom association of alleles at
  different loci — is a sensitive indicator of the population genetic forces
  that structure a genome. Because of the explosive growth of methods for
  assessing genetic variation at a fine scale, evolutionary biologists and
  human geneticists are increasingly exploiting linkage disequilibrium in order
  to understand past evolutionary and demographic events, to map genes that are
  associated with quantitative characters and inherited diseases, and to
  understand the joint evolution of linked sets of genes. This article
  introduces linkage disequilibrium, reviews the population genetic processes
  that affect it and describes some of its uses. At present, linkage
  disequilibrium is used much more extensively in the study of humans than in
  non-humans, but that is changing as technological advances make extensive
  genomic studies feasible in other species.%
    }
    \verb{doi}
    \verb 10.1038/nrg2361
    \endverb
    \verb{eprint}
    \verb 18427557
    \endverb
    \field{issn}{1471-0056}
    \field{number}{6}
    \field{pages}{477\bibrangedash 485}
    \field{shortjournal}{Nat Rev Genet}
    \field{title}{Linkage Disequilibrium — Understanding the Evolutionary
  Past and Mapping the Medical Future}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124487/
    \endverb
    \field{volume}{9}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\WC9XQHPS\\Slatkin - 2008 - Linkag
    \verb e disequilibrium — understanding the evoluti.pdf
    \endverb
    \field{journaltitle}{Nature reviews. Genetics}
    \field{eprinttype}{pmid}
    \field{month}{06}
    \field{year}{2008}
    \field{urlday}{05}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{mountjoyOpenApproachSystematically2021}{article}{}
    \name{author}{19}{}{%
      {{hash=ME}{%
         family={Mountjoy},
         familyi={M\bibinitperiod},
         given={Edward},
         giveni={E\bibinitperiod},
      }}%
      {{hash=SEM}{%
         family={Schmidt},
         familyi={S\bibinitperiod},
         given={Ellen\bibnamedelima M.},
         giveni={E\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=CM}{%
         family={Carmona},
         familyi={C\bibinitperiod},
         given={Miguel},
         giveni={M\bibinitperiod},
      }}%
      {{hash=SJ}{%
         family={Schwartzentruber},
         familyi={S\bibinitperiod},
         given={Jeremy},
         giveni={J\bibinitperiod},
      }}%
      {{hash=PG}{%
         family={Peat},
         familyi={P\bibinitperiod},
         given={Gareth},
         giveni={G\bibinitperiod},
      }}%
      {{hash=MA}{%
         family={Miranda},
         familyi={M\bibinitperiod},
         given={Alfredo},
         giveni={A\bibinitperiod},
      }}%
      {{hash=FL}{%
         family={Fumis},
         familyi={F\bibinitperiod},
         given={Luca},
         giveni={L\bibinitperiod},
      }}%
      {{hash=HJ}{%
         family={Hayhurst},
         familyi={H\bibinitperiod},
         given={James},
         giveni={J\bibinitperiod},
      }}%
      {{hash=BA}{%
         family={Buniello},
         familyi={B\bibinitperiod},
         given={Annalisa},
         giveni={A\bibinitperiod},
      }}%
      {{hash=KMA}{%
         family={Karim},
         familyi={K\bibinitperiod},
         given={Mohd\bibnamedelima Anisul},
         giveni={M\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=WD}{%
         family={Wright},
         familyi={W\bibinitperiod},
         given={Daniel},
         giveni={D\bibinitperiod},
      }}%
      {{hash=HA}{%
         family={Hercules},
         familyi={H\bibinitperiod},
         given={Andrew},
         giveni={A\bibinitperiod},
      }}%
      {{hash=PE}{%
         family={Papa},
         familyi={P\bibinitperiod},
         given={Eliseo},
         giveni={E\bibinitperiod},
      }}%
      {{hash=FEB}{%
         family={Fauman},
         familyi={F\bibinitperiod},
         given={Eric\bibnamedelima B.},
         giveni={E\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=BJC}{%
         family={Barrett},
         familyi={B\bibinitperiod},
         given={Jeffrey\bibnamedelima C.},
         giveni={J\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=TJA}{%
         family={Todd},
         familyi={T\bibinitperiod},
         given={John\bibnamedelima A.},
         giveni={J\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=OD}{%
         family={Ochoa},
         familyi={O\bibinitperiod},
         given={David},
         giveni={D\bibinitperiod},
      }}%
      {{hash=DI}{%
         family={Dunham},
         familyi={D\bibinitperiod},
         given={Ian},
         giveni={I\bibinitperiod},
      }}%
      {{hash=GM}{%
         family={Ghoussaini},
         familyi={G\bibinitperiod},
         given={Maya},
         giveni={M\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Data processing,Genome-wide association studies}
    \strng{namehash}{ME+1}
    \strng{fullhash}{MESEMCMSJPGMAFLHJBAKMAWDHAPEFEBBJCTJAODDIGM1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2021}
    \field{labeldatesource}{}
    \field{abstract}{%
    Genome-wide association studies (GWASs) have identified many variants
  associated with complex traits, but identifying the causal gene(s) is a major
  challenge. In the present study, we present an open resource that provides
  systematic fine mapping and gene prioritization across 133,441 published
  human GWAS loci. We integrate genetics (GWAS Catalog and UK Biobank) with
  transcriptomic, proteomic and epigenomic data, including systematic
  disease–disease and disease–molecular trait colocalization results across
  92 cell types and tissues. We identify 729 loci fine mapped to a
  single-coding causal variant and colocalized with a single gene. We trained a
  machine-learning model using the fine-mapped genetics and functional genomics
  data and 445 gold-standard curated GWAS loci to distinguish causal genes from
  neighboring genes, outperforming a naive distance-based model. Our
  prioritized genes were enriched for known approved drug targets (odds
  ratio\,=\,8.1, 95\% confidence interval\,=\,5.7, 11.5). These results are
  publicly available through a web portal ( http://genetics.opentargets.org ),
  enabling users to easily prioritize genes at disease-associated loci and
  assess their potential as drug targets. Open Targets Genetics is a community
  resource that provides systematic fine mapping at human GWAS loci, enabling
  users to prioritize genes at disease-associated regions and assess their
  potential as drug targets.%
    }
    \verb{doi}
    \verb 10.1038/s41588-021-00945-5
    \endverb
    \field{issn}{1546-1718}
    \field{issue}{11}
    \field{number}{11}
    \field{pages}{1527\bibrangedash 1533}
    \field{shortjournal}{Nat Genet}
    \field{title}{An Open Approach to Systematically Prioritize Causal Variants
  and Genes at All Published Human {{GWAS}} Trait-Associated Loci}
    \verb{url}
    \verb https://www.nature.com/articles/s41588-021-00945-5
    \endverb
    \field{volume}{53}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\ZQ4JKC9Q\\Mountjoy et al. - 2021
    \verb - An open approach to systematically prioritize caus.pdf;C\:\\Users\\
    \verb torbe\\Zotero\\storage\\G8C3PI7Z\\s41588-021-00945-5.html
    \endverb
    \field{journaltitle}{Nature Genetics}
    \field{month}{11}
    \field{year}{2021}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{zerbinoEnsemblRegulatoryBuild2015}{article}{}
    \name{author}{5}{}{%
      {{hash=ZDR}{%
         family={Zerbino},
         familyi={Z\bibinitperiod},
         given={Daniel\bibnamedelima R.},
         giveni={D\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=WSP}{%
         family={Wilder},
         familyi={W\bibinitperiod},
         given={Steven\bibnamedelima P.},
         giveni={S\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=JN}{%
         family={Johnson},
         familyi={J\bibinitperiod},
         given={Nathan},
         giveni={N\bibinitperiod},
      }}%
      {{hash=JT}{%
         family={Juettemann},
         familyi={J\bibinitperiod},
         given={Thomas},
         giveni={T\bibinitperiod},
      }}%
      {{hash=FPR}{%
         family={Flicek},
         familyi={F\bibinitperiod},
         given={Paul\bibnamedelima R.},
         giveni={P\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
    }
    \keyw{Computational Biology,Databases; Genetic,Epigenesis;
  Genetic,Genomics,Humans,Internet,Software,Transcription Factors,User-Computer
  Interface}
    \strng{namehash}{ZDR+1}
    \strng{fullhash}{ZDRWSPJNJTFPR1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2015}
    \field{labeldatesource}{}
    \field{abstract}{%
    Most genomic variants associated with phenotypic traits or disease do not
  fall within gene coding regions, but in regulatory regions, rendering their
  interpretation difficult. We collected public data on epigenetic marks and
  transcription factor binding in human cell types and used it to construct an
  intuitive summary of regulatory regions in the human genome. We verified it
  against independent assays for sensitivity. The Ensembl Regulatory Build will
  be progressively enriched when more data is made available. It is freely
  available on the Ensembl browser, from the Ensembl Regulation MySQL database
  server and in a dedicated track hub.%
    }
    \verb{doi}
    \verb 10.1186/s13059-015-0621-5
    \endverb
    \verb{eprint}
    \verb 25887522
    \endverb
    \field{issn}{1474-760X}
    \field{pages}{56}
    \field{shortjournal}{Genome Biol}
    \field{title}{The Ensembl Regulatory Build}
    \field{volume}{16}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\PGP9DIQW\\Zerbino et al. - 2015 -
    \verb  The ensembl regulatory build.pdf
    \endverb
    \field{journaltitle}{Genome Biology}
    \field{eprinttype}{pmid}
    \field{day}{24}
    \field{month}{03}
    \field{year}{2015}
  \endentry

  \entry{mooreExpandedEncyclopaediasDNA2020}{article}{}
    \name{author}{63}{}{%
      {{hash=MJE}{%
         family={Moore},
         familyi={M\bibinitperiod},
         given={Jill\bibnamedelima E.},
         giveni={J\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=PMJ}{%
         family={Purcaro},
         familyi={P\bibinitperiod},
         given={Michael\bibnamedelima J.},
         giveni={M\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=PHE}{%
         family={Pratt},
         familyi={P\bibinitperiod},
         given={Henry\bibnamedelima E.},
         giveni={H\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=ECB}{%
         family={Epstein},
         familyi={E\bibinitperiod},
         given={Charles\bibnamedelima B.},
         giveni={C\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=SN}{%
         family={Shoresh},
         familyi={S\bibinitperiod},
         given={Noam},
         giveni={N\bibinitperiod},
      }}%
      {{hash=AJ}{%
         family={Adrian},
         familyi={A\bibinitperiod},
         given={Jessika},
         giveni={J\bibinitperiod},
      }}%
      {{hash=KT}{%
         family={Kawli},
         familyi={K\bibinitperiod},
         given={Trupti},
         giveni={T\bibinitperiod},
      }}%
      {{hash=DCA}{%
         family={Davis},
         familyi={D\bibinitperiod},
         given={Carrie\bibnamedelima A.},
         giveni={C\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=DA}{%
         family={Dobin},
         familyi={D\bibinitperiod},
         given={Alexander},
         giveni={A\bibinitperiod},
      }}%
      {{hash=KR}{%
         family={Kaul},
         familyi={K\bibinitperiod},
         given={Rajinder},
         giveni={R\bibinitperiod},
      }}%
      {{hash=HJ}{%
         family={Halow},
         familyi={H\bibinitperiod},
         given={Jessica},
         giveni={J\bibinitperiod},
      }}%
      {{hash=VNEL}{%
         family={Van\bibnamedelima Nostrand},
         familyi={V\bibinitperiod\bibinitdelim N\bibinitperiod},
         given={Eric\bibnamedelima L.},
         giveni={E\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=FP}{%
         family={Freese},
         familyi={F\bibinitperiod},
         given={Peter},
         giveni={P\bibinitperiod},
      }}%
      {{hash=GDU}{%
         family={Gorkin},
         familyi={G\bibinitperiod},
         given={David\bibnamedelima U.},
         giveni={D\bibinitperiod\bibinitdelim U\bibinitperiod},
      }}%
      {{hash=SY}{%
         family={Shen},
         familyi={S\bibinitperiod},
         given={Yin},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=HY}{%
         family={He},
         familyi={H\bibinitperiod},
         given={Yupeng},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=MM}{%
         family={Mackiewicz},
         familyi={M\bibinitperiod},
         given={Mark},
         giveni={M\bibinitperiod},
      }}%
      {{hash=PBF}{%
         family={Pauli-Behn},
         familyi={P\bibinithyphendelim B\bibinitperiod},
         given={Florencia},
         giveni={F\bibinitperiod},
      }}%
      {{hash=WBA}{%
         family={Williams},
         familyi={W\bibinitperiod},
         given={Brian\bibnamedelima A.},
         giveni={B\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=MA}{%
         family={Mortazavi},
         familyi={M\bibinitperiod},
         given={Ali},
         giveni={A\bibinitperiod},
      }}%
      {{hash=KCA}{%
         family={Keller},
         familyi={K\bibinitperiod},
         given={Cheryl\bibnamedelima A.},
         giveni={C\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=ZXO}{%
         family={Zhang},
         familyi={Z\bibinitperiod},
         given={Xiao-Ou},
         giveni={X\bibinithyphendelim O\bibinitperiod},
      }}%
      {{hash=ESI}{%
         family={Elhajjajy},
         familyi={E\bibinitperiod},
         given={Shaimae\bibnamedelima I.},
         giveni={S\bibinitperiod\bibinitdelim I\bibinitperiod},
      }}%
      {{hash=HJ}{%
         family={Huey},
         familyi={H\bibinitperiod},
         given={Jack},
         giveni={J\bibinitperiod},
      }}%
      {{hash=DDE}{%
         family={Dickel},
         familyi={D\bibinitperiod},
         given={Diane\bibnamedelima E.},
         giveni={D\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=SV}{%
         family={Snetkova},
         familyi={S\bibinitperiod},
         given={Valentina},
         giveni={V\bibinitperiod},
      }}%
      {{hash=WX}{%
         family={Wei},
         familyi={W\bibinitperiod},
         given={Xintao},
         giveni={X\bibinitperiod},
      }}%
      {{hash=WX}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Xiaofeng},
         giveni={X\bibinitperiod},
      }}%
      {{hash=RMJC}{%
         family={Rivera-Mulia},
         familyi={R\bibinithyphendelim M\bibinitperiod},
         given={Juan\bibnamedelima Carlos},
         giveni={J\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=RJ}{%
         family={Rozowsky},
         familyi={R\bibinitperiod},
         given={Joel},
         giveni={J\bibinitperiod},
      }}%
      {{hash=ZJ}{%
         family={Zhang},
         familyi={Z\bibinitperiod},
         given={Jing},
         giveni={J\bibinitperiod},
      }}%
      {{hash=CSB}{%
         family={Chhetri},
         familyi={C\bibinitperiod},
         given={Surya\bibnamedelima B.},
         giveni={S\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=ZJ}{%
         family={Zhang},
         familyi={Z\bibinitperiod},
         given={Jialing},
         giveni={J\bibinitperiod},
      }}%
      {{hash=VA}{%
         family={Victorsen},
         familyi={V\bibinitperiod},
         given={Alec},
         giveni={A\bibinitperiod},
      }}%
      {{hash=WKP}{%
         family={White},
         familyi={W\bibinitperiod},
         given={Kevin\bibnamedelima P.},
         giveni={K\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=VA}{%
         family={Visel},
         familyi={V\bibinitperiod},
         given={Axel},
         giveni={A\bibinitperiod},
      }}%
      {{hash=YGW}{%
         family={Yeo},
         familyi={Y\bibinitperiod},
         given={Gene\bibnamedelima W.},
         giveni={G\bibinitperiod\bibinitdelim W\bibinitperiod},
      }}%
      {{hash=BCB}{%
         family={Burge},
         familyi={B\bibinitperiod},
         given={Christopher\bibnamedelima B.},
         giveni={C\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=LE}{%
         family={Lécuyer},
         familyi={L\bibinitperiod},
         given={Eric},
         giveni={E\bibinitperiod},
      }}%
      {{hash=GDM}{%
         family={Gilbert},
         familyi={G\bibinitperiod},
         given={David\bibnamedelima M.},
         giveni={D\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=DJ}{%
         family={Dekker},
         familyi={D\bibinitperiod},
         given={Job},
         giveni={J\bibinitperiod},
      }}%
      {{hash=RJ}{%
         family={Rinn},
         familyi={R\bibinitperiod},
         given={John},
         giveni={J\bibinitperiod},
      }}%
      {{hash=MEM}{%
         family={Mendenhall},
         familyi={M\bibinitperiod},
         given={Eric\bibnamedelima M.},
         giveni={E\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=EJR}{%
         family={Ecker},
         familyi={E\bibinitperiod},
         given={Joseph\bibnamedelima R.},
         giveni={J\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=KM}{%
         family={Kellis},
         familyi={K\bibinitperiod},
         given={Manolis},
         giveni={M\bibinitperiod},
      }}%
      {{hash=KRJ}{%
         family={Klein},
         familyi={K\bibinitperiod},
         given={Robert\bibnamedelima J.},
         giveni={R\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=NWS}{%
         family={Noble},
         familyi={N\bibinitperiod},
         given={William\bibnamedelima S.},
         giveni={W\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=KA}{%
         family={Kundaje},
         familyi={K\bibinitperiod},
         given={Anshul},
         giveni={A\bibinitperiod},
      }}%
      {{hash=GR}{%
         family={Guigó},
         familyi={G\bibinitperiod},
         given={Roderic},
         giveni={R\bibinitperiod},
      }}%
      {{hash=FPJ}{%
         family={Farnham},
         familyi={F\bibinitperiod},
         given={Peggy\bibnamedelima J.},
         giveni={P\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=CJM}{%
         family={Cherry},
         familyi={C\bibinitperiod},
         given={J.\bibnamedelima Michael},
         giveni={J\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=MRM}{%
         family={Myers},
         familyi={M\bibinitperiod},
         given={Richard\bibnamedelima M.},
         giveni={R\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=RB}{%
         family={Ren},
         familyi={R\bibinitperiod},
         given={Bing},
         giveni={B\bibinitperiod},
      }}%
      {{hash=GBR}{%
         family={Graveley},
         familyi={G\bibinitperiod},
         given={Brenton\bibnamedelima R.},
         giveni={B\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=GMB}{%
         family={Gerstein},
         familyi={G\bibinitperiod},
         given={Mark\bibnamedelima B.},
         giveni={M\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=PLA}{%
         family={Pennacchio},
         familyi={P\bibinitperiod},
         given={Len\bibnamedelima A.},
         giveni={L\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=SMP}{%
         family={Snyder},
         familyi={S\bibinitperiod},
         given={Michael\bibnamedelima P.},
         giveni={M\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=BBE}{%
         family={Bernstein},
         familyi={B\bibinitperiod},
         given={Bradley\bibnamedelima E.},
         giveni={B\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=WB}{%
         family={Wold},
         familyi={W\bibinitperiod},
         given={Barbara},
         giveni={B\bibinitperiod},
      }}%
      {{hash=HRC}{%
         family={Hardison},
         familyi={H\bibinitperiod},
         given={Ross\bibnamedelima C.},
         giveni={R\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=GTR}{%
         family={Gingeras},
         familyi={G\bibinitperiod},
         given={Thomas\bibnamedelima R.},
         giveni={T\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=SJA}{%
         family={Stamatoyannopoulos},
         familyi={S\bibinitperiod},
         given={John\bibnamedelima A.},
         giveni={J\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=WZ}{%
         family={Weng},
         familyi={W\bibinitperiod},
         given={Zhiping},
         giveni={Z\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Data integration,Epigenomics,Functional genomics}
    \strng{namehash}{MJE+1}
  \strng{fullhash}{MJEPMJPHEECBSNAJKTDCADAKRHJVNELFPGDUSYHYMMPBFWBAMAKCAZXOESIHJDDESVWXWXRMJCRJZJCSBZJVAWKPVAYGWBCBLEGDMDJRJMEMEJRKMKRJNWSKAGRFPJCJMMRMRBGBRGMBPLASMPBBEWBHRCGTRSJAWZ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2020}
    \field{labeldatesource}{}
    \field{abstract}{%
    The human and mouse genomes contain instructions that specify RNAs and
  proteins and govern the timing, magnitude, and cellular context of their
  production. To better delineate these elements, phase III of the Encyclopedia
  of DNA Elements (ENCODE) Project has expanded analysis of the cell and tissue
  repertoires of RNA transcription, chromatin structure and modification, DNA
  methylation, chromatin looping, and occupancy by transcription factors and
  RNA-binding proteins. Here we summarize these efforts, which have produced
  5,992 new experimental datasets, including systematic determinations across
  mouse fetal development. All data are available through the ENCODE data
  portal (https://www.encodeproject.org), including phase II ENCODE1 and
  Roadmap Epigenomics2 data. We have developed a registry of 926,535 human and
  339,815 mouse candidate cis-regulatory elements, covering 7.9 and 3.4\% of
  their respective genomes, by integrating selected datatypes associated with
  gene regulation, and constructed a web-based server (SCREEN;
  http://screen.encodeproject.org) to provide flexible, user-defined access to
  this resource. Collectively, the ENCODE data and registry provide an
  expansive resource for the scientific community to build a better
  understanding of the organization and function of the human and mouse
  genomes.%
    }
    \verb{doi}
    \verb 10.1038/s41586-020-2493-4
    \endverb
    \field{issn}{1476-4687}
    \field{issue}{7818}
    \field{number}{7818}
    \field{pages}{699\bibrangedash 710}
    \field{title}{Expanded Encyclopaedias of {{DNA}} Elements in the Human and
  Mouse Genomes}
    \verb{url}
    \verb https://www.nature.com/articles/s41586-020-2493-4
    \endverb
    \field{volume}{583}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\YQX84K4X\\Moore et al. - 2020 - E
    \verb xpanded encyclopaedias of DNA elements in the hum.pdf;C\:\\Users\\tor
    \verb be\\Zotero\\storage\\4PZZNC76\\s41586-020-2493-4.html
    \endverb
    \field{journaltitle}{Nature}
    \field{month}{07}
    \field{year}{2020}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{buenrostroTranspositionNativeChromatin2013}{article}{}
    \name{author}{5}{}{%
      {{hash=BJD}{%
         family={Buenrostro},
         familyi={B\bibinitperiod},
         given={Jason\bibnamedelima D.},
         giveni={J\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=GPG}{%
         family={Giresi},
         familyi={G\bibinitperiod},
         given={Paul\bibnamedelima G.},
         giveni={P\bibinitperiod\bibinitdelim G\bibinitperiod},
      }}%
      {{hash=ZLC}{%
         family={Zaba},
         familyi={Z\bibinitperiod},
         given={Lisa\bibnamedelima C.},
         giveni={L\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=CHY}{%
         family={Chang},
         familyi={C\bibinitperiod},
         given={Howard\bibnamedelima Y.},
         giveni={H\bibinitperiod\bibinitdelim Y\bibinitperiod},
      }}%
      {{hash=GWJ}{%
         family={Greenleaf},
         familyi={G\bibinitperiod},
         given={William\bibnamedelima J.},
         giveni={W\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Biotechnology,Chromatin analysis,Epigenetics,Epigenomics}
    \strng{namehash}{BJD+1}
    \strng{fullhash}{BJDGPGZLCCHYGWJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2013}
    \field{labeldatesource}{}
    \field{abstract}{%
    ATAC-seq queries the location of open chromatin, the binding of
  DNA-associated proteins and chromatin compaction at nucleotide resolution.%
    }
    \verb{doi}
    \verb 10.1038/nmeth.2688
    \endverb
    \field{issn}{1548-7105}
    \field{issue}{12}
    \field{number}{12}
    \field{pages}{1213\bibrangedash 1218}
    \field{shortjournal}{Nat Methods}
    \field{title}{Transposition of Native Chromatin for Fast and Sensitive
  Epigenomic Profiling of Open Chromatin, {{DNA-binding}} Proteins and
  Nucleosome Position}
    \verb{url}
    \verb https://www.nature.com/articles/nmeth.2688
    \endverb
    \field{volume}{10}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\3JYMJ3PW\\Buenrostro et al. - 201
    \verb 3 - Transposition of native chromatin for fast and sen.pdf;C\:\\Users
    \verb \\torbe\\Zotero\\storage\\TG6LU2F7\\nmeth.html
    \endverb
    \field{journaltitle}{Nature Methods}
    \field{month}{12}
    \field{year}{2013}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{buenrostroATACseqMethodAssaying2015}{article}{}
    \name{author}{4}{}{%
      {{hash=BJD}{%
         family={Buenrostro},
         familyi={B\bibinitperiod},
         given={Jason\bibnamedelima D.},
         giveni={J\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=WB}{%
         family={Wu},
         familyi={W\bibinitperiod},
         given={Beijing},
         giveni={B\bibinitperiod},
      }}%
      {{hash=CHY}{%
         family={Chang},
         familyi={C\bibinitperiod},
         given={Howard\bibnamedelima Y.},
         giveni={H\bibinitperiod\bibinitdelim Y\bibinitperiod},
      }}%
      {{hash=GWJ}{%
         family={Greenleaf},
         familyi={G\bibinitperiod},
         given={William\bibnamedelima J.},
         giveni={W\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
    }
    \keyw{ATAC-seq,chromatin accessibility,transposase}
    \strng{namehash}{BJD+1}
    \strng{fullhash}{BJDWBCHYGWJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{shorttitle}
    \field{labelyear}{2015}
    \field{extradate}{1}
    \field{labeldatesource}{}
    \field{abstract}{%
    This unit describes Assay for Transposase-Accessible Chromatin with
  high-throughput sequencing (ATAC-seq), a method for mapping chromatin
  accessibility genome-wide. This method probes DNA accessibility with
  hyperactive Tn5 transposase, which inserts sequencing adapters into
  accessible regions of chromatin. Sequencing reads can then be used to infer
  regions of increased accessibility, as well as to map regions of
  transcription-factor binding and nucleosome position. The method is a fast
  and sensitive alternative to DNase-seq for assaying chromatin accessibility
  genome-wide, or to MNase-seq for assaying nucleosome positions in accessible
  regions of the genome. © 2015 by John Wiley \& Sons, Inc.%
    }
    \verb{doi}
    \verb 10.1002/0471142727.mb2129s109
    \endverb
    \field{issn}{1934-3647}
    \field{number}{1}
    \field{pages}{21.29.1\bibrangedash 21.29.9}
    \field{shorttitle}{{{ATAC-seq}}}
    \field{title}{{{ATAC-seq}}: {{A Method}} for {{Assaying Chromatin
  Accessibility Genome-Wide}}}
    \verb{url}
    \verb https://onlinelibrary.wiley.com/doi/abs/10.1002/0471142727.mb2129s109
    \endverb
    \field{volume}{109}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\RKVYJG8G\\Buenrostro et al. - 201
    \verb 5 - ATAC-seq A Method for Assaying Chromatin Accessib.pdf;C\:\\Users\
    \verb \torbe\\Zotero\\storage\\8WLZLE3U\\0471142727.html
    \endverb
    \field{journaltitle}{Current Protocols in Molecular Biology}
    \field{annotation}{%
    \_eprint:
  https://onlinelibrary.wiley.com/doi/pdf/10.1002/0471142727.mb2129s109%
    }
    \field{year}{2015}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{buenrostroSinglecellChromatinAccessibility2015}{article}{}
    \name{author}{8}{}{%
      {{hash=BJD}{%
         family={Buenrostro},
         familyi={B\bibinitperiod},
         given={Jason\bibnamedelima D.},
         giveni={J\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=WB}{%
         family={Wu},
         familyi={W\bibinitperiod},
         given={Beijing},
         giveni={B\bibinitperiod},
      }}%
      {{hash=LUM}{%
         family={Litzenburger},
         familyi={L\bibinitperiod},
         given={Ulrike\bibnamedelima M.},
         giveni={U\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=RD}{%
         family={Ruff},
         familyi={R\bibinitperiod},
         given={Dave},
         giveni={D\bibinitperiod},
      }}%
      {{hash=GML}{%
         family={Gonzales},
         familyi={G\bibinitperiod},
         given={Michael\bibnamedelima L.},
         giveni={M\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=SMP}{%
         family={Snyder},
         familyi={S\bibinitperiod},
         given={Michael\bibnamedelima P.},
         giveni={M\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=CHY}{%
         family={Chang},
         familyi={C\bibinitperiod},
         given={Howard\bibnamedelima Y.},
         giveni={H\bibinitperiod\bibinitdelim Y\bibinitperiod},
      }}%
      {{hash=GWJ}{%
         family={Greenleaf},
         familyi={G\bibinitperiod},
         given={William\bibnamedelima J.},
         giveni={W\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Cellular noise,Chromatin,Epigenomics,Genomic analysis}
    \strng{namehash}{BJD+1}
    \strng{fullhash}{BJDWBLUMRDGMLSMPCHYGWJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2015}
    \field{extradate}{2}
    \field{labeldatesource}{}
    \field{abstract}{%
    A single-cell method for probing genome-wide chromatin accessibility has
  been developed; the results provide insight into the relationship between
  cell-to-cell variation associated with specific trans-factors and
  cis-elements, as well insights into the relationship between chromatin
  accessibility and three-dimensional genome organization.%
    }
    \verb{doi}
    \verb 10.1038/nature14590
    \endverb
    \field{issn}{1476-4687}
    \field{issue}{7561}
    \field{number}{7561}
    \field{pages}{486\bibrangedash 490}
    \field{title}{Single-Cell Chromatin Accessibility Reveals Principles of
  Regulatory Variation}
    \verb{url}
    \verb https://www.nature.com/articles/nature14590
    \endverb
    \field{volume}{523}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\TXNQWXSF\\Buenrostro et al. - 201
    \verb 5 - Single-cell chromatin accessibility reveals princi.pdf;C\:\\Users
    \verb \\torbe\\Zotero\\storage\\R9NFTEBY\\nature14590.html
    \endverb
    \field{journaltitle}{Nature}
    \field{month}{07}
    \field{year}{2015}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{fulcoActivitybycontactModelEnhancer2019a}{article}{}
    \name{author}{19}{}{%
      {{hash=FCP}{%
         family={Fulco},
         familyi={F\bibinitperiod},
         given={Charles\bibnamedelima P.},
         giveni={C\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=NJ}{%
         family={Nasser},
         familyi={N\bibinitperiod},
         given={Joseph},
         giveni={J\bibinitperiod},
      }}%
      {{hash=JTR}{%
         family={Jones},
         familyi={J\bibinitperiod},
         given={Thouis\bibnamedelima R.},
         giveni={T\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=MG}{%
         family={Munson},
         familyi={M\bibinitperiod},
         given={Glen},
         giveni={G\bibinitperiod},
      }}%
      {{hash=BDT}{%
         family={Bergman},
         familyi={B\bibinitperiod},
         given={Drew\bibnamedelima T.},
         giveni={D\bibinitperiod\bibinitdelim T\bibinitperiod},
      }}%
      {{hash=SV}{%
         family={Subramanian},
         familyi={S\bibinitperiod},
         given={Vidya},
         giveni={V\bibinitperiod},
      }}%
      {{hash=GSR}{%
         family={Grossman},
         familyi={G\bibinitperiod},
         given={Sharon\bibnamedelima R.},
         giveni={S\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=AR}{%
         family={Anyoha},
         familyi={A\bibinitperiod},
         given={Rockwell},
         giveni={R\bibinitperiod},
      }}%
      {{hash=DBR}{%
         family={Doughty},
         familyi={D\bibinitperiod},
         given={Benjamin\bibnamedelima R.},
         giveni={B\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=PTA}{%
         family={Patwardhan},
         familyi={P\bibinitperiod},
         given={Tejal\bibnamedelima A.},
         giveni={T\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=NTH}{%
         family={Nguyen},
         familyi={N\bibinitperiod},
         given={Tung\bibnamedelima H.},
         giveni={T\bibinitperiod\bibinitdelim H\bibinitperiod},
      }}%
      {{hash=KM}{%
         family={Kane},
         familyi={K\bibinitperiod},
         given={Michael},
         giveni={M\bibinitperiod},
      }}%
      {{hash=PEM}{%
         family={Perez},
         familyi={P\bibinitperiod},
         given={Elizabeth\bibnamedelima M.},
         giveni={E\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=DNC}{%
         family={Durand},
         familyi={D\bibinitperiod},
         given={Neva\bibnamedelima C.},
         giveni={N\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=LCA}{%
         family={Lareau},
         familyi={L\bibinitperiod},
         given={Caleb\bibnamedelima A.},
         giveni={C\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=SEK}{%
         family={Stamenova},
         familyi={S\bibinitperiod},
         given={Elena\bibnamedelima K.},
         giveni={E\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=AEL}{%
         family={Aiden},
         familyi={A\bibinitperiod},
         given={Erez\bibnamedelima Lieberman},
         giveni={E\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=LES}{%
         family={Lander},
         familyi={L\bibinitperiod},
         given={Eric\bibnamedelima S.},
         giveni={E\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=EJM}{%
         family={Engreitz},
         familyi={E\bibinitperiod},
         given={Jesse\bibnamedelima M.},
         giveni={J\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Epigenetics,Epigenomics,Functional genomics,Gene expression,Gene
  regulation}
    \strng{namehash}{FCP+1}
    \strng{fullhash}{FCPNJJTRMGBDTSVGSRARDBRPTANTHKMPEMDNCLCASEKAELLESEJM1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2019}
    \field{labeldatesource}{}
    \field{abstract}{%
    Enhancer elements in the human genome control how genes are expressed in
  specific cell types and harbor thousands of genetic variants that influence
  risk for common diseases1–4. Yet, we still do not know how enhancers
  regulate specific genes, and we lack general rules to predict enhancer–gene
  connections across cell types5,6. We developed an experimental approach,
  CRISPRi-FlowFISH, to perturb enhancers in the genome, and we applied it to
  test\,{$>$}3,500\,potential enhancer–gene connections for 30\,genes. We
  found that a simple activity-by-contact model substantially outperformed
  previous methods at predicting the complex connections in our CRISPR dataset.
  This activity-by-contact model allows us to construct genome-wide maps of
  enhancer–gene connections in a given cell type, on the basis of chromatin
  state measurements. Together, CRISPRi-FlowFISH and the activity-by-contact
  model provide a systematic approach to map and predict which enhancers
  regulate which genes, and will help to interpret the functions of the
  thousands of disease risk variants in the noncoding genome.%
    }
    \verb{doi}
    \verb 10.1038/s41588-019-0538-0
    \endverb
    \field{issn}{1546-1718}
    \field{issue}{12}
    \field{number}{12}
    \field{pages}{1664\bibrangedash 1669}
    \field{shortjournal}{Nat Genet}
    \field{title}{Activity-by-Contact Model of Enhancer–Promoter Regulation
  from Thousands of {{CRISPR}} Perturbations}
    \verb{url}
    \verb https://www.nature.com/articles/s41588-019-0538-0
    \endverb
    \field{volume}{51}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\4K39YZKC\\Fulco et al. - 2019 - A
    \verb ctivity-by-contact model of enhancer–promoter reg.pdf;C\:\\Users\\t
    \verb orbe\\Zotero\\storage\\E824PLUB\\s41588-019-0538-0.html
    \endverb
    \field{journaltitle}{Nature Genetics}
    \field{month}{12}
    \field{year}{2019}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{nasserGenomewideEnhancerMaps2021a}{article}{}
    \name{author}{32}{}{%
      {{hash=NJ}{%
         family={Nasser},
         familyi={N\bibinitperiod},
         given={Joseph},
         giveni={J\bibinitperiod},
      }}%
      {{hash=BDT}{%
         family={Bergman},
         familyi={B\bibinitperiod},
         given={Drew\bibnamedelima T.},
         giveni={D\bibinitperiod\bibinitdelim T\bibinitperiod},
      }}%
      {{hash=FCP}{%
         family={Fulco},
         familyi={F\bibinitperiod},
         given={Charles\bibnamedelima P.},
         giveni={C\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=GP}{%
         family={Guckelberger},
         familyi={G\bibinitperiod},
         given={Philine},
         giveni={P\bibinitperiod},
      }}%
      {{hash=DBR}{%
         family={Doughty},
         familyi={D\bibinitperiod},
         given={Benjamin\bibnamedelima R.},
         giveni={B\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=PTA}{%
         family={Patwardhan},
         familyi={P\bibinitperiod},
         given={Tejal\bibnamedelima A.},
         giveni={T\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=JTR}{%
         family={Jones},
         familyi={J\bibinitperiod},
         given={Thouis\bibnamedelima R.},
         giveni={T\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=NTH}{%
         family={Nguyen},
         familyi={N\bibinitperiod},
         given={Tung\bibnamedelima H.},
         giveni={T\bibinitperiod\bibinitdelim H\bibinitperiod},
      }}%
      {{hash=UJC}{%
         family={Ulirsch},
         familyi={U\bibinitperiod},
         given={Jacob\bibnamedelima C.},
         giveni={J\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=LF}{%
         family={Lekschas},
         familyi={L\bibinitperiod},
         given={Fritz},
         giveni={F\bibinitperiod},
      }}%
      {{hash=MK}{%
         family={Mualim},
         familyi={M\bibinitperiod},
         given={Kristy},
         giveni={K\bibinitperiod},
      }}%
      {{hash=NHM}{%
         family={Natri},
         familyi={N\bibinitperiod},
         given={Heini\bibnamedelima M.},
         giveni={H\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=WEM}{%
         family={Weeks},
         familyi={W\bibinitperiod},
         given={Elle\bibnamedelima M.},
         giveni={E\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=MG}{%
         family={Munson},
         familyi={M\bibinitperiod},
         given={Glen},
         giveni={G\bibinitperiod},
      }}%
      {{hash=KM}{%
         family={Kane},
         familyi={K\bibinitperiod},
         given={Michael},
         giveni={M\bibinitperiod},
      }}%
      {{hash=KHY}{%
         family={Kang},
         familyi={K\bibinitperiod},
         given={Helen\bibnamedelima Y.},
         giveni={H\bibinitperiod\bibinitdelim Y\bibinitperiod},
      }}%
      {{hash=CA}{%
         family={Cui},
         familyi={C\bibinitperiod},
         given={Ang},
         giveni={A\bibinitperiod},
      }}%
      {{hash=RJP}{%
         family={Ray},
         familyi={R\bibinitperiod},
         given={John\bibnamedelima P.},
         giveni={J\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=ETM}{%
         family={Eisenhaure},
         familyi={E\bibinitperiod},
         given={Thomas\bibnamedelima M.},
         giveni={T\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=CRL}{%
         family={Collins},
         familyi={C\bibinitperiod},
         given={Ryan\bibnamedelima L.},
         giveni={R\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=DK}{%
         family={Dey},
         familyi={D\bibinitperiod},
         given={Kushal},
         giveni={K\bibinitperiod},
      }}%
      {{hash=PH}{%
         family={Pfister},
         familyi={P\bibinitperiod},
         given={Hanspeter},
         giveni={H\bibinitperiod},
      }}%
      {{hash=PAL}{%
         family={Price},
         familyi={P\bibinitperiod},
         given={Alkes\bibnamedelima L.},
         giveni={A\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=ECB}{%
         family={Epstein},
         familyi={E\bibinitperiod},
         given={Charles\bibnamedelima B.},
         giveni={C\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=KA}{%
         family={Kundaje},
         familyi={K\bibinitperiod},
         given={Anshul},
         giveni={A\bibinitperiod},
      }}%
      {{hash=XRJ}{%
         family={Xavier},
         familyi={X\bibinitperiod},
         given={Ramnik\bibnamedelima J.},
         giveni={R\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=DMJ}{%
         family={Daly},
         familyi={D\bibinitperiod},
         given={Mark\bibnamedelima J.},
         giveni={M\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=HH}{%
         family={Huang},
         familyi={H\bibinitperiod},
         given={Hailiang},
         giveni={H\bibinitperiod},
      }}%
      {{hash=FHK}{%
         family={Finucane},
         familyi={F\bibinitperiod},
         given={Hilary\bibnamedelima K.},
         giveni={H\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=HN}{%
         family={Hacohen},
         familyi={H\bibinitperiod},
         given={Nir},
         giveni={N\bibinitperiod},
      }}%
      {{hash=LES}{%
         family={Lander},
         familyi={L\bibinitperiod},
         given={Eric\bibnamedelima S.},
         giveni={E\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=EJM}{%
         family={Engreitz},
         familyi={E\bibinitperiod},
         given={Jesse\bibnamedelima M.},
         giveni={J\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Gene expression,Gene regulation,Genome-wide association
  studies,Immunogenetics,Inflammatory bowel disease}
    \strng{namehash}{NJ+1}
  \strng{fullhash}{NJBDTFCPGPDBRPTAJTRNTHUJCLFMKNHMWEMMGKMKHYCARJPETMCRLDKPHPALECBKAXRJDMJHHFHKHNLESEJM1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2021}
    \field{labeldatesource}{}
    \field{abstract}{%
    Genome-wide association studies (GWAS) have identified thousands of
  noncoding loci that are associated with human diseases and complex traits,
  each of which could reveal insights into the mechanisms of disease1. Many of
  the underlying causal variants may affect enhancers2,3, but we lack accurate
  maps of enhancers and their target genes to interpret such variants. We
  recently developed the activity-by-contact (ABC) model to predict which
  enhancers regulate which genes and validated the model using CRISPR
  perturbations in several cell types4. Here we apply this ABC model to create
  enhancer–gene~maps in 131 human cell types and tissues, and use these maps
  to interpret the functions of GWAS variants. Across 72 diseases and complex
  traits, ABC links 5,036 GWAS signals to 2,249 unique genes, including a class
  of 577 genes that appear to influence multiple phenotypes through variants in
  enhancers that act in different cell types. In inflammatory bowel disease
  (IBD), causal variants are enriched in predicted enhancers by more than
  20-fold in particular cell types such as dendritic cells, and ABC achieves
  higher precision than other regulatory methods at connecting noncoding
  variants to target genes. These variant-to-function maps reveal an enhancer
  that contains an IBD risk variant and that regulates the expression of PPIF
  to alter the membrane potential of mitochondria in macrophages. Our study
  reveals principles of genome regulation, identifies genes that affect IBD and
  provides a resource and generalizable strategy to connect risk variants of
  common diseases to their molecular and cellular functions.%
    }
    \verb{doi}
    \verb 10.1038/s41586-021-03446-x
    \endverb
    \field{issn}{1476-4687}
    \field{issue}{7858}
    \field{number}{7858}
    \field{pages}{238\bibrangedash 243}
    \field{title}{Genome-Wide Enhancer Maps Link Risk Variants to Disease
  Genes}
    \verb{url}
    \verb https://www.nature.com/articles/s41586-021-03446-x
    \endverb
    \field{volume}{593}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\YHKVLZQU\\Nasser et al. - 2021 -
    \verb Genome-wide enhancer maps link risk variants to di.pdf;C\:\\Users\\to
    \verb rbe\\Zotero\\storage\\G89C36YN\\s41586-021-03446-x.html
    \endverb
    \field{journaltitle}{Nature}
    \field{month}{05}
    \field{year}{2021}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{lieberman-aidenComprehensiveMappingLongRange2009}{article}{useprefix}
    \name{author}{19}{}{%
      {{hash=LAE}{%
         family={Lieberman-Aiden},
         familyi={L\bibinithyphendelim A\bibinitperiod},
         given={Erez},
         giveni={E\bibinitperiod},
      }}%
      {{hash=vBNL}{%
         prefix={van},
         prefixi={v\bibinitperiod},
         family={Berkum},
         familyi={B\bibinitperiod},
         given={Nynke\bibnamedelima L.},
         giveni={N\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=WL}{%
         family={Williams},
         familyi={W\bibinitperiod},
         given={Louise},
         giveni={L\bibinitperiod},
      }}%
      {{hash=IM}{%
         family={Imakaev},
         familyi={I\bibinitperiod},
         given={Maxim},
         giveni={M\bibinitperiod},
      }}%
      {{hash=RT}{%
         family={Ragoczy},
         familyi={R\bibinitperiod},
         given={Tobias},
         giveni={T\bibinitperiod},
      }}%
      {{hash=TA}{%
         family={Telling},
         familyi={T\bibinitperiod},
         given={Agnes},
         giveni={A\bibinitperiod},
      }}%
      {{hash=AI}{%
         family={Amit},
         familyi={A\bibinitperiod},
         given={Ido},
         giveni={I\bibinitperiod},
      }}%
      {{hash=LBR}{%
         family={Lajoie},
         familyi={L\bibinitperiod},
         given={Bryan\bibnamedelima R.},
         giveni={B\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=SPJ}{%
         family={Sabo},
         familyi={S\bibinitperiod},
         given={Peter\bibnamedelima J.},
         giveni={P\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=DMO}{%
         family={Dorschner},
         familyi={D\bibinitperiod},
         given={Michael\bibnamedelima O.},
         giveni={M\bibinitperiod\bibinitdelim O\bibinitperiod},
      }}%
      {{hash=SR}{%
         family={Sandstrom},
         familyi={S\bibinitperiod},
         given={Richard},
         giveni={R\bibinitperiod},
      }}%
      {{hash=BB}{%
         family={Bernstein},
         familyi={B\bibinitperiod},
         given={Bradley},
         giveni={B\bibinitperiod},
      }}%
      {{hash=BMA}{%
         family={Bender},
         familyi={B\bibinitperiod},
         given={M.\bibnamedelima A.},
         giveni={M\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=GM}{%
         family={Groudine},
         familyi={G\bibinitperiod},
         given={Mark},
         giveni={M\bibinitperiod},
      }}%
      {{hash=GA}{%
         family={Gnirke},
         familyi={G\bibinitperiod},
         given={Andreas},
         giveni={A\bibinitperiod},
      }}%
      {{hash=SJ}{%
         family={Stamatoyannopoulos},
         familyi={S\bibinitperiod},
         given={John},
         giveni={J\bibinitperiod},
      }}%
      {{hash=MLA}{%
         family={Mirny},
         familyi={M\bibinitperiod},
         given={Leonid\bibnamedelima A.},
         giveni={L\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=LES}{%
         family={Lander},
         familyi={L\bibinitperiod},
         given={Eric\bibnamedelima S.},
         giveni={E\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=DJ}{%
         family={Dekker},
         familyi={D\bibinitperiod},
         given={Job},
         giveni={J\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Association for the Advancement of Science}}%
    }
    \strng{namehash}{LAE+1}
    \strng{fullhash}{LAEvBNLWLIMRTTAAILBRSPJDMOSRBBBMAGMGASJMLALESDJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2009}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.1126/science.1181369
    \endverb
    \field{number}{5950}
    \field{pages}{289\bibrangedash 293}
    \field{title}{Comprehensive {{Mapping}} of {{Long-Range Interactions
  Reveals Folding Principles}} of the {{Human Genome}}}
    \verb{url}
    \verb https://www.science.org/doi/10.1126/science.1181369
    \endverb
    \field{volume}{326}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\GYIE3BDF\\Lieberman-Aiden et al.
    \verb - 2009 - Comprehensive Mapping of Long-Range Interactions R.pdf
    \endverb
    \field{journaltitle}{Science}
    \field{day}{09}
    \field{month}{10}
    \field{year}{2009}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{witDecade3CTechnologies2012}{article}{}
    \name{author}{2}{}{%
      {{hash=dWE}{%
         prefix={de},
         prefixi={d\bibinitperiod},
         family={Wit},
         familyi={W\bibinitperiod},
         given={Elzo},
         giveni={E\bibinitperiod},
      }}%
      {{hash=dLW}{%
         prefix={de},
         prefixi={d\bibinitperiod},
         family={Laat},
         familyi={L\bibinitperiod},
         given={Wouter},
         giveni={W\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Cold Spring Harbor Lab}}%
    }
    \keyw{chromosome conformation capture,functional genomics,genome
  structure,nuclear organization}
    \strng{namehash}{WEdLWd1}
    \strng{fullhash}{WEdLWd1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{shorttitle}
    \field{labelyear}{2012}
    \field{labeldatesource}{}
    \field{abstract}{%
    Over the past 10 years, the development of chromosome conformation capture
  (3C) technology and the subsequent genomic variants thereof have enabled the
  analysis of nuclear organization at an unprecedented resolution and
  throughput. The technology relies on the original and, in hindsight,
  remarkably simple idea that digestion and religation of fixed chromatin in
  cells, followed by the quantification of ligation junctions, allows for the
  determination of DNA contact frequencies and insight into chromosome
  topology. Here we evaluate and compare the current 3C-based methods
  (including 4C [chromosome conformation capture-on-chip], 5C [chromosome
  conformation capture carbon copy], HiC, and ChIA-PET), summarize their
  contribution to our current understanding of genome structure, and discuss
  how shape influences genome function.%
    }
    \verb{doi}
    \verb 10.1101/gad.179804.111
    \endverb
    \verb{eprint}
    \verb 22215806
    \endverb
    \field{issn}{0890-9369, 1549-5477}
    \field{number}{1}
    \field{pages}{11\bibrangedash 24}
    \field{shortjournal}{Genes Dev.}
    \field{shorttitle}{A Decade of {{3C}} Technologies}
    \field{title}{A Decade of {{3C}} Technologies: Insights into Nuclear
  Organization}
    \verb{url}
    \verb http://genesdev.cshlp.org/content/26/1/11
    \endverb
    \field{volume}{26}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\2RXTZL7T\\Wit und Laat - 2012 - A
    \verb  decade of 3C technologies insights into nuclear.pdf;C\:\\Users\\torb
    \verb e\\Zotero\\storage\\LATD4ZSX\\11.html
    \endverb
    \field{journaltitle}{Genes \& Development}
    \field{eprinttype}{pmid}
    \field{day}{01}
    \field{month}{01}
    \field{year}{2012}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{dixonTopologicalDomainsMammalian2012}{article}{}
    \name{author}{9}{}{%
      {{hash=DJR}{%
         family={Dixon},
         familyi={D\bibinitperiod},
         given={Jesse\bibnamedelima R.},
         giveni={J\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=SS}{%
         family={Selvaraj},
         familyi={S\bibinitperiod},
         given={Siddarth},
         giveni={S\bibinitperiod},
      }}%
      {{hash=YF}{%
         family={Yue},
         familyi={Y\bibinitperiod},
         given={Feng},
         giveni={F\bibinitperiod},
      }}%
      {{hash=KA}{%
         family={Kim},
         familyi={K\bibinitperiod},
         given={Audrey},
         giveni={A\bibinitperiod},
      }}%
      {{hash=LY}{%
         family={Li},
         familyi={L\bibinitperiod},
         given={Yan},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=SY}{%
         family={Shen},
         familyi={S\bibinitperiod},
         given={Yin},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=HM}{%
         family={Hu},
         familyi={H\bibinitperiod},
         given={Ming},
         giveni={M\bibinitperiod},
      }}%
      {{hash=LJS}{%
         family={Liu},
         familyi={L\bibinitperiod},
         given={Jun\bibnamedelima S.},
         giveni={J\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=RB}{%
         family={Ren},
         familyi={R\bibinitperiod},
         given={Bing},
         giveni={B\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Chromatin analysis,Chromosomes,Genomics}
    \strng{namehash}{DJR+1}
    \strng{fullhash}{DJRSSYFKALYSYHMLJSRB1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2012}
    \field{labeldatesource}{}
    \field{abstract}{%
    The three-dimensional organization of the human and mouse genomes in
  embryonic stem cells and terminally differentiated cell types is
  investigated, revealing that large, megabase-sized chromatin interaction
  domains are a pervasive and conserved structural feature of genome
  organization.%
    }
    \verb{doi}
    \verb 10.1038/nature11082
    \endverb
    \field{issn}{1476-4687}
    \field{issue}{7398}
    \field{number}{7398}
    \field{pages}{376\bibrangedash 380}
    \field{title}{Topological Domains in Mammalian Genomes Identified by
  Analysis of Chromatin Interactions}
    \verb{url}
    \verb https://www.nature.com/articles/nature11082
    \endverb
    \field{volume}{485}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\4MR956R4\\Dixon et al. - 2012 - T
    \verb opological domains in mammalian genomes identifie.pdf;C\:\\Users\\tor
    \verb be\\Zotero\\storage\\BGQJK3DZ\\nature11082.html
    \endverb
    \field{journaltitle}{Nature}
    \field{month}{05}
    \field{year}{2012}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{wang3DGenomeBrowser2018}{article}{}
    \name{author}{13}{}{%
      {{hash=WY}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Yanli},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=SF}{%
         family={Song},
         familyi={S\bibinitperiod},
         given={Fan},
         giveni={F\bibinitperiod},
      }}%
      {{hash=ZB}{%
         family={Zhang},
         familyi={Z\bibinitperiod},
         given={Bo},
         giveni={B\bibinitperiod},
      }}%
      {{hash=ZL}{%
         family={Zhang},
         familyi={Z\bibinitperiod},
         given={Lijun},
         giveni={L\bibinitperiod},
      }}%
      {{hash=XJ}{%
         family={Xu},
         familyi={X\bibinitperiod},
         given={Jie},
         giveni={J\bibinitperiod},
      }}%
      {{hash=KD}{%
         family={Kuang},
         familyi={K\bibinitperiod},
         given={Da},
         giveni={D\bibinitperiod},
      }}%
      {{hash=LD}{%
         family={Li},
         familyi={L\bibinitperiod},
         given={Daofeng},
         giveni={D\bibinitperiod},
      }}%
      {{hash=CMNK}{%
         family={Choudhary},
         familyi={C\bibinitperiod},
         given={Mayank N.\bibnamedelima K.},
         giveni={M\bibinitperiod\bibinitdelim N\bibinitperiod\bibinitdelim
  K\bibinitperiod},
      }}%
      {{hash=LY}{%
         family={Li},
         familyi={L\bibinitperiod},
         given={Yun},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=HM}{%
         family={Hu},
         familyi={H\bibinitperiod},
         given={Ming},
         giveni={M\bibinitperiod},
      }}%
      {{hash=HR}{%
         family={Hardison},
         familyi={H\bibinitperiod},
         given={Ross},
         giveni={R\bibinitperiod},
      }}%
      {{hash=WT}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Ting},
         giveni={T\bibinitperiod},
      }}%
      {{hash=YF}{%
         family={Yue},
         familyi={Y\bibinitperiod},
         given={Feng},
         giveni={F\bibinitperiod},
      }}%
    }
    \keyw{Chromatin Interaction Data,Enhancer-promoter Interactions,Roadmap
  Epigenomics Project,Topologically Associating Domains (TADs),WashU Epigenome
  Browser}
    \strng{namehash}{WY+2}
    \strng{fullhash}{WYSFZBZLXJKDLDCMNKLYHMHRWTYF1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{shorttitle}
    \field{labelyear}{2018}
    \field{extradate}{2}
    \field{labeldatesource}{}
    \field{abstract}{%
    Here, we introduce the 3D Genome Browser, http://3dgenome.org, which allows
  users to conveniently explore both their own and over 300 publicly available
  chromatin interaction data of different types. We design a new binary data
  format for Hi-C data that reduces the file size by at least a magnitude and
  allows users to visualize chromatin interactions over millions of base pairs
  within seconds. Our browser provides multiple methods linking distal
  cis-regulatory elements with their potential target genes. Users can
  seamlessly integrate thousands of other omics data to gain a comprehensive
  view of both regulatory landscape and 3D genome structure.%
    }
    \verb{doi}
    \verb 10.1186/s13059-018-1519-9
    \endverb
    \field{issn}{1474-760X}
    \field{number}{1}
    \field{pages}{151}
    \field{shortjournal}{Genome Biology}
    \field{shorttitle}{The {{3D Genome Browser}}}
    \field{title}{The {{3D Genome Browser}}: A Web-Based Browser for
  Visualizing {{3D}} Genome Organization and Long-Range Chromatin Interactions}
    \verb{url}
    \verb https://doi.org/10.1186/s13059-018-1519-9
    \endverb
    \field{volume}{19}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\YNVPV74T\\Wang et al. - 2018 - Th
    \verb e 3D Genome Browser a web-based browser for vis.pdf;C\:\\Users\\torbe
    \verb \\Zotero\\storage\\ER58Y24K\\s13059-018-1519-9.html
    \endverb
    \field{journaltitle}{Genome Biology}
    \field{day}{04}
    \field{month}{10}
    \field{year}{2018}
    \field{urlday}{07}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{pomboThreedimensionalGenomeArchitecture2015}{article}{}
    \name{author}{2}{}{%
      {{hash=PA}{%
         family={Pombo},
         familyi={P\bibinitperiod},
         given={Ana},
         giveni={A\bibinitperiod},
      }}%
      {{hash=DN}{%
         family={Dillon},
         familyi={D\bibinitperiod},
         given={Niall},
         giveni={N\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Chromatin structure,Nuclear organization}
    \strng{namehash}{PADN1}
    \strng{fullhash}{PADN1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{shorttitle}
    \field{labelyear}{2015}
    \field{labeldatesource}{}
    \field{abstract}{%
    Contacts between distant genomic regions in the same or in different
  chromosomes are important in the regulation of gene expression, as
  highlighted by the activation of genes by chromatin contacts between
  promoters and enhancers that can lie hundreds of kb away.Chromatin contacts
  are currently measured by two main approaches: chromosome conformation
  capture (3C)-based techniques and nuclear imaging methods such as
  fluorescence in situ hybridization (FISH). Both approaches have caveats, and
  the field is ripe for further technical development.The formation of
  chromatin contacts is promoted by chromatin-binding proteins that can bind
  two or more genomic regions simultaneously. Such proteins include
  transcription factors, RNA and DNA polymerases, Polycomb repressive complexes
  and chromosomal scaffold proteins such as cohesin.Topologically associating
  domains (TADs) are genomic regions enriched with contacts within them. TADs
  have specific sizes and positions in the genome and are found in a wide range
  of metazoans. The factors and mechanisms that promote TAD formation are a
  matter of considerable debate.The three-dimensional organization of the
  genome also depends on the formation of chromatin contacts with nuclear
  domains and compartments such as the nuclear lamina and the nucleolus.
  Specific sets of chromatin contacts are formed within each chromosome, and
  between them and nuclear domains. The mechanisms that govern chromosome
  localization, volume and shape remain poorly understood.Many cellular
  processes such as division, differentiation and senescence, present
  challenges to the maintenance of nuclear organization, gene expression
  programs and cell identity. At the same time, they can also offer
  opportunities for chromatin remodelling and the reinforcement of gene
  expression patterns.%
    }
    \verb{doi}
    \verb 10.1038/nrm3965
    \endverb
    \field{issn}{1471-0080}
    \field{issue}{4}
    \field{number}{4}
    \field{pages}{245\bibrangedash 257}
    \field{shortjournal}{Nat Rev Mol Cell Biol}
    \field{shorttitle}{Three-Dimensional Genome Architecture}
    \field{title}{Three-Dimensional Genome Architecture: Players and
  Mechanisms}
    \verb{url}
    \verb https://www.nature.com/articles/nrm3965
    \endverb
    \field{volume}{16}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\I589ZII7\\Pombo und Dillon - 2015
    \verb  - Three-dimensional genome architecture players and.pdf;C\:\\Users\\
    \verb torbe\\Zotero\\storage\\N84G4FH4\\nrm3965.html
    \endverb
    \field{journaltitle}{Nature Reviews Molecular Cell Biology}
    \field{month}{04}
    \field{year}{2015}
    \field{urlday}{28}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{burtenshawReactiveOxygenSpecies2019}{article}{}
    \name{author}{5}{}{%
      {{hash=BD}{%
         family={Burtenshaw},
         familyi={B\bibinitperiod},
         given={Denise},
         giveni={D\bibinitperiod},
      }}%
      {{hash=KM}{%
         family={Kitching},
         familyi={K\bibinitperiod},
         given={Michael},
         giveni={M\bibinitperiod},
      }}%
      {{hash=REM}{%
         family={Redmond},
         familyi={R\bibinitperiod},
         given={Eileen\bibnamedelima M.},
         giveni={E\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=MIL}{%
         family={Megson},
         familyi={M\bibinitperiod},
         given={Ian\bibnamedelima L.},
         giveni={I\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=CPA}{%
         family={Cahill},
         familyi={C\bibinitperiod},
         given={Paul\bibnamedelima A.},
         giveni={P\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
    }
    \strng{namehash}{BD+1}
    \strng{fullhash}{BDKMREMMILCPA1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2019}
    \field{labeldatesource}{}
    \field{abstract}{%
    Arteriosclerosis causes significant morbidity and mortality worldwide.
  Central to this process is the development of subclinical non-atherosclerotic
  intimal lesions before the appearance of pathologic intimal thickening and
  advanced atherosclerotic plaques. Intimal thickening is associated with
  several risk factors, including oxidative stress due to reactive oxygen
  species (ROS), inflammatory cytokines and lipid. The main ROS producing
  systems in-vivo are reduced nicotinamide dinucleotide phosphate (NADPH)
  oxidase (NOX). ROS effects are context specific. Exogenous ROS induces
  apoptosis and senescence, whereas intracellular ROS promotes stem cell
  differentiation, proliferation, and migration. Lineage tracing studies using
  murine models of subclinical atherosclerosis have revealed the contributory
  role of medial smooth muscle cells (SMCs), resident vascular stem cells,
  circulating bone-marrow progenitors and endothelial cells that undergo
  endothelial-mesenchymal-transition (EndMT). This review will address the
  putative physiological and patho-physiological roles of ROS in controlling
  vascular cell fate and ROS contribution to vascular regeneration and disease
  progression.%
    }
    \verb{doi}
    \verb 10.3389/fcvm.2019.00089
    \endverb
    \verb{eprint}
    \verb 31428618
    \endverb
    \field{issn}{2297-055X}
    \field{pages}{89}
    \field{shortjournal}{Front Cardiovasc Med}
    \field{title}{Reactive {{Oxygen Species}} ({{ROS}}), {{Intimal
  Thickening}}, and {{Subclinical Atherosclerotic Disease}}}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688526/
    \endverb
    \field{volume}{6}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\KAPQAR8I\\Burtenshaw et al. - 201
    \verb 9 - Reactive Oxygen Species (ROS), Intimal Thickening,.pdf
    \endverb
    \field{journaltitle}{Frontiers in Cardiovascular Medicine}
    \field{eprinttype}{pmid}
    \field{day}{02}
    \field{month}{08}
    \field{year}{2019}
    \field{urlday}{05}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{aragamDiscoverySystematicCharacterization2021}{article}{}
    \name{author}{94}{}{%
      {{hash=AKG}{%
         family={Aragam},
         familyi={A\bibinitperiod},
         given={Krishna\bibnamedelima G.},
         giveni={K\bibinitperiod\bibinitdelim G\bibinitperiod},
      }}%
      {{hash=JT}{%
         family={Jiang},
         familyi={J\bibinitperiod},
         given={Tao},
         giveni={T\bibinitperiod},
      }}%
      {{hash=GA}{%
         family={Goel},
         familyi={G\bibinitperiod},
         given={Anuj},
         giveni={A\bibinitperiod},
      }}%
      {{hash=KS}{%
         family={Kanoni},
         familyi={K\bibinitperiod},
         given={Stavroula},
         giveni={S\bibinitperiod},
      }}%
      {{hash=WBN}{%
         family={Wolford},
         familyi={W\bibinitperiod},
         given={Brooke\bibnamedelima N.},
         giveni={B\bibinitperiod\bibinitdelim N\bibinitperiod},
      }}%
      {{hash=WEM}{%
         family={Weeks},
         familyi={W\bibinitperiod},
         given={Elle\bibnamedelima M.},
         giveni={E\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=WM}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Minxian},
         giveni={M\bibinitperiod},
      }}%
      {{hash=HG}{%
         family={Hindy},
         familyi={H\bibinitperiod},
         given={George},
         giveni={G\bibinitperiod},
      }}%
      {{hash=ZW}{%
         family={Zhou},
         familyi={Z\bibinitperiod},
         given={Wei},
         giveni={W\bibinitperiod},
      }}%
      {{hash=GC}{%
         family={Grace},
         familyi={G\bibinitperiod},
         given={Christopher},
         giveni={C\bibinitperiod},
      }}%
      {{hash=RC}{%
         family={Roselli},
         familyi={R\bibinitperiod},
         given={Carolina},
         giveni={C\bibinitperiod},
      }}%
      {{hash=MNA}{%
         family={Marston},
         familyi={M\bibinitperiod},
         given={Nicholas\bibnamedelima A.},
         giveni={N\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=KFK}{%
         family={Kamanu},
         familyi={K\bibinitperiod},
         given={Frederick\bibnamedelima K.},
         giveni={F\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=SI}{%
         family={Surakka},
         familyi={S\bibinitperiod},
         given={Ida},
         giveni={I\bibinitperiod},
      }}%
      {{hash=VLM}{%
         family={Venegas},
         familyi={V\bibinitperiod},
         given={Loreto\bibnamedelima Muñoz},
         giveni={L\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=SP}{%
         family={Sherliker},
         familyi={S\bibinitperiod},
         given={Paul},
         giveni={P\bibinitperiod},
      }}%
      {{hash=KS}{%
         family={Koyama},
         familyi={K\bibinitperiod},
         given={Satoshi},
         giveni={S\bibinitperiod},
      }}%
      {{hash=IK}{%
         family={Ishigaki},
         familyi={I\bibinitperiod},
         given={Kazuyoshi},
         giveni={K\bibinitperiod},
      }}%
      {{hash=ABO}{%
         family={Aasvold},
         familyi={A\bibinitperiod},
         given={Bjørn\bibnamedelima O.},
         giveni={B\bibinitperiod\bibinitdelim O\bibinitperiod},
      }}%
      {{hash=BMR}{%
         family={Brown},
         familyi={B\bibinitperiod},
         given={Michael\bibnamedelima R.},
         giveni={M\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=BB}{%
         family={Brumpton},
         familyi={B\bibinitperiod},
         given={Ben},
         giveni={B\bibinitperiod},
      }}%
      {{hash=dVPS}{%
         prefix={de},
         prefixi={d\bibinitperiod},
         family={Vries},
         familyi={V\bibinitperiod},
         given={Paul\bibnamedelima S.},
         giveni={P\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=GO}{%
         family={Giannakopoulou},
         familyi={G\bibinitperiod},
         given={Olga},
         giveni={O\bibinitperiod},
      }}%
      {{hash=GP}{%
         family={Giardoglou},
         familyi={G\bibinitperiod},
         given={Panagiota},
         giveni={P\bibinitperiod},
      }}%
      {{hash=GDF}{%
         family={Gudbjartsson},
         familyi={G\bibinitperiod},
         given={Daniel\bibnamedelima F.},
         giveni={D\bibinitperiod\bibinitdelim F\bibinitperiod},
      }}%
      {{hash=GU}{%
         family={Güldener},
         familyi={G\bibinitperiod},
         given={Ulrich},
         giveni={U\bibinitperiod},
      }}%
      {{hash=HSMI}{%
         family={Haider},
         familyi={H\bibinitperiod},
         given={Syed M.\bibnamedelima Ijlal},
         giveni={S\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim
  I\bibinitperiod},
      }}%
      {{hash=HA}{%
         family={Helgadottir},
         familyi={H\bibinitperiod},
         given={Anna},
         giveni={A\bibinitperiod},
      }}%
      {{hash=IM}{%
         family={Ibrahim},
         familyi={I\bibinitperiod},
         given={Maysson},
         giveni={M\bibinitperiod},
      }}%
      {{hash=KA}{%
         family={Kastrati},
         familyi={K\bibinitperiod},
         given={Adnan},
         giveni={A\bibinitperiod},
      }}%
      {{hash=KT}{%
         family={Kessler},
         familyi={K\bibinitperiod},
         given={Thorsten},
         giveni={T\bibinitperiod},
      }}%
      {{hash=LL}{%
         family={Li},
         familyi={L\bibinitperiod},
         given={Ling},
         giveni={L\bibinitperiod},
      }}%
      {{hash=ML}{%
         family={Ma},
         familyi={M\bibinitperiod},
         given={Lijiang},
         giveni={L\bibinitperiod},
      }}%
      {{hash=MT}{%
         family={Meitinger},
         familyi={M\bibinitperiod},
         given={Thomas},
         giveni={T\bibinitperiod},
      }}%
      {{hash=MS}{%
         family={Mucha},
         familyi={M\bibinitperiod},
         given={Sören},
         giveni={S\bibinitperiod},
      }}%
      {{hash=MM}{%
         family={Munz},
         familyi={M\bibinitperiod},
         given={Matthias},
         giveni={M\bibinitperiod},
      }}%
      {{hash=MF}{%
         family={Murgia},
         familyi={M\bibinitperiod},
         given={Federico},
         giveni={F\bibinitperiod},
      }}%
      {{hash=NJB}{%
         family={Nielsen},
         familyi={N\bibinitperiod},
         given={Jonas\bibnamedelima B.},
         giveni={J\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=NMM}{%
         family={Nöthen},
         familyi={N\bibinitperiod},
         given={Markus\bibnamedelima M.},
         giveni={M\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=PS}{%
         family={Pang},
         familyi={P\bibinitperiod},
         given={Shichao},
         giveni={S\bibinitperiod},
      }}%
      {{hash=RT}{%
         family={Reinberger},
         familyi={R\bibinitperiod},
         given={Tobias},
         giveni={T\bibinitperiod},
      }}%
      {{hash=TG}{%
         family={Thorleifsson},
         familyi={T\bibinitperiod},
         given={Gudmar},
         giveni={G\bibinitperiod},
      }}%
      {{hash=vSM}{%
         prefix={von},
         prefixi={v\bibinitperiod},
         family={Scheidt},
         familyi={S\bibinitperiod},
         given={Moritz},
         giveni={M\bibinitperiod},
      }}%
      {{hash=UJK}{%
         family={Ulirsch},
         familyi={U\bibinitperiod},
         given={Jacob\bibnamedelima K.},
         giveni={J\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=CEC}{%
         family={Consortium},
         familyi={C\bibinitperiod},
         given={Epic-Cvd},
         giveni={E\bibinithyphendelim C\bibinitperiod},
      }}%
      {{hash=JB}{%
         family={Japan},
         familyi={J\bibinitperiod},
         given={Biobank},
         giveni={B\bibinitperiod},
      }}%
      {{hash=ADO}{%
         family={Arnar},
         familyi={A\bibinitperiod},
         given={David\bibnamedelima O.},
         giveni={D\bibinitperiod\bibinitdelim O\bibinitperiod},
      }}%
      {{hash=ADS}{%
         family={Atri},
         familyi={A\bibinitperiod},
         given={Deepak\bibnamedelima S.},
         giveni={D\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=BNP}{%
         family={Burtt},
         familyi={B\bibinitperiod},
         given={Noël\bibnamedelima P.},
         giveni={N\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=CMC}{%
         family={Costanzo},
         familyi={C\bibinitperiod},
         given={Maria\bibnamedelima C.},
         giveni={M\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=FJ}{%
         family={Flannick},
         familyi={F\bibinitperiod},
         given={Jason},
         giveni={J\bibinitperiod},
      }}%
      {{hash=GRM}{%
         family={Gupta},
         familyi={G\bibinitperiod},
         given={Rajat\bibnamedelima M.},
         giveni={R\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=IK}{%
         family={Ito},
         familyi={I\bibinitperiod},
         given={Kaoru},
         giveni={K\bibinitperiod},
      }}%
      {{hash=JDK}{%
         family={Jang},
         familyi={J\bibinitperiod},
         given={Dong-Keun},
         giveni={D\bibinithyphendelim K\bibinitperiod},
      }}%
      {{hash=KY}{%
         family={Kamatani},
         familyi={K\bibinitperiod},
         given={Yoichiro},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=KAV}{%
         family={Khera},
         familyi={K\bibinitperiod},
         given={Amit\bibnamedelima V.},
         giveni={A\bibinitperiod\bibinitdelim V\bibinitperiod},
      }}%
      {{hash=KI}{%
         family={Komuro},
         familyi={K\bibinitperiod},
         given={Issei},
         giveni={I\bibinitperiod},
      }}%
      {{hash=KIJ}{%
         family={Kullo},
         familyi={K\bibinitperiod},
         given={Iftikhar\bibnamedelima J.},
         giveni={I\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=LLA}{%
         family={Lotta},
         familyi={L\bibinitperiod},
         given={Luca\bibnamedelima A.},
         giveni={L\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=NCP}{%
         family={Nelson},
         familyi={N\bibinitperiod},
         given={Christopher\bibnamedelima P.},
         giveni={C\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=RR}{%
         family={Roberts},
         familyi={R\bibinitperiod},
         given={Robert},
         giveni={R\bibinitperiod},
      }}%
      {{hash=TG}{%
         family={Thorgeirsson},
         familyi={T\bibinitperiod},
         given={Gudmundur},
         giveni={G\bibinitperiod},
      }}%
      {{hash=TU}{%
         family={Thorsteinsdottir},
         familyi={T\bibinitperiod},
         given={Unnur},
         giveni={U\bibinitperiod},
      }}%
      {{hash=WTR}{%
         family={Webb},
         familyi={W\bibinitperiod},
         given={Thomas\bibnamedelima R.},
         giveni={T\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=BA}{%
         family={Baras},
         familyi={B\bibinitperiod},
         given={Aris},
         giveni={A\bibinitperiod},
      }}%
      {{hash=BJL}{%
         family={Björkegren},
         familyi={B\bibinitperiod},
         given={Johan\bibnamedelima LM},
         giveni={J\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=BE}{%
         family={Boerwinkle},
         familyi={B\bibinitperiod},
         given={Eric},
         giveni={E\bibinitperiod},
      }}%
      {{hash=DG}{%
         family={Dedoussis},
         familyi={D\bibinitperiod},
         given={George},
         giveni={G\bibinitperiod},
      }}%
      {{hash=HH}{%
         family={Holm},
         familyi={H\bibinitperiod},
         given={Hilma},
         giveni={H\bibinitperiod},
      }}%
      {{hash=HK}{%
         family={Hveem},
         familyi={H\bibinitperiod},
         given={Kristian},
         giveni={K\bibinitperiod},
      }}%
      {{hash=MO}{%
         family={Melander},
         familyi={M\bibinitperiod},
         given={Olle},
         giveni={O\bibinitperiod},
      }}%
      {{hash=MAC}{%
         family={Morrison},
         familyi={M\bibinitperiod},
         given={Alanna\bibnamedelima C.},
         giveni={A\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=OMM}{%
         family={Orho-Melander},
         familyi={O\bibinithyphendelim M\bibinitperiod},
         given={Marju},
         giveni={M\bibinitperiod},
      }}%
      {{hash=RLS}{%
         family={Rallidis},
         familyi={R\bibinitperiod},
         given={Loukianos\bibnamedelima S.},
         giveni={L\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=RA}{%
         family={Ruusalepp},
         familyi={R\bibinitperiod},
         given={Arno},
         giveni={A\bibinitperiod},
      }}%
      {{hash=SMS}{%
         family={Sabatine},
         familyi={S\bibinitperiod},
         given={Marc\bibnamedelima S.},
         giveni={M\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=SK}{%
         family={Stefansson},
         familyi={S\bibinitperiod},
         given={Kari},
         giveni={K\bibinitperiod},
      }}%
      {{hash=ZP}{%
         family={Zalloua},
         familyi={Z\bibinitperiod},
         given={Pierre},
         giveni={P\bibinitperiod},
      }}%
      {{hash=EPT}{%
         family={Ellinor},
         familyi={E\bibinitperiod},
         given={Patrick\bibnamedelima T.},
         giveni={P\bibinitperiod\bibinitdelim T\bibinitperiod},
      }}%
      {{hash=FM}{%
         family={Farrall},
         familyi={F\bibinitperiod},
         given={Martin},
         giveni={M\bibinitperiod},
      }}%
      {{hash=DJ}{%
         family={Danesh},
         familyi={D\bibinitperiod},
         given={John},
         giveni={J\bibinitperiod},
      }}%
      {{hash=RCT}{%
         family={Ruff},
         familyi={R\bibinitperiod},
         given={Christian\bibnamedelima T.},
         giveni={C\bibinitperiod\bibinitdelim T\bibinitperiod},
      }}%
      {{hash=FHK}{%
         family={Finucane},
         familyi={F\bibinitperiod},
         given={Hilary\bibnamedelima K.},
         giveni={H\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=HJC}{%
         family={Hopewell},
         familyi={H\bibinitperiod},
         given={Jemma\bibnamedelima C.},
         giveni={J\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=CR}{%
         family={Clarke},
         familyi={C\bibinitperiod},
         given={Robert},
         giveni={R\bibinitperiod},
      }}%
      {{hash=EJ}{%
         family={Erdmann},
         familyi={E\bibinitperiod},
         given={Jeanette},
         giveni={J\bibinitperiod},
      }}%
      {{hash=SNJ}{%
         family={Samani},
         familyi={S\bibinitperiod},
         given={Nilesh\bibnamedelima J.},
         giveni={N\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=SH}{%
         family={Schunkert},
         familyi={S\bibinitperiod},
         given={Heribert},
         giveni={H\bibinitperiod},
      }}%
      {{hash=WH}{%
         family={Watkins},
         familyi={W\bibinitperiod},
         given={Hugh},
         giveni={H\bibinitperiod},
      }}%
      {{hash=WCJ}{%
         family={Willer},
         familyi={W\bibinitperiod},
         given={Cristen\bibnamedelima J.},
         giveni={C\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=DP}{%
         family={Deloukas},
         familyi={D\bibinitperiod},
         given={Panos},
         giveni={P\bibinitperiod},
      }}%
      {{hash=KS}{%
         family={Kathiresan},
         familyi={K\bibinitperiod},
         given={Sekar},
         giveni={S\bibinitperiod},
      }}%
      {{hash=BAS}{%
         family={Butterworth},
         familyi={B\bibinitperiod},
         given={Adam\bibnamedelima S.},
         giveni={A\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=CobotC}{%
         family={Consortium},
         familyi={C\bibinitperiod},
         given={on\bibnamedelima behalf of the\bibnamedelima
  CARDIoGRAMplusC4D},
         giveni={o\bibinitperiod\bibinitdelim b\bibinitperiod\bibinitdelim
  o\bibinitperiod\bibinitdelim t\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{medRxiv}}%
    }
    \strng{namehash}{AKG+1}
  \strng{fullhash}{AKGJTGAKSWBNWEMWMHGZWGCRCMNAKFKSIVLMSPKSIKABOBMRBBVPSdGOGPGDFGUHSMIHAIMKAKTLLMLMTMSMMMFNJBNMMPSRTTGSMvUJKCECJBADOADSBNPCMCFJGRMIKJDKKYKAVKIKIJLLANCPRRTGTUWTRBABJLBEDGHHHKMOMACOMMRLSRASMSSKZPEPTFMDJRCTFHKHJCCREJSNJSHWHWCJDPKSBASCobotC1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2021}
    \field{labeldatesource}{}
    \field{abstract}{%
    Rapid progress of the discovery of genetic loci associated with common,
  complex diseases has outpaced the elucidation of mechanisms pertinent to
  disease pathogenesis. To address relevant barriers for coronary artery
  disease (CAD), we combined genetic discovery analyses with downstream
  characterization of likely causal variants, genes, and biological pathways.
  Specifically, we conducted a genome-wide association study (GWAS) comprising
  181,522 cases of CAD among 1,165,690 participants. We detected 241
  associations, including 54 associations and 30 loci not previously linked to
  CAD. Next, we prioritized likely causal variants using functionally-informed
  fine-mapping, yielding 42 associations with fewer than five variants in the
  95\% credible set. Combining eight complementary predictors, we prioritized
  185 candidate causal genes, including 94 genes supported by three or more
  predictors. Similarity-based clustering underscored a role for early
  developmental processes, cell cycle signaling, and vascular proliferation in
  the pathogenesis of CAD. Our analysis identifies and systematically
  characterizes risk loci for CAD to inform experimental interrogation of
  putative causal mechanisms for CAD.%
    }
    \verb{doi}
    \verb 10.1101/2021.05.24.21257377
    \endverb
    \field{pages}{2021.05.24.21257377}
    \field{title}{Discovery and Systematic Characterization of Risk Variants
  and Genes for Coronary Artery Disease in over a Million Participants}
    \verb{url}
    \verb https://www.medrxiv.org/content/10.1101/2021.05.24.21257377v1
    \endverb
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\HW5PYJTJ\\Aragam et al. - 2021 -
    \verb Discovery and systematic characterization of risk .pdf;C\:\\Users\\to
    \verb rbe\\Zotero\\storage\\DFUSPBU8\\2021.05.24.html
    \endverb
    \field{day}{02}
    \field{month}{06}
    \field{year}{2021}
    \field{urlday}{31}
    \field{urlmonth}{03}
    \field{urlyear}{2022}
  \endentry

  \entry{huggettStandardisationReportingNucleic2011}{article}{}
    \name{author}{2}{}{%
      {{hash=HJ}{%
         family={Huggett},
         familyi={H\bibinitperiod},
         given={Jim},
         giveni={J\bibinitperiod},
      }}%
      {{hash=BSA}{%
         family={Bustin},
         familyi={B\bibinitperiod},
         given={Stephen\bibnamedelima A.},
         giveni={S\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
    }
    \keyw{DNA,FRET,Pathogen,Quantification,Real-time polymerase chain
  reaction,RNA}
    \strng{namehash}{HJBSA1}
    \strng{fullhash}{HJBSA1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2011}
    \field{labeldatesource}{}
    \field{abstract}{%
    The real-time quantitative polymerase chain reaction (qPCR) is probably the
  most common molecular technique in use today, having become the method of
  choice for nucleic acid detection and quantification and underpinning
  applications ranging from basic research through biotechnology and forensic
  applications to clinical diagnostics. This key technology relies on
  fluorescence to detect and quantify nucleic acid amplification products, and
  its homogeneous assay format has transformed legacy polymerase chain reaction
  (PCR) from a low-throughput qualitative gel-based technique to a frequently
  automated, rapid, high-throughput quantitative technology. However, the
  enormous range of protocols together with frequently inappropriate pre-assay
  conditions, poor assay design and unsuitable data analysis methodologies are
  impeding its status as a mature, ‘gold standard’ technology. This,
  combined with inconsistent and insufficient reporting procedures, has
  resulted in the widespread publication of data that can be misleading, in
  particular when this technology is used to quantify cellular mRNA or miRNA
  levels by RT-qPCR. This affects the integrity of the scientific literature,
  with consequences for not only basic research, but with potentially major
  implications for the potential development of molecular diagnostic and
  prognostic monitoring tools. These issues have been addressed by a set of
  guidelines that propose a minimum standard for the provision of information
  for qPCR experiments (‘MIQE’). MIQE aims to systematise current variable
  qPCR methods into a more consistent format that will encourage detailed
  auditing of experimental detail, data analysis and reporting principles.
  General implementation of these guidelines is an important requisite for the
  maturing of qPCR into a robust, accurate and reliable nucleic acid
  quantification technology.%
    }
    \verb{doi}
    \verb 10.1007/s00769-011-0769-y
    \endverb
    \field{issn}{1432-0517}
    \field{number}{8}
    \field{pages}{399}
    \field{shortjournal}{Accred Qual Assur}
    \field{title}{Standardisation and Reporting for Nucleic Acid
  Quantification}
    \verb{url}
    \verb https://doi.org/10.1007/s00769-011-0769-y
    \endverb
    \field{volume}{16}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\2N4G7LL8\\Huggett und Bustin - 20
    \verb 11 - Standardisation and reporting for nucleic acid qua.pdf
    \endverb
    \field{journaltitle}{Accreditation and Quality Assurance}
    \field{day}{19}
    \field{month}{03}
    \field{year}{2011}
    \field{urlday}{05}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{agilenttechnologiesHowAgilentSeahorse2022}{online}{}
    \name{author}{1}{}{%
      {{hash=A}{%
         family={{AgilentTechnologies}},
         familyi={A\bibinitperiod},
      }}%
    }
    \strng{namehash}{A1}
    \strng{fullhash}{A1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{labeldatesource}{}
    \field{title}{How {{Agilent Seahorse XF Analyzers Work}} | {{Agilent}}}
    \verb{url}
    \verb https://www.agilent.com/en/products/cell-analysis/how-seahorse-xf-ana
    \verb lyzers-work
    \endverb
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\XRMRGTUL\\how-seahorse-xf-analyze
    \verb rs-work.html
    \endverb
    \field{year}{2022}
    \field{urlday}{05}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{thermofisherscientificinc.CellROXGreenReagent2022}{online}{}
    \name{author}{1}{}{%
      {{hash=T}{%
         family={{Thermo Fisher Scientific Inc.}},
         familyi={T\bibinitperiod},
      }}%
    }
    \strng{namehash}{T2}
    \strng{fullhash}{T2}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{labeldatesource}{}
    \field{abstract}{%
    CellROX Green Reagent is a novel fluorogenic probe for measuring oxidative
  stress in live cells. The cell-permeant dye is weakly fluorescent while in a
  reduced state and exhibits bright green photostable fluorescence upon
  oxidation by reactive%
    }
    \field{title}{{{CellROX Green Reagent}}, for Oxidative Stress Detection}
    \verb{url}
    \verb https://www.thermofisher.com/order/catalog/product/C10444
    \endverb
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\ZHMVQ3S3\\C10444.html
    \endverb
    \field{year}{2022}
    \field{urlday}{05}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{newmanMultipleCellTypes2021a}{article}{}
    \name{author}{17}{}{%
      {{hash=NAAC}{%
         family={Newman},
         familyi={N\bibinitperiod},
         given={Alexandra A.\bibnamedelima C.},
         giveni={A\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim
  C\bibinitperiod},
      }}%
      {{hash=SV}{%
         family={Serbulea},
         familyi={S\bibinitperiod},
         given={Vlad},
         giveni={V\bibinitperiod},
      }}%
      {{hash=BRA}{%
         family={Baylis},
         familyi={B\bibinitperiod},
         given={Richard\bibnamedelima A.},
         giveni={R\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=SLS}{%
         family={Shankman},
         familyi={S\bibinitperiod},
         given={Laura\bibnamedelima S.},
         giveni={L\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=BX}{%
         family={Bradley},
         familyi={B\bibinitperiod},
         given={Xenia},
         giveni={X\bibinitperiod},
      }}%
      {{hash=AGF}{%
         family={Alencar},
         familyi={A\bibinitperiod},
         given={Gabriel\bibnamedelima F.},
         giveni={G\bibinitperiod\bibinitdelim F\bibinitperiod},
      }}%
      {{hash=OK}{%
         family={Owsiany},
         familyi={O\bibinitperiod},
         given={Katherine},
         giveni={K\bibinitperiod},
      }}%
      {{hash=DRA}{%
         family={Deaton},
         familyi={D\bibinitperiod},
         given={Rebecca\bibnamedelima A.},
         giveni={R\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=KS}{%
         family={Karnewar},
         familyi={K\bibinitperiod},
         given={Santosh},
         giveni={S\bibinitperiod},
      }}%
      {{hash=SS}{%
         family={Shamsuzzaman},
         familyi={S\bibinitperiod},
         given={Sohel},
         giveni={S\bibinitperiod},
      }}%
      {{hash=SA}{%
         family={Salamon},
         familyi={S\bibinitperiod},
         given={Anita},
         giveni={A\bibinitperiod},
      }}%
      {{hash=RMS}{%
         family={Reddy},
         familyi={R\bibinitperiod},
         given={Mahima\bibnamedelima S.},
         giveni={M\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=GL}{%
         family={Guo},
         familyi={G\bibinitperiod},
         given={Liang},
         giveni={L\bibinitperiod},
      }}%
      {{hash=FA}{%
         family={Finn},
         familyi={F\bibinitperiod},
         given={Aloke},
         giveni={A\bibinitperiod},
      }}%
      {{hash=VR}{%
         family={Virmani},
         familyi={V\bibinitperiod},
         given={Renu},
         giveni={R\bibinitperiod},
      }}%
      {{hash=COA}{%
         family={Cherepanova},
         familyi={C\bibinitperiod},
         given={Olga\bibnamedelima A.},
         giveni={O\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=OGK}{%
         family={Owens},
         familyi={O\bibinitperiod},
         given={Gary\bibnamedelima K.},
         giveni={G\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Atherosclerosis,Obesity}
    \strng{namehash}{NAAC+1}
    \strng{fullhash}{NAACSVBRASLSBXAGFOKDRAKSSSSARMSGLFAVRCOAOGK1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2021}
    \field{extradate}{2}
    \field{labeldatesource}{}
    \field{abstract}{%
    Stable atherosclerotic plaques are characterized by a thick, extracellular
  matrix-rich fibrous cap populated by protective ACTA2+ myofibroblast
  (MF)-like cells, assumed to be almost exclusively derived from smooth muscle
  cells (SMCs). Herein, we show that in murine and human lesions, 20\% to 40\%
  of ACTA2+ fibrous cap cells, respectively, are derived from non-SMC sources,
  including endothelial cells (ECs) or macrophages that have undergone an
  endothelial-to-mesenchymal transition (EndoMT) or a macrophage-to-mesenchymal
  transition (MMT). In addition, we show that SMC-specific knockout of the
  Pdgfrb gene, which encodes platelet-derived growth factor receptor beta
  (PDGFRβ), in Apoe−/− mice fed a Western diet for 18 weeks resulted in
  brachiocephalic artery lesions nearly devoid of SMCs but with no changes in
  lesion size, remodelling or indices of stability, including the percentage of
  ACTA2+ fibrous cap cells. However, prolonged Western diet feeding of SMC
  Pdgfrb-knockout mice resulted in reduced indices of stability, indicating
  that EndoMT- and MMT-derived MFs cannot compensate indefinitely for loss of
  SMC-derived MFs. Using single-cell and bulk RNA-sequencing analyses of the
  brachiocephalic artery region and in vitro models, we provide evidence that
  SMC-to-MF transitions are induced by PDGF and transforming growth factor-β
  and dependent on aerobic glycolysis, while EndoMT is induced by
  interleukin-1β and transforming growth factor-β. Together, we provide
  evidence that the ACTA2+ fibrous cap originates from a tapestry of cell
  types, which transition to an MF-like state through distinct signalling
  pathways that are either dependent on or associated with extensive metabolic
  reprogramming.%
    }
    \verb{doi}
    \verb 10.1038/s42255-020-00338-8
    \endverb
    \field{issn}{2522-5812}
    \field{issue}{2}
    \field{number}{2}
    \field{pages}{166\bibrangedash 181}
    \field{shortjournal}{Nat Metab}
    \field{title}{Multiple Cell Types Contribute to the Atherosclerotic Lesion
  Fibrous Cap by {{PDGFRβ}} and Bioenergetic Mechanisms}
    \verb{url}
    \verb https://www.nature.com/articles/s42255-020-00338-8
    \endverb
    \field{volume}{3}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\6Q2M72Z4\\Newman et al. - 2021 -
    \verb Multiple cell types contribute to the atherosclero.pdf;C\:\\Users\\to
    \verb rbe\\Zotero\\storage\\D8GXP2NV\\s42255-020-00338-8.html
    \endverb
    \field{journaltitle}{Nature Metabolism}
    \field{month}{02}
    \field{year}{2021}
    \field{urlday}{03}
    \field{urlmonth}{05}
    \field{urlyear}{2022}
  \endentry

  \entry{bokehdevelopmentteamBokehPythonLibrary2022}{misc}{}
    \name{author}{1}{}{%
      {{hash=B}{%
         family={{Bokeh Development Team}},
         familyi={B\bibinitperiod},
      }}%
    }
    \strng{namehash}{B1}
    \strng{fullhash}{B1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{labeldatesource}{}
    \field{abstract}{%
    Purpose: Bokeh server makes it easy to create interactive web applications
  that connect front-end UI events to running Python code. Bokeh creates
  high-level Python models, such as plots, ranges, ax...%
    }
    \field{title}{Bokeh: {{Python}} Library for Interactive Visualization}
    \verb{url}
    \verb https://bokeh.org/
    \endverb
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\AQFW7CAX\\server.html
    \endverb
    \field{year}{2022}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{langtangenUsingWebFrameworks2015}{online}{}
    \name{author}{2}{}{%
      {{hash=LHP}{%
         family={Langtangen},
         familyi={L\bibinitperiod},
         given={Hans\bibnamedelima Peter},
         giveni={H\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=JAE}{%
         family={Johansen},
         familyi={J\bibinitperiod},
         given={Anders\bibnamedelima E.},
         giveni={A\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
    }
    \strng{namehash}{LHPJAE1}
    \strng{fullhash}{LHPJAE1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2015}
    \field{labeldatesource}{}
    \field{title}{Using {{Web Frameworks}} for {{Scientific Applications}}}
    \verb{url}
    \verb http://hplgit.github.io/web4sciapps/doc/pub/web4sa_plain_all.html#wf:
    \verb bokeh:flask
    \endverb
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\2GMXUITN\\web4sa_plain_all.html
    \endverb
    \field{year}{2015}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{tipneyIntroductionEffectiveUse2010}{article}{}
    \name{author}{2}{}{%
      {{hash=TH}{%
         family={Tipney},
         familyi={T\bibinitperiod},
         given={Hannah},
         giveni={H\bibinitperiod},
      }}%
      {{hash=HL}{%
         family={Hunter},
         familyi={H\bibinitperiod},
         given={Lawrence},
         giveni={L\bibinitperiod},
      }}%
    }
    \keyw{enrichment,gene enrichment analysis,gene list,gene
  ontology,GSEA,pathway analysis,software}
    \strng{namehash}{THHL1}
    \strng{fullhash}{THHL1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2010}
    \field{labeldatesource}{}
    \field{abstract}{%
    In recent years, there has been an explosion in the range of software
  available for annotation enrichment analysis. Three classes of enrichment
  algorithms and their associated software implementations are introduced
  here.%
    }
    \verb{doi}
    \verb 10.1186/1479-7364-4-3-202
    \endverb
    \field{issn}{1479-7364}
    \field{number}{3}
    \field{pages}{202}
    \field{shortjournal}{Human Genomics}
    \field{title}{An Introduction to Effective Use of Enrichment Analysis
  Software}
    \verb{url}
    \verb https://doi.org/10.1186/1479-7364-4-3-202
    \endverb
    \field{volume}{4}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\PIPA4IPU\\Tipney und Hunter - 201
    \verb 0 - An introduction to effective use of enrichment ana.pdf;C\:\\Users
    \verb \\torbe\\Zotero\\storage\\CELJAI75\\1479-7364-4-3-202.html
    \endverb
    \field{journaltitle}{Human Genomics}
    \field{day}{01}
    \field{month}{02}
    \field{year}{2010}
    \field{urlday}{05}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{liuKruppellikeFactorAbrogates2005}{article}{}
    \name{author}{6}{}{%
      {{hash=LY}{%
         family={Liu},
         familyi={L\bibinitperiod},
         given={Yan},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=SS}{%
         family={Sinha},
         familyi={S\bibinitperiod},
         given={Sanjay},
         giveni={S\bibinitperiod},
      }}%
      {{hash=MOG}{%
         family={McDonald},
         familyi={M\bibinitperiod},
         given={Oliver\bibnamedelima G.},
         giveni={O\bibinitperiod\bibinitdelim G\bibinitperiod},
      }}%
      {{hash=SY}{%
         family={Shang},
         familyi={S\bibinitperiod},
         given={Yueting},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=HMH}{%
         family={Hoofnagle},
         familyi={H\bibinitperiod},
         given={Mark\bibnamedelima H.},
         giveni={M\bibinitperiod\bibinitdelim H\bibinitperiod},
      }}%
      {{hash=OGK}{%
         family={Owens},
         familyi={O\bibinitperiod},
         given={Gary\bibnamedelima K.},
         giveni={G\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Elsevier}}%
    }
    \strng{namehash}{LY+1}
    \strng{fullhash}{LYSSMOGSYHMHOGK1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2005}
    \field{labeldatesource}{}
    \field{abstract}{%
    {$<$}p{$>$}Platelet-derived growth factor BB (PDGF-BB) has been shown to be
  an extremely potent negative regulator of smooth muscle cell (SMC)
  differentiation. Moreover, previous studies have demonstrated that the
  Kruppel-like transcription factor (KLF) 4 potently represses the expression
  of multiple SMC genes. However, the mechanisms whereby KLF4 suppresses SMC
  gene expression are not known, nor is it clear whether KLF4 contributes to
  PDGF-BB-induced down-regulation of SMC genes. The goals of the present
  studies were to determine the molecular mechanisms by which KLF4 represses
  expression of SMC genes and whether it contributes to PDGF-BB-induced
  suppression of these genes. Results demonstrated that KLF4 markedly repressed
  both myocardin-induced activation of SMC genes and expression of myocardin.
  KLF4 was rapidly up-regulated in PDGF-BB-treated, cultured SMC, and a small
  interfering RNA to KLF4 partially blocked PDGF-BB-induced SMC gene
  repression. Both PDGF-BB and KLF4 markedly reduced serum response factor
  binding to CArG containing regions within intact chromatin. Finally, KLF4,
  which is normally not expressed in differentiated SMC in \emph{vivo}, was
  rapidly up-regulated \emph{in vivo} in response to vascular injury. Taken
  together, results indicate that KLF4 represses SMC genes by both
  down-regulating myocardin expression and preventing serum response
  factor/myocardin from associating with SMC gene promoters, and suggest that
  KLF4 may be a key effector of PDGF-BB and injury-induced phenotypic switching
  of SMC.{$<$}/p{$>$}%
    }
    \verb{doi}
    \verb 10.1074/jbc.M412862200
    \endverb
    \field{issn}{0021-9258, 1083-351X}
    \field{number}{10}
    \field{pages}{9719\bibrangedash 9727}
    \field{shortjournal}{Journal of Biological Chemistry}
    \field{title}{Kruppel-like {{Factor}} 4 {{Abrogates Myocardin-induced
  Activation}} of {{Smooth Muscle Gene Expression}} *}
    \verb{url}
    \verb https://www.jbc.org/article/S0021-9258(19)62994-7/abstract
    \endverb
    \field{volume}{280}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\3E6GXCK6\\Liu et al. - 2005 - Kru
    \verb ppel-like Factor 4 Abrogates Myocardin-induced .pdf;C\:\\Users\\torbe
    \verb \\Zotero\\storage\\3AD67Z89\\fulltext.html
    \endverb
    \field{journaltitle}{Journal of Biological Chemistry}
    \field{day}{11}
    \field{month}{03}
    \field{year}{2005}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{deatonSp1dependentActivationKLF42009}{article}{}
    \name{author}{3}{}{%
      {{hash=DRA}{%
         family={Deaton},
         familyi={D\bibinitperiod},
         given={Rebecca\bibnamedelima A.},
         giveni={R\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
      {{hash=GQ}{%
         family={Gan},
         familyi={G\bibinitperiod},
         given={Qiong},
         giveni={Q\bibinitperiod},
      }}%
      {{hash=OGK}{%
         family={Owens},
         familyi={O\bibinitperiod},
         given={Gary\bibnamedelima K.},
         giveni={G\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
    }
    \keyw{Angiogenesis Inducing Agents,Animals,Base Sequence,Becaplermin,Cells;
  Cultured,Disease Models; Animal,Kruppel-Like Factor 4,Kruppel-Like
  Transcription Factors,Male,Molecular Sequence Data,Muscle; Smooth;
  Vascular,Phenotype,Platelet-Derived Growth Factor,Protein
  Binding,Proto-Oncogene Proteins c-sis,Rats,Rats; Sprague-Dawley,RNA; Small
  Interfering,Sp1 Transcription Factor,Transfection,Up-Regulation,Vascular
  Diseases}
    \strng{namehash}{DRA+1}
    \strng{fullhash}{DRAGQOGK1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2009}
    \field{labeldatesource}{}
    \field{abstract}{%
    There is clear evidence that the phenotypic modulation of smooth muscle
  cells (SMCs) contributes to the pathophysiology of vascular disease.
  Phenotypic modulation refers to the unique ability of SMCs to alter their
  phenotype in response to extracellular stimuli and is hallmarked by the loss
  of SMC marker gene expression. The transcription factor Krüppel-like factor
  4 (KLF4) is a known powerful negative regulator of SMC marker gene expression
  that works, in part, by decreasing the expression of the serum response
  factor (SRF) myocardin. KLF4 is not expressed in healthy adult SMCs but is
  increased in SMCs in response to vascular injury in vivo or PDGF-BB treatment
  in vitro. The aim of the present study was to determine the molecular
  mechanisms that regulate the expression of KLF4 in phenotypically modulated
  SMCs. The results demonstrated that the transcription factor stimulating
  protein-1 (Sp1) regulated the expression of KLF4 in SMCs. The KLF4 promoter
  contains three consensus Sp1 binding sites. Using a series of truncated KLF4
  promoters, we showed that only fragments containing these Sp1 sites could be
  activated by PDGF-BB. In addition, overexpression of Sp1 alone was sufficient
  to increase the activity of the KLF4 promoter. Moreover, inhibiting Sp1
  expression with small-interfering RNA attenuated the effects of PDGF-BB on
  KLF4 expression. Mutation of the three Sp1 sites within the KLF4 promoter
  abolished both baseline and PDGF-BB-induced activity. Finally, the results
  demonstrated enhanced Sp1 binding to the KLF4 promoter in SMCs treated with
  PDGF-BB in vitro and following vascular injury in vivo. Taken together, the
  results suggest a novel role for Sp1 in increasing the expression of KLF4 in
  phenotypically modulated SMCs.%
    }
    \verb{doi}
    \verb 10.1152/ajpheart.01230.2008
    \endverb
    \verb{eprint}
    \verb 19168719
    \endverb
    \field{issn}{0363-6135}
    \field{number}{4}
    \field{pages}{H1027\bibrangedash 1037}
    \field{shortjournal}{Am J Physiol Heart Circ Physiol}
    \field{title}{Sp1-Dependent Activation of {{KLF4}} Is Required for
  {{PDGF-BB-induced}} Phenotypic Modulation of Smooth Muscle}
    \field{volume}{296}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\IASRVPWZ\\Deaton et al. - 2009 -
    \verb Sp1-dependent activation of KLF4 is required for P.pdf
    \endverb
    \field{journaltitle}{American Journal of Physiology. Heart and Circulatory
  Physiology}
    \field{eprinttype}{pmid}
    \field{month}{04}
    \field{year}{2009}
  \endentry

  \entry{wangMyocardinTernaryComplex2004}{article}{}
    \name{author}{6}{}{%
      {{hash=WZ}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Zhigao},
         giveni={Z\bibinitperiod},
      }}%
      {{hash=WDZ}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Da-Zhi},
         giveni={D\bibinithyphendelim Z\bibinitperiod},
      }}%
      {{hash=HD}{%
         family={Hockemeyer},
         familyi={H\bibinitperiod},
         given={Dirk},
         giveni={D\bibinitperiod},
      }}%
      {{hash=MJ}{%
         family={McAnally},
         familyi={M\bibinitperiod},
         given={John},
         giveni={J\bibinitperiod},
      }}%
      {{hash=NA}{%
         family={Nordheim},
         familyi={N\bibinitperiod},
         given={Alfred},
         giveni={A\bibinitperiod},
      }}%
      {{hash=OEN}{%
         family={Olson},
         familyi={O\bibinitperiod},
         given={Eric\bibnamedelima N.},
         giveni={E\bibinitperiod\bibinitdelim N\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Humanities and Social Sciences,multidisciplinary,Science}
    \strng{namehash}{WZ+1}
    \strng{fullhash}{WZWDZHDMJNAOEN1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2004}
    \field{labeldatesource}{}
    \field{abstract}{%
    Smooth muscle cells switch between differentiated and proliferative
  phenotypes in response to extracellular cues1, but the transcriptional
  mechanisms that confer such phenotypic plasticity remain unclear. Serum
  response factor (SRF) activates genes involved in smooth muscle
  differentiation and proliferation by recruiting muscle-restricted cofactors,
  such as the transcriptional coactivator myocardin, and ternary complex
  factors (TCFs) of the ETS-domain family, respectively2,3,4,5,6,7,8,9. Here we
  show that growth signals repress smooth muscle genes by triggering the
  displacement of myocardin from SRF by Elk-1, a TCF that acts as a myogenic
  repressor. The opposing influences of myocardin and Elk-1 on smooth muscle
  gene expression are mediated by structurally related SRF-binding motifs that
  compete for a common docking site on SRF. A mutant smooth muscle promoter,
  retaining responsiveness to myocardin and SRF but defective in TCF binding,
  directs ectopic transcription in the embryonic heart, demonstrating a role
  for TCFs in suppression of smooth muscle gene expression in vivo. We conclude
  that growth and developmental signals modulate smooth muscle gene expression
  by regulating the association of SRF with antagonistic cofactors.%
    }
    \verb{doi}
    \verb 10.1038/nature02382
    \endverb
    \field{issn}{1476-4687}
    \field{issue}{6979}
    \field{number}{6979}
    \field{pages}{185\bibrangedash 189}
    \field{title}{Myocardin and Ternary Complex Factors Compete for {{SRF}} to
  Control Smooth Muscle Gene Expression}
    \verb{url}
    \verb https://www.nature.com/articles/nature02382
    \endverb
    \field{volume}{428}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\36HDSJH8\\Wang et al. - 2004 - My
    \verb ocardin and ternary complex factors compete for .pdf;C\:\\Users\\torb
    \verb e\\Zotero\\storage\\R29MLV2I\\nature02382.html
    \endverb
    \field{journaltitle}{Nature}
    \field{month}{03}
    \field{year}{2004}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{guoDedicatorCytokinesisNovel2015}{article}{}
    \name{author}{6}{}{%
      {{hash=GX}{%
         family={Guo},
         familyi={G\bibinitperiod},
         given={Xia},
         giveni={X\bibinitperiod},
      }}%
      {{hash=SN}{%
         family={Shi},
         familyi={S\bibinitperiod},
         given={Ning},
         giveni={N\bibinitperiod},
      }}%
      {{hash=CXB}{%
         family={Cui},
         familyi={C\bibinitperiod},
         given={Xiao-Bing},
         giveni={X\bibinithyphendelim B\bibinitperiod},
      }}%
      {{hash=WJN}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Jia-Ning},
         giveni={J\bibinithyphendelim N\bibinitperiod},
      }}%
      {{hash=FY}{%
         family={Fukui},
         familyi={F\bibinitperiod},
         given={Yoshinori},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=CSY}{%
         family={Chen},
         familyi={C\bibinitperiod},
         given={Shi-You},
         giveni={S\bibinithyphendelim Y\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Heart Association}}%
    }
    \keyw{cell proliferation,dedicator of cytokinesis 2,vascular remodeling}
    \strng{namehash}{GX+1}
    \strng{fullhash}{GXSNCXBWJNFYCSY1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2015}
    \field{labeldatesource}{}
    \field{abstract}{%
    Rationale: Vascular smooth muscle cell (SMC) phenotypic modulation and
  vascular remodeling contribute to the development of several vascular
  disorders such as restenosis after angioplasty, transplant vasculopathy, and
  atherosclerosis. The mechanisms underlying these processes, however, remain
  largely unknown. Objective: The objective of this study is to determine the
  role of dedicator of cytokinesis 2 (DOCK2) in SMC phenotypic modulation and
  vascular remodeling. Methods and Results: Platelet-derived growth factor-BB
  induced DOCK2 expression while modulating SMC phenotype. DOCK2 deficiency
  diminishes platelet-derived growth factor-BB or serum-induced downregulation
  of SMC markers. Conversely, DOCK2 overexpression inhibits SMC marker
  expression in primary cultured SMC. Mechanistically, DOCK2 inhibits myocardin
  expression, blocks serum response factor nuclear location, attenuates
  myocardin binding to serum response factor, and thus attenuates
  myocardin-induced smooth muscle marker promoter activity. Moreover, DOCK2 and
  Kruppel-like factor 4 cooperatively inhibit myocardin–serum response factor
  interaction. In a rat carotid artery balloon-injury model, DOCK2 is induced
  in media layer SMC initially and neointima SMC subsequently after vascular
  injury. Knockdown of DOCK2 dramatically inhibits the neointima formation by
  60\%. Most importantly, knockout of DOCK2 in mice markedly blocks
  ligation-induced intimal hyperplasia while restoring SMC contractile protein
  expression. Conclusions: Our studies identified DOCK2 as a novel regulator
  for SMC phenotypic modulation and vascular lesion formation after vascular
  injury. Therefore, targeting DOCK2 may be a potential therapeutic strategy
  for the prevention of vascular remodeling in proliferative vascular
  diseases.%
    }
    \verb{doi}
    \verb 10.1161/CIRCRESAHA.116.305863
    \endverb
    \field{number}{10}
    \field{pages}{e71\bibrangedash e80}
    \field{title}{Dedicator of {{Cytokinesis}} 2, {{A Novel Regulator}} for
  {{Smooth Muscle Phenotypic Modulation}} and {{Vascular Remodeling}}}
    \verb{url}
    \verb https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.116.305863
    \endverb
    \field{volume}{116}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\TDLMDSKC\\Guo et al. - 2015 - Ded
    \verb icator of Cytokinesis 2, A Novel Regulator for .pdf
    \endverb
    \field{journaltitle}{Circulation Research}
    \field{day}{08}
    \field{month}{05}
    \field{year}{2015}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{longMyocardinSufficientSmooth2008}{article}{}
    \name{author}{5}{}{%
      {{hash=LX}{%
         family={Long},
         familyi={L\bibinitperiod},
         given={Xiaochun},
         giveni={X\bibinitperiod},
      }}%
      {{hash=BRD}{%
         family={Bell},
         familyi={B\bibinitperiod},
         given={Robert\bibnamedelima D.},
         giveni={R\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=GWT}{%
         family={Gerthoffer},
         familyi={G\bibinitperiod},
         given={William\bibnamedelima T.},
         giveni={W\bibinitperiod\bibinitdelim T\bibinitperiod},
      }}%
      {{hash=ZBV}{%
         family={Zlokovic},
         familyi={Z\bibinitperiod},
         given={Berislav\bibnamedelima V.},
         giveni={B\bibinitperiod\bibinitdelim V\bibinitperiod},
      }}%
      {{hash=MJM}{%
         family={Miano},
         familyi={M\bibinitperiod},
         given={Joseph\bibnamedelima M.},
         giveni={J\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Heart Association}}%
    }
    \keyw{contraction,knockdown,myocardin,serum response factor,smooth muscle}
    \strng{namehash}{LX+1}
    \strng{fullhash}{LXBRDGWTZBVMJM1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2008}
    \field{labeldatesource}{}
    \field{abstract}{%
    Background— Myocardin (Myocd) is a strong coactivator that binds the
  serum response factor (SRF) transcription factor over CArG elements embedded
  within smooth muscle cell (SMC) and cardiac muscle cyto-contractile genes.
  Here, we sought to ascertain whether Myocd-mediated gene expression confers a
  structural and physiological cardiac or SMC phenotype. Methods and Results—
  Adenoviral-mediated expression of Myocd in the BC3H1 cell line induces
  cardiac and SMC genes while suppressing both skeletal muscle markers and cell
  growth. Immunofluorescence microscopy shows that SRF and a SMC-like
  cyto-contractile apparatus are elevated with Myocd overexpression. A short
  hairpin RNA to Srf impairs BC3H1 cyto-architecture; however, cotransduction
  with Myocd results in complete restoration of the cyto-architecture. Electron
  microscopic studies demonstrate a SMC ultrastructural phenotype with no
  evidence for cardiac sarcomerogenesis. Biochemical and time-lapsed
  videomicroscopy assays reveal clear evidence for Myocd-induced SMC-like
  contraction. Conclusion— Myocd is sufficient for the establishment of a
  SMC-like contractile phenotype.%
    }
    \verb{doi}
    \verb 10.1161/ATVBAHA.108.166066
    \endverb
    \field{number}{8}
    \field{pages}{1505\bibrangedash 1510}
    \field{title}{Myocardin {{Is Sufficient}} for a {{Smooth Muscle-Like
  Contractile Phenotype}}}
    \verb{url}
    \verb https://www.ahajournals.org/doi/10.1161/atvbaha.108.166066
    \endverb
    \field{volume}{28}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\MAZHL66A\\Long et al. - 2008 - My
    \verb ocardin Is Sufficient for a Smooth Muscle-Like C.pdf
    \endverb
    \field{journaltitle}{Arteriosclerosis, Thrombosis, and Vascular Biology}
    \field{month}{08}
    \field{year}{2008}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{owensMolecularRegulationVascular2004}{article}{}
    \name{author}{3}{}{%
      {{hash=OGK}{%
         family={Owens},
         familyi={O\bibinitperiod},
         given={Gary\bibnamedelima K.},
         giveni={G\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=KMS}{%
         family={Kumar},
         familyi={K\bibinitperiod},
         given={Meena\bibnamedelima S.},
         giveni={M\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=WBR}{%
         family={Wamhoff},
         familyi={W\bibinitperiod},
         given={Brian\bibnamedelima R.},
         giveni={B\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Physiological Society}}%
    }
    \strng{namehash}{OGK+1}
    \strng{fullhash}{OGKKMSWBR1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2004}
    \field{labeldatesource}{}
    \field{abstract}{%
    The focus of this review is to provide an overview of the current state of
  knowledge of molecular mechanisms/processes that control differentiation of
  vascular smooth muscle cells (SMC) during normal development and maturation
  of the vasculature, as well as how these mechanisms/processes are altered in
  vascular injury or disease. A major challenge in understanding
  differentiation of the vascular SMC is that this cell can exhibit a wide
  range of different phenotypes at different stages of development, and even in
  adult organisms the cell is not terminally differentiated. Indeed, the SMC is
  capable of major changes in its phenotype in response to changes in local
  environmental cues including growth factors/inhibitors, mechanical
  influences, cell-cell and cell-matrix interactions, and various inflammatory
  mediators. There has been much progress in recent years to identify
  mechanisms that control expression of the repertoire of genes that are
  specific or selective for the vascular SMC and required for its
  differentiated function. One of the most exciting recent discoveries was the
  identification of the serum response factor (SRF) coactivator gene myocardin
  that appears to be required for expression of many SMC differentiation marker
  genes, and for initial differentiation of SMC during development. However, it
  is critical to recognize that overall control of SMC
  differentiation/maturation, and regulation of its responses to changing
  environmental cues, is extremely complex and involves the cooperative
  interaction of many factors and signaling pathways that are just beginning to
  be understood. There is also relatively recent evidence that circulating stem
  cell populations can give rise to smooth muscle-like cells in association
  with vascular injury and atherosclerotic lesion development, although the
  exact role and properties of these cells remain to be clearly elucidated. The
  goal of this review is to summarize the current state of our knowledge in
  this area and to attempt to identify some of the key unresolved challenges
  and questions that require further study.%
    }
    \verb{doi}
    \verb 10.1152/physrev.00041.2003
    \endverb
    \field{issn}{0031-9333}
    \field{number}{3}
    \field{pages}{767\bibrangedash 801}
    \field{title}{Molecular {{Regulation}} of {{Vascular Smooth Muscle Cell
  Differentiation}} in {{Development}} and {{Disease}}}
    \verb{url}
    \verb https://journals.physiology.org/doi/full/10.1152/physrev.00041.2003
    \endverb
    \field{volume}{84}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\56BJ9S9G\\Owens et al. - 2004 - M
    \verb olecular Regulation of Vascular Smooth Muscle Cel.pdf
    \endverb
    \field{journaltitle}{Physiological Reviews}
    \field{month}{07}
    \field{year}{2004}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{dobnikarDiseaserelevantTranscriptionalSignatures2018}{article}{}
    \name{author}{10}{}{%
      {{hash=DL}{%
         family={Dobnikar},
         familyi={D\bibinitperiod},
         given={Lina},
         giveni={L\bibinitperiod},
      }}%
      {{hash=TAL}{%
         family={Taylor},
         familyi={T\bibinitperiod},
         given={Annabel\bibnamedelima L.},
         giveni={A\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=CJ}{%
         family={Chappell},
         familyi={C\bibinitperiod},
         given={Joel},
         giveni={J\bibinitperiod},
      }}%
      {{hash=OP}{%
         family={Oldach},
         familyi={O\bibinitperiod},
         given={Phoebe},
         giveni={P\bibinitperiod},
      }}%
      {{hash=HJL}{%
         family={Harman},
         familyi={H\bibinitperiod},
         given={Jennifer\bibnamedelima L.},
         giveni={J\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=OE}{%
         family={Oerton},
         familyi={O\bibinitperiod},
         given={Erin},
         giveni={E\bibinitperiod},
      }}%
      {{hash=DE}{%
         family={Dzierzak},
         familyi={D\bibinitperiod},
         given={Elaine},
         giveni={E\bibinitperiod},
      }}%
      {{hash=BMR}{%
         family={Bennett},
         familyi={B\bibinitperiod},
         given={Martin\bibnamedelima R.},
         giveni={M\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=SM}{%
         family={Spivakov},
         familyi={S\bibinitperiod},
         given={Mikhail},
         giveni={M\bibinitperiod},
      }}%
      {{hash=JHF}{%
         family={Jørgensen},
         familyi={J\bibinitperiod},
         given={Helle\bibnamedelima F.},
         giveni={H\bibinitperiod\bibinitdelim F\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{Nature Publishing Group}}%
    }
    \keyw{Atherosclerosis,Muscle,Transcriptomics}
    \strng{namehash}{DL+1}
    \strng{fullhash}{DLTALCJOPHJLOEDEBMRSMJHF1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2018}
    \field{labeldatesource}{}
    \field{abstract}{%
    Vascular smooth muscle cells (VSMCs) show pronounced heterogeneity across
  and within vascular beds, with direct implications for their function in
  injury response and atherosclerosis. Here we combine single-cell
  transcriptomics with lineage tracing to examine VSMC heterogeneity in healthy
  mouse vessels. The transcriptional profiles of single VSMCs consistently
  reflect their region-specific developmental history and show heterogeneous
  expression of vascular disease-associated genes involved in inflammation,
  adhesion and migration. We detect a rare population of VSMC-lineage cells
  that express the multipotent progenitor marker Sca1, progressively
  downregulate contractile VSMC genes and upregulate genes associated with VSMC
  response to inflammation and growth factors. We find that Sca1 upregulation
  is a hallmark of VSMCs undergoing phenotypic switching in vitro and in vivo,
  and reveal an equivalent population of Sca1-positive VSMC-lineage cells in
  atherosclerotic plaques. Together, our analyses identify disease-relevant
  transcriptional signatures in VSMC-lineage cells in healthy blood vessels,
  with implications for disease susceptibility, diagnosis and prevention.%
    }
    \verb{doi}
    \verb 10.1038/s41467-018-06891-x
    \endverb
    \field{issn}{2041-1723}
    \field{issue}{1}
    \field{number}{1}
    \field{pages}{4567}
    \field{shortjournal}{Nat Commun}
    \field{title}{Disease-Relevant Transcriptional Signatures Identified in
  Individual Smooth Muscle Cells from Healthy Mouse Vessels}
    \verb{url}
    \verb https://www.nature.com/articles/s41467-018-06891-x
    \endverb
    \field{volume}{9}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\XMAZZN3Y\\Dobnikar et al. - 2018
    \verb - Disease-relevant transcriptional signatures identi.pdf;C\:\\Users\\
    \verb torbe\\Zotero\\storage\\Y3XAYVUC\\s41467-018-06891-x.html
    \endverb
    \field{journaltitle}{Nature Communications}
    \field{day}{01}
    \field{month}{11}
    \field{year}{2018}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{johnsonMetalloproteinasesAtherosclerosis2017}{article}{}
    \name{author}{1}{}{%
      {{hash=JJL}{%
         family={Johnson},
         familyi={J\bibinitperiod},
         given={Jason\bibnamedelima L.},
         giveni={J\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
    }
    \keyw{ADAM,ADAMTS
  cell,Animals,Atherosclerosis,Humans,Metalloproteases,Metalloproteinase,MMP,Proteases,TIMP}
    \strng{namehash}{JJL1}
    \strng{fullhash}{JJL1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2017}
    \field{labeldatesource}{}
    \field{abstract}{%
    Atherosclerosis underlies most cardiovascular diseases, and is accepted as
  a primary cause of mortality worldwide. Proteases have been implicated in the
  development and progression of atherosclerosis, due to their ability to
  provoke focal destruction of the vascular extracellular matrix. Members of
  the metalloproteinase family, especially matrix metalloproteinases (MMPs),
  and their endogenous tissue inhibitors (TIMPs) have been suggested to perform
  complex dual roles during late-stage progression and rupture of
  atherosclerotic plaques. Proposed favourable actions of metalloproteinases
  include the promotion of vascular smooth muscle growth and survival which
  stabilises plaques, while conversely extracellular matrix destruction
  alongside interminable monocyte/macrophage accumulation can encourage plaque
  rupture. This review provides a summary of the cogent evidence connecting the
  contribution of individual metalloproteinases to atherosclerotic plaque
  development, progression, and instability. Topics discussed include
  structural, functional and cell-specific diversity of MMP members; evidence
  from animal models of atherosclerosis and comparisons with findings in
  humans; the dual role of MMPs and the requirement to selectively target
  individual MMPs; and the need for efficient surrogate markers of MMP
  inhibition. Accordingly, as our knowledge of the complex roles individual
  MMPs play especially during the progression and rupture of atherosclerotic
  plaques expands, new impetus is required for clinical trials evaluating the
  therapeutic potential of selective MMP inhibition, which could limit
  cardiovascular morbidity and mortality worldwide.%
    }
    \verb{doi}
    \verb 10.1016/j.ejphar.2017.09.007
    \endverb
    \verb{eprint}
    \verb 28893577
    \endverb
    \field{issn}{1879-0712}
    \field{pages}{93\bibrangedash 106}
    \field{shortjournal}{Eur J Pharmacol}
    \field{title}{Metalloproteinases in Atherosclerosis}
    \field{volume}{816}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\5DKTYS8E\\Johnson - 2017 - Metall
    \verb oproteinases in atherosclerosis.pdf
    \endverb
    \field{journaltitle}{European Journal of Pharmacology}
    \field{eprinttype}{pmid}
    \field{day}{05}
    \field{month}{12}
    \field{year}{2017}
  \endentry

  \entry{galisIncreasedExpressionMatrix1994}{article}{}
    \name{author}{4}{}{%
      {{hash=GZS}{%
         family={Galis},
         familyi={G\bibinitperiod},
         given={Z.\bibnamedelima S.},
         giveni={Z\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=SGK}{%
         family={Sukhova},
         familyi={S\bibinitperiod},
         given={G.\bibnamedelima K.},
         giveni={G\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=LMW}{%
         family={Lark},
         familyi={L\bibinitperiod},
         given={M.\bibnamedelima W.},
         giveni={M\bibinitperiod\bibinitdelim W\bibinitperiod},
      }}%
      {{hash=LP}{%
         family={Libby},
         familyi={L\bibinitperiod},
         given={P.},
         giveni={P\bibinitperiod},
      }}%
    }
    \keyw{Arteries,Arteriosclerosis,Carotid
  Arteries,Collagenases,Elastin,Extracellular Matrix,Frozen
  Sections,Glycoproteins,Humans,Immunohistochemistry,Leukocyte Common
  Antigens,Matrix Metalloproteinase 1,Matrix Metalloproteinase 3,Matrix
  Metalloproteinase 9,Metalloendopeptidases,Proteins,Tissue Distribution,Tissue
  Inhibitor of Metalloproteinase-2,Tissue Inhibitor of Metalloproteinases}
    \strng{namehash}{GZS+1}
    \strng{fullhash}{GZSSGKLMWLP1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{1994}
    \field{labeldatesource}{}
    \field{abstract}{%
    Dysregulated extracellular matrix (ECM) metabolism may contribute to
  vascular remodeling during the development and complication of human
  atherosclerotic lesions. We investigated the expression of matrix
  metalloproteinases (MMPs), a family of enzymes that degrade ECM components in
  human atherosclerotic plaques (n = 30) and in uninvolved arterial specimens
  (n = 11). We studied members of all three MMP classes (interstitial
  collagenase, MMP-1; gelatinases, MMP-2 and MMP-9; and stromelysin, MMP-3) and
  their endogenous inhibitors (TIMPs 1 and 2) by immunocytochemistry,
  zymography, and immunoprecipitation. Normal arteries stained uniformly for
  72-kD gelatinase and TIMPs. In contrast, plaques' shoulders and regions of
  foam cell accumulation displayed locally increased expression of 92-kD
  gelatinase, stromelysin, and interstitial collagenase. However, the mere
  presence of MMP does not establish their catalytic capacity, as the zymogens
  lack activity, and TIMPs may block activated MMPs. All plaque extracts
  contained activated forms of gelatinases determined zymographically and by
  degradation of 3H-collagen type IV. To test directly whether atheromata
  actually contain active matrix-degrading enzymes in situ, we devised a method
  which allows the detection and microscopic localization of MMP enzymatic
  activity directly in tissue sections. In situ zymography revealed
  gelatinolytic and caseinolytic activity in frozen sections of atherosclerotic
  but not of uninvolved arterial tissues. The MMP inhibitors, EDTA and
  1,10-phenanthroline, as well as recombinant TIMP-1, reduced these activities
  which colocalized with regions of increased immunoreactive MMP expression,
  i.e., the shoulders, core, and microvasculature of the plaques. Focal
  overexpression of activated MMP may promote destabilization and complication
  of atherosclerotic plaques and provide novel targets for therapeutic
  intervention.%
    }
    \verb{doi}
    \verb 10.1172/JCI117619
    \endverb
    \verb{eprint}
    \verb 7989608
    \endverb
    \field{issn}{0021-9738}
    \field{number}{6}
    \field{pages}{2493\bibrangedash 2503}
    \field{shortjournal}{J Clin Invest}
    \field{title}{Increased Expression of Matrix Metalloproteinases and Matrix
  Degrading Activity in Vulnerable Regions of Human Atherosclerotic Plaques}
    \field{volume}{94}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\A3RFR4FE\\Galis et al. - 1994 - I
    \verb ncreased expression of matrix metalloproteinases .pdf
    \endverb
    \field{journaltitle}{The Journal of Clinical Investigation}
    \field{eprinttype}{pmid}
    \field{month}{12}
    \field{year}{1994}
  \endentry

  \entry{langleyExtracellularMatrixProteomics2017}{article}{}
    \name{author}{27}{}{%
      {{hash=LSR}{%
         family={Langley},
         familyi={L\bibinitperiod},
         given={Sarah\bibnamedelima R.},
         giveni={S\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=WK}{%
         family={Willeit},
         familyi={W\bibinitperiod},
         given={Karin},
         giveni={K\bibinitperiod},
      }}%
      {{hash=DA}{%
         family={Didangelos},
         familyi={D\bibinitperiod},
         given={Athanasios},
         giveni={A\bibinitperiod},
      }}%
      {{hash=MLP}{%
         family={Matic},
         familyi={M\bibinitperiod},
         given={Ljubica\bibnamedelima Perisic},
         giveni={L\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
      {{hash=SP}{%
         family={Skroblin},
         familyi={S\bibinitperiod},
         given={Philipp},
         giveni={P\bibinitperiod},
      }}%
      {{hash=BBJ}{%
         family={Barallobre-Barreiro},
         familyi={B\bibinithyphendelim B\bibinitperiod},
         given={Javier},
         giveni={J\bibinitperiod},
      }}%
      {{hash=LM}{%
         family={Lengquist},
         familyi={L\bibinitperiod},
         given={Mariette},
         giveni={M\bibinitperiod},
      }}%
      {{hash=RG}{%
         family={Rungger},
         familyi={R\bibinitperiod},
         given={Gregor},
         giveni={G\bibinitperiod},
      }}%
      {{hash=KA}{%
         family={Kapustin},
         familyi={K\bibinitperiod},
         given={Alexander},
         giveni={A\bibinitperiod},
      }}%
      {{hash=KL}{%
         family={Kedenko},
         familyi={K\bibinitperiod},
         given={Ludmilla},
         giveni={L\bibinitperiod},
      }}%
      {{hash=MC}{%
         family={Molenaar},
         familyi={M\bibinitperiod},
         given={Chris},
         giveni={C\bibinitperiod},
      }}%
      {{hash=LR}{%
         family={Lu},
         familyi={L\bibinitperiod},
         given={Ruifang},
         giveni={R\bibinitperiod},
      }}%
      {{hash=BT}{%
         family={Barwari},
         familyi={B\bibinitperiod},
         given={Temo},
         giveni={T\bibinitperiod},
      }}%
      {{hash=SG}{%
         family={Suna},
         familyi={S\bibinitperiod},
         given={Gonca},
         giveni={G\bibinitperiod},
      }}%
      {{hash=YX}{%
         family={Yin},
         familyi={Y\bibinitperiod},
         given={Xiaoke},
         giveni={X\bibinitperiod},
      }}%
      {{hash=IB}{%
         family={Iglseder},
         familyi={I\bibinitperiod},
         given={Bernhard},
         giveni={B\bibinitperiod},
      }}%
      {{hash=PB}{%
         family={Paulweber},
         familyi={P\bibinitperiod},
         given={Bernhard},
         giveni={B\bibinitperiod},
      }}%
      {{hash=WP}{%
         family={Willeit},
         familyi={W\bibinitperiod},
         given={Peter},
         giveni={P\bibinitperiod},
      }}%
      {{hash=SJ}{%
         family={Shalhoub},
         familyi={S\bibinitperiod},
         given={Joseph},
         giveni={J\bibinitperiod},
      }}%
      {{hash=PG}{%
         family={Pasterkamp},
         familyi={P\bibinitperiod},
         given={Gerard},
         giveni={G\bibinitperiod},
      }}%
      {{hash=DAH}{%
         family={Davies},
         familyi={D\bibinitperiod},
         given={Alun\bibnamedelima H.},
         giveni={A\bibinitperiod\bibinitdelim H\bibinitperiod},
      }}%
      {{hash=MC}{%
         family={Monaco},
         familyi={M\bibinitperiod},
         given={Claudia},
         giveni={C\bibinitperiod},
      }}%
      {{hash=HU}{%
         family={Hedin},
         familyi={H\bibinitperiod},
         given={Ulf},
         giveni={U\bibinitperiod},
      }}%
      {{hash=SCM}{%
         family={Shanahan},
         familyi={S\bibinitperiod},
         given={Catherine\bibnamedelima M.},
         giveni={C\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=WJ}{%
         family={Willeit},
         familyi={W\bibinitperiod},
         given={Johann},
         giveni={J\bibinitperiod},
      }}%
      {{hash=KS}{%
         family={Kiechl},
         familyi={K\bibinitperiod},
         given={Stefan},
         giveni={S\bibinitperiod},
      }}%
      {{hash=MM}{%
         family={Mayr},
         familyi={M\bibinitperiod},
         given={Manuel},
         giveni={M\bibinitperiod},
      }}%
    }
    \strng{namehash}{LSR+1}
  \strng{fullhash}{LSRWKDAMLPSPBBJLMRGKAKLMCLRBTSGYXIBPBWPSJPGDAHMCHUSCMWJKSMM1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2017}
    \field{labeldatesource}{}
    \field{abstract}{%
    BACKGROUND. The identification of patients with high-risk atherosclerotic
  plaques prior to the manifestation of clinical events remains challenging.
  Recent findings question histology- and imaging-based definitions of the
  “vulnerable plaque,” necessitating an improved approach for predicting
  onset of symptoms., METHODS. We performed a proteomics comparison of the
  vascular extracellular matrix and associated molecules in human carotid
  endarterectomy specimens from 6 symptomatic versus 6 asymptomatic patients to
  identify a protein signature for high-risk atherosclerotic plaques.
  Proteomics data were integrated with gene expression profiling of 121 carotid
  endarterectomies and an analysis of protein secretion by lipid-loaded human
  vascular smooth muscle cells. Finally, epidemiological validation of
  candidate biomarkers was performed in two community-based studies., RESULTS.
  Proteomics and at least one of the other two approaches identified a
  molecular signature of plaques from symptomatic patients that comprised
  matrix metalloproteinase 9, chitinase 3-like-1, S100 calcium binding protein
  A8 (S100A8), S100A9, cathepsin B, fibronectin, and galectin-3-binding
  protein. Biomarker candidates measured in 685 subjects in the Bruneck study
  were associated with progression to advanced atherosclerosis and incidence of
  cardiovascular disease over a 10-year follow-up period. A 4-biomarker
  signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D, and
  galectin-3-binding protein) improved risk prediction and was successfully
  replicated in an independent cohort, the SAPHIR study., CONCLUSION. The
  identified 4-biomarker signature may improve risk prediction and diagnostics
  for the management of cardiovascular disease. Further, our study highlights
  the strength of tissue-based proteomics for biomarker discovery., FUNDING.
  UK: British Heart Foundation (BHF); King’s BHF Center; and the National
  Institute for Health Research Biomedical Research Center based at Guy’s and
  St Thomas’ NHS Foundation Trust and King’s College London in partnership
  with King’s College Hospital. Austria: Federal Ministry for Transport,
  Innovation and Technology (BMVIT); Federal Ministry of Science, Research and
  Economy (BMWFW); Wirtschaftsagentur Wien; and Standortagentur Tirol.%
    }
    \verb{doi}
    \verb 10.1172/JCI86924
    \endverb
    \verb{eprint}
    \verb 28319050
    \endverb
    \field{issn}{0021-9738}
    \field{number}{4}
    \field{pages}{1546\bibrangedash 1560}
    \field{shortjournal}{J Clin Invest}
    \field{title}{Extracellular Matrix Proteomics Identifies Molecular
  Signature of Symptomatic Carotid Plaques}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373893/
    \endverb
    \field{volume}{127}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\A55XT9S4\\Langley et al. - Extrac
    \verb ellular matrix proteomics identifies molecul.pdf
    \endverb
    \field{journaltitle}{The Journal of Clinical Investigation}
    \field{eprinttype}{pmid}
    \field{year}{2017}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{peprotecheclimitedRecombinantHumanPDGFBB2022}{online}{}
    \name{author}{1}{}{%
      {{hash=P}{%
         family={{PeproTech EC Limited}},
         familyi={P\bibinitperiod},
      }}%
    }
    \list{organization}{1}{%
      {{PeproTech}}%
    }
    \strng{namehash}{P1}
    \strng{fullhash}{P1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{labeldatesource}{}
    \field{abstract}{%
    PDGFs are disulfide-linked dimers consisting of two 12.0-13.5 kDa
  polypeptide chains, designated PDGF-A and PDGF-B chains. The three naturally%
    }
    \field{title}{Recombinant {{Human PDGF-BB}}}
    \verb{url}
    \verb https://www.peprotech.com/recombinant-human-pdgf-bb
    \endverb
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\LWDEA6JR\\recombinant-human-pdgf-
    \verb bb.html
    \endverb
    \field{year}{2022}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{gravesPlateletderivedGrowthFactor1996a}{article}{}
    \name{author}{8}{}{%
      {{hash=GLM}{%
         family={Graves},
         familyi={G\bibinitperiod},
         given={L.\bibnamedelima M.},
         giveni={L\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=BKE}{%
         family={Bornfeldt},
         familyi={B\bibinitperiod},
         given={K.\bibnamedelima E.},
         giveni={K\bibinitperiod\bibinitdelim E\bibinitperiod},
      }}%
      {{hash=SJS}{%
         family={Sidhu},
         familyi={S\bibinitperiod},
         given={J.\bibnamedelima S.},
         giveni={J\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=AGM}{%
         family={Argast},
         familyi={A\bibinitperiod},
         given={G.\bibnamedelima M.},
         giveni={G\bibinitperiod\bibinitdelim M\bibinitperiod},
      }}%
      {{hash=REW}{%
         family={Raines},
         familyi={R\bibinitperiod},
         given={E.\bibnamedelima W.},
         giveni={E\bibinitperiod\bibinitdelim W\bibinitperiod},
      }}%
      {{hash=RR}{%
         family={Ross},
         familyi={R\bibinitperiod},
         given={R.},
         giveni={R\bibinitperiod},
      }}%
      {{hash=LCC}{%
         family={Leslie},
         familyi={L\bibinitperiod},
         given={C.\bibnamedelima C.},
         giveni={C\bibinitperiod\bibinitdelim C\bibinitperiod},
      }}%
      {{hash=KEG}{%
         family={Krebs},
         familyi={K\bibinitperiod},
         given={E.\bibnamedelima G.},
         giveni={E\bibinitperiod\bibinitdelim G\bibinitperiod},
      }}%
    }
    \keyw{1-Methyl-3-isobutylxanthine,Amino Acid Sequence,Cells;
  Cultured,Cyclic AMP,Cyclic AMP-Dependent Protein Kinases,Enzyme
  Activation,Humans,Molecular Sequence Data,Muscle; Smooth;
  Vascular,Phosphodiesterase Inhibitors,Phospholipases A,Phospholipases
  A2,Phosphorylation,Platelet-Derived Growth Factor}
    \strng{namehash}{GLM+1}
    \strng{fullhash}{GLMBKESJSAGMREWRRLCCKEG1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{1996}
    \field{labeldatesource}{}
    \field{abstract}{%
    The abilities of platelet-derived growth factor (PDGF) and insulin-like
  growth factor (IGF-I) to regulate cAMP metabolism and mitogen-activated
  protein kinase (MAP kinase) activity were compared in human arterial smooth
  muscle cells (hSMC). PDGF-BB stimulated cAMP accumulation up to 150-fold in a
  concentration-dependent manner (EC50 approximately 0.7 nM). The peak of cAMP
  formation and cAMP-dependent protein kinase (PKA) activity occurred
  approximately 5 min after the addition of PDGF and rapidly declined
  thereafter. Incubating cells with PDGF and 3-isobutyl-1-methylxanthine (IBMX,
  a phosphodiesterase inhibitor) enhanced the accumulation of cAMP and PKA
  activity by an additional 2.5-3-fold, whereas IBMX alone was essentially
  without effect. The PDGF-stimulated increase in cAMP was prevented by
  addition of the cyclooxygenase inhibitor indomethacin, consistent with
  release of prostaglandins stimulating cAMP. PDGF, but not IGF-I, stimulated
  MAPK activity, cytosolic phospholipase A2 (cPLA2) phosphorylation, and cAMP
  synthesis which indicated a key role for MAP kinase in the activation of
  cPLA2. Further, PDGF stimulated the rapid release of arachidonic acid and
  synthesis of prostaglandin E2 (PGE2) which could be inhibited by a cPLA2
  inhibitor (AACOCF3). Calcium mobilization was required for PDGF-induced
  arachidonic acid release and PGE2 synthesis but not for MAPK activation,
  whereas PKC was required for PGE2-mediated activation of PKA. In summary,
  these results demonstrated that PDGF increases cAMP formation and PKA
  activity through a MAP kinase-mediated activation of cPLA2, arachidonic acid
  release, and PGE2 synthesis in human arterial smooth muscle cells.%
    }
    \verb{doi}
    \verb 10.1074/jbc.271.1.505
    \endverb
    \verb{eprint}
    \verb 8550611
    \endverb
    \field{issn}{0021-9258}
    \field{number}{1}
    \field{pages}{505\bibrangedash 511}
    \field{shortjournal}{J Biol Chem}
    \field{title}{Platelet-Derived Growth Factor Stimulates Protein Kinase
  {{A}} through a Mitogen-Activated Protein Kinase-Dependent Pathway in Human
  Arterial Smooth Muscle Cells}
    \field{volume}{271}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\P5IHVC5Y\\Graves et al. - 1996 -
    \verb Platelet-derived growth factor stimulates protein .pdf
    \endverb
    \field{journaltitle}{The Journal of Biological Chemistry}
    \field{eprinttype}{pmid}
    \field{day}{05}
    \field{month}{01}
    \field{year}{1996}
  \endentry

  \entry{wangSTATROSCycleExtends2018}{article}{}
    \name{author}{7}{}{%
      {{hash=WY}{%
         family={Wang},
         familyi={W\bibinitperiod},
         given={Yan},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=YX}{%
         family={Yu},
         familyi={Y\bibinitperiod},
         given={Xiaoyu},
         giveni={X\bibinitperiod},
      }}%
      {{hash=SH}{%
         family={Song},
         familyi={S\bibinitperiod},
         given={Hongtao},
         giveni={H\bibinitperiod},
      }}%
      {{hash=FD}{%
         family={Feng},
         familyi={F\bibinitperiod},
         given={Di},
         giveni={D\bibinitperiod},
      }}%
      {{hash=JY}{%
         family={Jiang},
         familyi={J\bibinitperiod},
         given={Yang},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=WS}{%
         family={Wu},
         familyi={W\bibinitperiod},
         given={Shuang},
         giveni={S\bibinitperiod},
      }}%
      {{hash=GJ}{%
         family={Geng},
         familyi={G\bibinitperiod},
         given={Jingshu},
         giveni={J\bibinitperiod},
      }}%
    }
    \keyw{Apoptosis,Breast Neoplasms,Female,HeLa Cells,Humans,Interferons,MCF-7
  Cells,Reactive Oxygen Species,STAT Transcription Factors,Uterine Cervical
  Neoplasms}
    \strng{namehash}{WY+1}
    \strng{fullhash}{WYYXSHFDJYWSGJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2018}
    \field{extradate}{1}
    \field{labeldatesource}{}
    \field{abstract}{%
    In mammals, the signal transducer and activator of transcription (STAT)
  protein processes mitochondria importation targets and mitochondria
  respiratory complexes, and triggers reactive oxygen species (ROS) generation,
  which conversely rapidly initiates the activation of STAT. Interferon (IFN)
  administration increases cancer cell apoptosis via STAT activation and ROS
  accumulation. However, the existence of a STAT-ROS cycle and how it affects
  IFN‑induced cancer cellular apoptosis are unclear. In the present study, we
  used MCF7 breast cancer cells and confirmed that a combination of
  IFN‑α/β/γ incubation induced STAT1/3 phosphorylation and mitochondria
  importation, which increased mitochondria respiratory complexes, the cellular
  oxygen consumption rate (OCR), and ROS production, followed by cellular
  apoptosis. We also found that STAT1/3 overexpression induced mitochondria
  respiratory complexes and ROS production. Additionally, ROS induced by H2O2
  induced phosphorylation of STAT1/3 and promoted mitochondria importation.
  STAT1/3 deletion suppressed H2O2-induced acute cellular OCR, increasing the
  ROS level and indicating that STAT1/3 is necessary for ROS-induced
  mitochondria OCR and further ROS production, suggesting the existence of a
  STAT-ROS cycle. We next found that IFN induced mitochondria respiratory
  complexes followed by induction of OCR, ROS, and apoptosis, which were
  partially blocked by STAT1/3 deletion. Additionally, the suppression of ROS
  inhibited IFN‑induced STAT1/3 activation. Finally, we discovered that this
  cycle exists also in A431 and HeLa cancer cells. These results indicate that
  a STAT-ROS cycle extends IFN‑induced cellular apoptosis.%
    }
    \verb{doi}
    \verb 10.3892/ijo.2017.4196
    \endverb
    \verb{eprint}
    \verb 29115415
    \endverb
    \field{issn}{1791-2423}
    \field{number}{1}
    \field{pages}{305\bibrangedash 313}
    \field{shortjournal}{Int J Oncol}
    \field{title}{The {{STAT-ROS}} Cycle Extends {{IFN}}‑induced Cancer Cell
  Apoptosis}
    \field{volume}{52}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\4695VMWZ\\Wang et al. - 2018 - Th
    \verb e STAT-ROS cycle extends IFN‑induced cancer cell.pdf
    \endverb
    \field{journaltitle}{International Journal of Oncology}
    \field{eprinttype}{pmid}
    \field{month}{01}
    \field{year}{2018}
  \endentry

  \entry{leeRoleSTAT1IRF12007}{article}{}
    \name{author}{12}{}{%
      {{hash=LHJ}{%
         family={Lee},
         familyi={L\bibinitperiod},
         given={Hyun\bibnamedelima Jung},
         giveni={H\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=OYK}{%
         family={Oh},
         familyi={O\bibinitperiod},
         given={Yeo\bibnamedelima Kyoung},
         giveni={Y\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=RM}{%
         family={Rhee},
         familyi={R\bibinitperiod},
         given={Marie},
         giveni={M\bibinitperiod},
      }}%
      {{hash=LJY}{%
         family={Lim},
         familyi={L\bibinitperiod},
         given={Joong-Yeon},
         giveni={J\bibinithyphendelim Y\bibinitperiod},
      }}%
      {{hash=HJY}{%
         family={Hwang},
         familyi={H\bibinitperiod},
         given={Ji-Young},
         giveni={J\bibinithyphendelim Y\bibinitperiod},
      }}%
      {{hash=PYS}{%
         family={Park},
         familyi={P\bibinitperiod},
         given={Yoon\bibnamedelima Shin},
         giveni={Y\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=KY}{%
         family={Kwon},
         familyi={K\bibinitperiod},
         given={Yongil},
         giveni={Y\bibinitperiod},
      }}%
      {{hash=CKH}{%
         family={Choi},
         familyi={C\bibinitperiod},
         given={Kyung-Hee},
         giveni={K\bibinithyphendelim H\bibinitperiod},
      }}%
      {{hash=JI}{%
         family={Jo},
         familyi={J\bibinitperiod},
         given={Inho},
         giveni={I\bibinitperiod},
      }}%
      {{hash=PSI}{%
         family={Park},
         familyi={P\bibinitperiod},
         given={Sang\bibnamedelima Ick},
         giveni={S\bibinitperiod\bibinitdelim I\bibinitperiod},
      }}%
      {{hash=GB}{%
         family={Gao},
         familyi={G\bibinitperiod},
         given={Bin},
         giveni={B\bibinitperiod},
      }}%
      {{hash=KWH}{%
         family={Kim},
         familyi={K\bibinitperiod},
         given={Won-Ho},
         giveni={W\bibinithyphendelim H\bibinitperiod},
      }}%
    }
    \keyw{hepatitis,iNOS,liver injury,ROS,STAT1}
    \strng{namehash}{LHJ+1}
    \strng{fullhash}{LHJOYKRMLJYHJYPYSKYCKHJIPSIGBKWH1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2007}
    \field{labeldatesource}{}
    \field{abstract}{%
    Previously, we demonstrated that signal transducer and activator of
  transcription factor 1 (STAT1) plays an essential role in liver injury
  induced by lipopolysaccharide (LPS)/d-galactosamine (d-GalN); however, the
  underlying mechanism involved remains unclear. Here, we showed that
  LPS/d-GalN administration induced secretion of tumor necrosis factor α
  (TNF-α) and interferon γ (IFN-γ), which mediated apoptosis
  synergistically. Moreover, LPS/d-GalN-induced apoptosis was associated with
  increased inducible nitric oxide synthase (iNOS) and nitric oxide (NO)
  production, as well as elevated reactive oxygen species (ROS) production,
  which were all strongly inhibited by treatment with the antioxidant
  N-acetyl-l-cysteine (NAC) and an iNOS/NO inhibitor, l-NMMA. Although STAT1
  activation and expression did not change significantly in
  TNF-α/IFN-γ-cotreated cells compared with cells treated with IFN-γ alone,
  the absence of STAT1 or interferon regulatory factor 1 (IRF-1) in genetic
  knockout mice strongly abrogated the observed effects of TNF-α/IFN-γ on
  iNOS/NO induction, ROS production, loss of mitochondrial transmembrane
  potential (ΔΨm), and apoptosis compared with STAT1(+/+) and IRF-1(+/+)
  mice. Additionally, the synergistic effects of TNF-α/IFN-γ on iNOS/NO
  induction, ROS production, and apoptosis were significantly inhibited by
  overexpression of dominant negative STAT1 in contrast to overexpression of
  wild-type STAT1. In STAT1-deficient mice, nuclear factor κB (NF-κB)
  activation by TNF-α/IFN-γ was attenuated and strongly inhibited by both NAC
  and l-NMMA. Moreover, the proteasome inhibitor, MG132, inhibited NF-κB
  activation and strongly inhibited iNOS/NO induction, ROS production, and loss
  of ΔΨm induced by TNF-α/IFN-γ, thereby inhibiting apoptosis.
  Interestingly, it appears peroxynitrite, which is produced by TNF-α/IFN-γ,
  may interfere with STAT1 phosphorylation by inducing STAT1 nitration.
  Collectively, these findings demonstrate that TNF-α/IFN-γ synergistically
  potentiates iNOS/NO induction, ROS production, and loss of ΔΨm via STAT1
  overexpression, playing an important role in promoting apoptosis and liver
  injury induced by LPS/d-GalN.%
    }
    \verb{doi}
    \verb 10.1016/j.jmb.2007.03.072
    \endverb
    \field{issn}{0022-2836}
    \field{number}{4}
    \field{pages}{967\bibrangedash 984}
    \field{shortjournal}{Journal of Molecular Biology}
    \field{title}{The {{Role}} of {{STAT1}}/{{IRF-1}} on {{Synergistic ROS
  Production}} and {{Loss}} of {{Mitochondrial Transmembrane Potential}} during
  {{Hepatic Cell Death Induced}} by {{LPS}}/d-{{GalN}}}
    \verb{url}
    \verb https://www.sciencedirect.com/science/article/pii/S002228360700438X
    \endverb
    \field{volume}{369}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\L8XHFJXG\\Lee et al. - 2007 - The
    \verb  Role of STAT1IRF-1 on Synergistic ROS Product.pdf;C\:\\Users\\torbe\
    \verb \Zotero\\storage\\NS5XN8LG\\S002228360700438X.html
    \endverb
    \field{journaltitle}{Journal of Molecular Biology}
    \field{day}{15}
    \field{month}{06}
    \field{year}{2007}
    \field{urlday}{29}
    \field{urlmonth}{06}
    \field{urlyear}{2022}
  \endentry

  \entry{kaasCurrentResearchOrganization2014}{article}{}
    \name{author}{2}{}{%
      {{hash=KJH}{%
         family={Kaas},
         familyi={K\bibinitperiod},
         given={Jon\bibnamedelima H},
         giveni={J\bibinitperiod\bibinitdelim H\bibinitperiod},
      }}%
      {{hash=BP}{%
         family={Balaram},
         familyi={B\bibinitperiod},
         given={Pooja},
         giveni={P\bibinitperiod},
      }}%
    }
    \strng{namehash}{KJHBP1}
    \strng{fullhash}{KJHBP1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2014}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.2147/EB.S64016
    \endverb
    \verb{eprint}
    \verb 26388695
    \endverb
    \field{issn}{1179-2744}
    \field{issue}{Suppl 1}
    \field{pages}{1\bibrangedash 4}
    \field{shortjournal}{Eye Brain}
    \field{title}{Current Research on the Organization and Function of the
  Visual System in Primates}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574956/
    \endverb
    \field{volume}{6}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\FWZP3NII\\Kaas und Balaram - 2014
    \verb  - Current research on the organization and function .pdf
    \endverb
    \field{journaltitle}{Eye and Brain}
    \field{eprinttype}{pmid}
    \field{day}{23}
    \field{month}{09}
    \field{year}{2014}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{mattsonSuperiorPatternProcessing2014}{article}{}
    \name{author}{1}{}{%
      {{hash=MMP}{%
         family={Mattson},
         familyi={M\bibinitperiod},
         given={Mark\bibnamedelima P.},
         giveni={M\bibinitperiod\bibinitdelim P\bibinitperiod},
      }}%
    }
    \strng{namehash}{MMP1}
    \strng{fullhash}{MMP1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2014}
    \field{labeldatesource}{}
    \field{abstract}{%
    Humans have long pondered the nature of their mind/brain and, particularly
  why its capacities for reasoning, communication and abstract thought are far
  superior to other species, including closely related anthropoids. This
  article considers superior pattern processing (SPP) as the fundamental basis
  of most, if not all, unique features of the human brain including
  intelligence, language, imagination, invention, and the belief in imaginary
  entities such as ghosts and gods. SPP involves the electrochemical, neuronal
  network-based, encoding, integration, and transfer to other individuals of
  perceived or mentally-fabricated patterns. During human evolution, pattern
  processing capabilities became increasingly sophisticated as the result of
  expansion of the cerebral cortex, particularly the prefrontal cortex and
  regions involved in processing of images. Specific patterns, real or
  imagined, are reinforced by emotional experiences, indoctrination and even
  psychedelic drugs. Impaired or dysregulated SPP is fundamental to cognitive
  and psychiatric disorders. A broader understanding of SPP mechanisms, and
  their roles in normal and abnormal function of the human brain, may enable
  the development of interventions that reduce irrational decisions and
  destructive behaviors.%
    }
    \verb{doi}
    \verb 10.3389/fnins.2014.00265
    \endverb
    \verb{eprint}
    \verb 25202234
    \endverb
    \field{issn}{1662-4548}
    \field{pages}{265}
    \field{shortjournal}{Front Neurosci}
    \field{title}{Superior Pattern Processing Is the Essence of the Evolved
  Human Brain}
    \verb{url}
    \verb https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141622/
    \endverb
    \field{volume}{8}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\SYQL2VM5\\Mattson - 2014 - Superi
    \verb or pattern processing is the essence of the .pdf
    \endverb
    \field{journaltitle}{Frontiers in Neuroscience}
    \field{eprinttype}{pmid}
    \field{day}{22}
    \field{month}{08}
    \field{year}{2014}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{oraclecorporationWhatDatabase2022}{online}{}
    \name{author}{1}{}{%
      {{hash=O}{%
         family={{Oracle Corporation}},
         familyi={O\bibinitperiod},
      }}%
    }
    \strng{namehash}{O1}
    \strng{fullhash}{O1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{extradate}{1}
    \field{labeldatesource}{}
    \field{abstract}{%
    Learn everything you need to know about database and how it can help your
  business.%
    }
    \field{title}{What Is a Database?}
    \verb{url}
    \verb https://www.oracle.com/database/what-is-database/
    \endverb
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\LSKXTFSM\\what-is-database.html
    \endverb
    \field{year}{2022}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{oraclecorporationWhatRelationalDatabase2022}{online}{}
    \name{author}{1}{}{%
      {{hash=O}{%
         family={{Oracle Corporation}},
         familyi={O\bibinitperiod},
      }}%
    }
    \strng{namehash}{O1}
    \strng{fullhash}{O1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{extradate}{2}
    \field{labeldatesource}{}
    \field{title}{What {{Is}} a {{Relational Database}} | {{Oracle}}}
    \verb{url}
    \verb https://www.oracle.com/database/what-is-a-relational-database/
    \endverb
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\4W5JRUSC\\what-is-a-relational-da
    \verb tabase.html
    \endverb
    \field{year}{2022}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{thesqliteconsortiumSQLite2022}{online}{}
    \name{author}{1}{}{%
      {{hash=T}{%
         family={{The SQLite Consortium}},
         familyi={T\bibinitperiod},
      }}%
    }
    \strng{namehash}{T1}
    \strng{fullhash}{T1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2022}
    \field{labeldatesource}{}
    \field{title}{About {{SQLite}}}
    \verb{url}
    \verb https://www.sqlite.org/about.html
    \endverb
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\JAPYUK5F\\about.html
    \endverb
    \field{year}{2022}
    \field{urlday}{13}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{carterAssociationCardiovascularDisease2019}{article}{}
    \name{author}{10}{}{%
      {{hash=CP}{%
         family={Carter},
         familyi={C\bibinitperiod},
         given={Paul},
         giveni={P\bibinitperiod},
      }}%
      {{hash=LJ}{%
         family={Lagan},
         familyi={L\bibinitperiod},
         given={Jakub},
         giveni={J\bibinitperiod},
      }}%
      {{hash=FC}{%
         family={Fortune},
         familyi={F\bibinitperiod},
         given={Christien},
         giveni={C\bibinitperiod},
      }}%
      {{hash=BDL}{%
         family={Bhatt},
         familyi={B\bibinitperiod},
         given={Deepak\bibnamedelima L.},
         giveni={D\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=VJ}{%
         family={Vestbo},
         familyi={V\bibinitperiod},
         given={Jørgen},
         giveni={J\bibinitperiod},
      }}%
      {{hash=NR}{%
         family={Niven},
         familyi={N\bibinitperiod},
         given={Robert},
         giveni={R\bibinitperiod},
      }}%
      {{hash=CN}{%
         family={Chaudhuri},
         familyi={C\bibinitperiod},
         given={Nazia},
         giveni={N\bibinitperiod},
      }}%
      {{hash=SEB}{%
         family={Schelbert},
         familyi={S\bibinitperiod},
         given={Erik\bibnamedelima B.},
         giveni={E\bibinitperiod\bibinitdelim B\bibinitperiod},
      }}%
      {{hash=PR}{%
         family={Potluri},
         familyi={P\bibinitperiod},
         given={Rahul},
         giveni={R\bibinitperiod},
      }}%
      {{hash=MCA}{%
         family={Miller},
         familyi={M\bibinitperiod},
         given={Christopher\bibnamedelima A.},
         giveni={C\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
    }
    \keyw{asthma,chronic obstructive pulmonary disease,heart
  failure,interstitial lung fibrosis,ischemic heart disease}
    \strng{namehash}{CP+1}
    \strng{fullhash}{CPLJFCBDLVJNRCNSEBPRMCA1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2019}
    \field{labeldatesource}{}
    \field{abstract}{%
    Background The relationship between respiratory diseases and individual
  cardiovascular diseases, and the impact of cardiovascular diseases on
  mortality in patients with respiratory disease, are unclear. Objectives This
  study sought to determine the relationship between chronic obstructive
  pulmonary disease (COPD), asthma and interstitial lung disease (ILD), and
  individual cardiovascular diseases, and evaluate the impact of individual
  cardiovascular diseases on all-cause mortality in respiratory conditions.
  Methods The authors conducted a cohort study of all patients admitted to 7
  National Health Service hospitals across the North West of England, between
  January 1, 2000, and March 31, 2013, with relevant respiratory diagnoses,
  with age-matched and sex-matched control groups. Results A total of 31,646
  COPD, 60,424 asthma, and 1,662 ILD patients were included. Control groups
  comprised 158,230, 302,120, and 8,310 patients, respectively (total follow-up
  2,968,182 patient-years). COPD was independently associated with ischemic
  heart disease (IHD), heart failure (HF), atrial fibrillation, and peripheral
  vascular disease, all of which were associated with all-cause mortality
  (e.g., odds ratio for the association of COPD with HF: 2.18 [95\% confidence
  interval (CI): 2.08 to 2.26]; hazard ratio for the contribution of HF to
  mortality in COPD: 1.65 [95\% CI: 1.61 to 1.68]). Asthma was independently
  associated with IHD, and multiple cardiovascular diseases contributed to
  mortality (e.g., HF hazard ratio: 1.81 [95\% CI: 1.75 to 1.87]). ILD was
  independently associated with IHD and HF, both of which were associated with
  mortality. Patients with lung disease were less likely to receive coronary
  revascularization. Conclusions Lung disease is independently associated with
  cardiovascular diseases, particularly IHD and HF, which contribute
  significantly to all-cause mortality. However, patients with lung disease are
  less likely to receive coronary revascularization.%
    }
    \verb{doi}
    \verb 10.1016/j.jacc.2018.11.063
    \endverb
    \field{issn}{0735-1097}
    \field{number}{17}
    \field{pages}{2166\bibrangedash 2177}
    \field{shortjournal}{Journal of the American College of Cardiology}
    \field{title}{Association of {{Cardiovascular Disease With Respiratory
  Disease}}}
    \verb{url}
    \verb https://www.sciencedirect.com/science/article/pii/S0735109719304577
    \endverb
    \field{volume}{73}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\QYYGWMLT\\Carter et al. - 2019 -
    \verb Association of Cardiovascular Disease With Respira.pdf;C\:\\Users\\to
    \verb rbe\\Zotero\\storage\\36269TXW\\S0735109719304577.html
    \endverb
    \field{journaltitle}{Journal of the American College of Cardiology}
    \field{day}{07}
    \field{month}{05}
    \field{year}{2019}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{hanPulmonaryDiseasesHeart2007}{article}{}
    \name{author}{4}{}{%
      {{hash=HMK}{%
         family={Han},
         familyi={H\bibinitperiod},
         given={MeiLan\bibnamedelima K.},
         giveni={M\bibinitperiod\bibinitdelim K\bibinitperiod},
      }}%
      {{hash=MVV}{%
         family={McLaughlin},
         familyi={M\bibinitperiod},
         given={Vallerie\bibnamedelima V.},
         giveni={V\bibinitperiod\bibinitdelim V\bibinitperiod},
      }}%
      {{hash=CGJ}{%
         family={Criner},
         familyi={C\bibinitperiod},
         given={Gerard\bibnamedelima J.},
         giveni={G\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=MFJ}{%
         family={Martinez},
         familyi={M\bibinitperiod},
         given={Fernando\bibnamedelima J.},
         giveni={F\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Heart Association}}%
    }
    \keyw{hypertension; pulmonary,inflammation,pulmonary disease; chronic
  obstructive,pulmonary heart disease}
    \strng{namehash}{HMK+1}
    \strng{fullhash}{HMKMVVCGJMFJ1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2007}
    \field{labeldatesource}{}
    \field{abstract}{%
    The complex nature of interactions between the pulmonary and cardiovascular
  systems is becoming increasingly appreciated. Pulmonary vascular
  abnormalities are frequently present in patients with respiratory disorders,
  including chronic obstructive pulmonary disease, idiopathic pulmonary
  fibrosis, sarcoidosis, neuromuscular or chest wall disorders, and disorders
  of ventilatory control including sleep apnea syndromes and obesity
  hypoventilation syndrome. Pulmonary hypertension, classified as group III in
  the World Health Organization classification scheme for pulmonary
  hypertension, may result in severe right ventricular dysfunction caused by
  lung disease, also known as cor pulmonale. The development of cor pulmonale
  is generally associated with poorer prognosis and increased death. Systemic
  manifestations of lung disease, particularly obstructive disorders, are also
  particularly relevant because they are associated with increased cardiac
  death and impaired health status. This article will discuss the most common
  pulmonary diseases and disorders of ventilatory control that cause pulmonary
  vascular abnormalities and cor pulmonale, with particular concentration on
  how treatment of these diseases may affect the heart. In addition, the
  complex nature of cardiac and lung disease will also be explored,
  particularly with respect to the relationship between chronic obstructive
  pulmonary disease, systemic inflammation, atherosclerosis, and cardiovascular
  death, which is currently a very active focus of research.%
    }
    \verb{doi}
    \verb 10.1161/CIRCULATIONAHA.106.685206
    \endverb
    \field{number}{25}
    \field{pages}{2992\bibrangedash 3005}
    \field{title}{Pulmonary {{Diseases}} and the {{Heart}}}
    \verb{url}
    \verb https://www.ahajournals.org/doi/10.1161/circulationaha.106.685206
    \endverb
    \field{volume}{116}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\EG26CRJK\\Han et al. - 2007 - Pul
    \verb monary Diseases and the Heart.pdf
    \endverb
    \field{journaltitle}{Circulation}
    \field{day}{18}
    \field{month}{12}
    \field{year}{2007}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{auyeungAssociationGeneticInstrumental2018}{article}{}
    \name{author}{3}{}{%
      {{hash=AYSL}{%
         family={Au\bibnamedelima Yeung},
         familyi={A\bibinitperiod\bibinitdelim Y\bibinitperiod},
         given={Shiu\bibnamedelima Lun},
         giveni={S\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
      {{hash=BMC}{%
         family={Borges},
         familyi={B\bibinitperiod},
         given={Maria-Carolina},
         giveni={M\bibinithyphendelim C\bibinitperiod},
      }}%
      {{hash=LDA}{%
         family={Lawlor},
         familyi={L\bibinitperiod},
         given={Debbie\bibnamedelima A.},
         giveni={D\bibinitperiod\bibinitdelim A\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Heart Association}}%
    }
    \keyw{coronary artery disease,forced expiratory volume,lung,Mendelian
  randomization analysis,odds ratio,vital capacity}
    \strng{namehash}{AYSL+1}
    \strng{fullhash}{AYSLBMCLDA1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2018}
    \field{labeldatesource}{}
    \field{abstract}{%
    Background: Lung function, assessed by forced expiratory volume in 1 second
  (FEV1) and forced vital capacity (FVC), is inversely associated with coronary
  artery disease (CAD), but these associations could be because of confounding
  or reversed causality. We conducted a 2-sample Mendelian randomization study,
  using publicly available data from relevant genome-wide association studies,
  to examine the role of FEV1 or FVC on CAD. Methods: We used the most recent
  genome-wide association studies on lung function to extract genetic
  instruments related to FEV1 and FVC (n=92\,749). Data on the association
  between genetic instruments and CAD were obtained from Coronary Artery
  Disease Genome wide Replication and Meta-analysis plus The Coronary Artery
  Disease Genetics 1000 Genomes-based genome-wide association studies (60\,801
  CAD cases and 123\,504 controls). We used inverse-variance weighting with a
  multiplicative random effect to estimate the genetic instrumented association
  of FEV1 and FVC on CAD. Sensitivity analyses included weighted median and
  MR-Egger methods. Results: Each SD greater FEV1 was associated with a lower
  risk of CAD (odds ratio, 0.78 per SD; 95\% confidence interval, 0.62–0.98)
  with a similar magnitude for FVC on CAD risk (odds ratio, 0.82 per SD; 95\%
  confidence interval, 0.64–1.06). Estimates for FEV1 were similar when using
  MR-Egger method (odds ratio, 0.80 per SD; 95\% confidence interval,
  0.33–1.94) although the magnitude was smaller for weighted median method
  (odds ratio, 0.93 per SD; 95\% confidence interval, 0.75–1.17). Estimates
  for FVC in the sensitivity analyses were attenuated (median) or changed
  direction (MR-Egger). Conclusions: Our study suggested an inverse relation
  between FEV1 and CAD, but for FVC, evidence is less clear.%
    }
    \verb{doi}
    \verb 10.1161/CIRCGEN.117.001952
    \endverb
    \field{number}{4}
    \field{pages}{e001952}
    \field{title}{Association of {{Genetic Instrumental Variables}} for {{Lung
  Function}} on {{Coronary Artery Disease Risk}}}
    \verb{url}
    \verb https://www.ahajournals.org/doi/10.1161/CIRCGEN.117.001952
    \endverb
    \field{volume}{11}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\37LYSF9Q\\Au Yeung et al. - 2018
    \verb - Association of Genetic Instrumental Variables for .pdf
    \endverb
    \field{journaltitle}{Circulation: Genomic and Precision Medicine}
    \field{month}{04}
    \field{year}{2018}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{nowakLungFunctionCoronary2018}{article}{}
    \name{author}{1}{}{%
      {{hash=NC}{%
         family={Nowak},
         familyi={N\bibinitperiod},
         given={Christoph},
         giveni={C\bibinitperiod},
      }}%
    }
    \list{publisher}{1}{%
      {{American Heart Association}}%
    }
    \keyw{Editorials,exercise,motivation,public health,smoking}
    \strng{namehash}{NC1}
    \strng{fullhash}{NC1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2018}
    \field{labeldatesource}{}
    \verb{doi}
    \verb 10.1161/CIRCGEN.118.002137
    \endverb
    \field{number}{4}
    \field{pages}{e002137}
    \field{title}{Lung {{Function}} and {{Coronary Artery Disease Risk}}}
    \verb{url}
    \verb https://www.ahajournals.org/doi/10.1161/CIRCGEN.118.002137
    \endverb
    \field{volume}{11}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\PVZKAWI2\\Nowak - 2018 - Lung Fun
    \verb ction and Coronary Artery Disease Risk.pdf
    \endverb
    \field{journaltitle}{Circulation: Genomic and Precision Medicine}
    \field{month}{04}
    \field{year}{2018}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{kapellosHumanMonocyteSubsets2019}{article}{}
    \name{author}{7}{}{%
      {{hash=KTS}{%
         family={Kapellos},
         familyi={K\bibinitperiod},
         given={Theodore\bibnamedelima S.},
         giveni={T\bibinitperiod\bibinitdelim S\bibinitperiod},
      }}%
      {{hash=BL}{%
         family={Bonaguro},
         familyi={B\bibinitperiod},
         given={Lorenzo},
         giveni={L\bibinitperiod},
      }}%
      {{hash=GI}{%
         family={Gemünd},
         familyi={G\bibinitperiod},
         given={Ioanna},
         giveni={I\bibinitperiod},
      }}%
      {{hash=RN}{%
         family={Reusch},
         familyi={R\bibinitperiod},
         given={Nico},
         giveni={N\bibinitperiod},
      }}%
      {{hash=SA}{%
         family={Saglam},
         familyi={S\bibinitperiod},
         given={Adem},
         giveni={A\bibinitperiod},
      }}%
      {{hash=HER}{%
         family={Hinkley},
         familyi={H\bibinitperiod},
         given={Emily\bibnamedelima R.},
         giveni={E\bibinitperiod\bibinitdelim R\bibinitperiod},
      }}%
      {{hash=SJL}{%
         family={Schultze},
         familyi={S\bibinitperiod},
         given={Joachim\bibnamedelima L.},
         giveni={J\bibinitperiod\bibinitdelim L\bibinitperiod},
      }}%
    }
    \strng{namehash}{KTS+1}
    \strng{fullhash}{KTSBLGIRNSAHERSJL1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2019}
    \field{labeldatesource}{}
    \field{abstract}{%
    Human monocytes are divided in three major populations; classical
  (CD14+CD16−), non-classical (CD14dimCD16+), and intermediate (CD14+CD16+).
  Each of these subsets is distinguished from each other by the expression of
  distinct surface markers and by their functions in homeostasis and disease.
  In this review, we discuss the most up-to-date phenotypic classification of
  human monocytes that has been greatly aided by the application of novel
  single-cell transcriptomic and mass cytometry technologies. Furthermore, we
  shed light on the role of these plastic immune cells in already recognized
  and emerging human chronic diseases, such as obesity, atherosclerosis,
  chronic obstructive pulmonary disease, lung fibrosis, lung cancer, and
  Alzheimer's disease. Our aim is to provide an insight into the contribution
  of human monocytes to the progression of these diseases and highlight their
  candidacy as potential therapeutic cell targets.%
    }
    \field{issn}{1664-3224}
    \field{title}{Human {{Monocyte Subsets}} and {{Phenotypes}} in {{Major
  Chronic Inflammatory Diseases}}}
    \verb{url}
    \verb https://www.frontiersin.org/articles/10.3389/fimmu.2019.02035
    \endverb
    \field{volume}{10}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\NTB24ECJ\\Kapellos et al. - 2019
    \verb - Human Monocyte Subsets and Phenotypes in Major Chr.pdf
    \endverb
    \field{journaltitle}{Frontiers in Immunology}
    \field{year}{2019}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry

  \entry{wrigleyCD14CD16Monocytes2013}{article}{}
    \name{author}{4}{}{%
      {{hash=WBJ}{%
         family={Wrigley},
         familyi={W\bibinitperiod},
         given={Benjamin\bibnamedelima J.},
         giveni={B\bibinitperiod\bibinitdelim J\bibinitperiod},
      }}%
      {{hash=SE}{%
         family={Shantsila},
         familyi={S\bibinitperiod},
         given={Eduard},
         giveni={E\bibinitperiod},
      }}%
      {{hash=TLD}{%
         family={Tapp},
         familyi={T\bibinitperiod},
         given={Luke\bibnamedelima D.},
         giveni={L\bibinitperiod\bibinitdelim D\bibinitperiod},
      }}%
      {{hash=LGYH}{%
         family={Lip},
         familyi={L\bibinitperiod},
         given={Gregory Y.\bibnamedelima H.},
         giveni={G\bibinitperiod\bibinitdelim Y\bibinitperiod\bibinitdelim
  H\bibinitperiod},
      }}%
    }
    \keyw{Ischaemic heart failure,monocyte subsets,monocytes}
    \strng{namehash}{WBJ+1}
    \strng{fullhash}{WBJSETLDLGYH1}
    \field{labelnamesource}{author}
    \field{labeltitlesource}{title}
    \field{labelyear}{2013}
    \field{labeldatesource}{}
    \field{abstract}{%
    Background Monocytes play important roles in inflammation, angiogenesis and
  tissue repair and may contribute to the pathophysiology of heart failure
  (HF). Objectives We examined differences in monocyte subset numbers and
  expression of cell surface markers of activation (CD14) and chemotaxis (CCR2)
  in patients with acute HF (AHF), stable HF (SHF), and controls and evaluated
  their impact on clinical outcomes. Methods Three monocyte subsets
  [CD14++CD16−CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2−
  (Mon3)] were analysed by flow cytometry in 51 patients with AHF, 42 patients
  with SHF, 44 patients with stable coronary artery disease and without HF
  (CAD) and 40 healthy controls (HC). The prognostic impact of monocyte subsets
  was examined in AHF. Results Patients with AHF had significantly higher Mon1
  counts compared to the three control groups (P {$<$} 0·001 for all).
  Similarly, Mon2 levels were increased in AHF compared to SHF (P = 0·004) and
  CAD (P {$<$} 0·001) and increased in SHF vs. CAD (P = 0·009). There were no
  differences in Mon3 counts between the groups. Twenty patients (39·2\%) with
  AHF reached the primary end-point of death or re-hospitalisation, and after
  adjustment for confounders, Mon2 count remained negatively associated with a
  combined end-point of death and re-hospitalisation [hazard ratio (per 10
  cells/μL): 0·79; confidence interval: 0·66–0·94; P = 0·009].
  Conclusions Mon2 counts are increased in patients with both acute and stable
  HF, with enhanced expression of surface markers of activation (CD14) and
  chemotaxis (CCR2). This subset was also associated with an adverse prognosis
  in patients with AHF.%
    }
    \verb{doi}
    \verb 10.1111/eci.12023
    \endverb
    \field{issn}{1365-2362}
    \field{number}{2}
    \field{pages}{121\bibrangedash 130}
    \field{title}{{{CD14}}++{{CD16}}+ Monocytes in Patients with Acute
  Ischaemic Heart Failure}
    \verb{url}
    \verb https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.12023
    \endverb
    \field{volume}{43}
    \field{langid}{english}
    \verb{file}
    \verb C\:\\Users\\torbe\\Zotero\\storage\\A8NEGXCA\\Wrigley et al. - 2013 -
    \verb  CD14++CD16+ monocytes in patients with acute ischa.pdf;C\:\\Users\\t
    \verb orbe\\Zotero\\storage\\CH3RJXSE\\eci.html
    \endverb
    \field{journaltitle}{European Journal of Clinical Investigation}
    \field{annotation}{%
    \_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/eci.12023%
    }
    \field{year}{2013}
    \field{urlday}{14}
    \field{urlmonth}{07}
    \field{urlyear}{2022}
  \endentry
\enddatalist
\endinput
